ARO_id,DNA Sequence,Gene Family,Resistance Mechanism,Drug Class,Mega id,type,MEGARes_header,Source_header,label
,atgaaaacagtatttatccttatctccatgcttttccctgtcgcagttatggcacagaaaagcgtaaaaatatccgatgacatcagtatcacccaactctcggacaaagtgtacacttatgtatccctcgccgaaatcgaaggatggggtatggtaccttccaacgggatgattgttatcaacaaccaccaggcagcgttgctggacacaccgatcaatgacgcacaaacggaaacgctggtcaactgggtgacagactctttgcatgccaaagtcaccacgtttatcccgaaccactggcacggcgattgtattggcggactgggttacctgcaaaagaaaggtgtccgatcatacgcgaaccagatgacgatagacctcgccaaggaaaaaggattgcccgtaccggaacatggattcaccgattcactgaccgtcagcttggacggcatgcctctccaatgctattatttaggaggcgggcatgcgaccgacaatatcgtggtttggctgccgacagagaatatcctttttggcggatgtatgcttaaagacaaccagacgacaagcatcggcaacatctcggacgcggacgtgacggcatggccgaaaactctcgataaggtaaaagccaagttcccctcggcccgctacgtcgtgcccggacatggtaactatggcggaaccgaactgatagagcataccaagcagatcgtgaaccaatatatagaaagcacttcaaagccatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_1659,Drugs,MEG_1659|Drugs|betalactams|Class_B_betalactamases|CFIA,1028084268|WP_063843236.1|NG_047630|1|1|cfiA11|cfiA|subclass_B1_metallo-beta-lactamase_CfiA11 NG_047630:101-850,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattatgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggcacaactaccggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_567,Drugs,MEG_567|Drugs|betalactams|Class_C_betalactamases|ADC,746220970|WP_039270258.1|NG_064700|1|1|blaADC-145|blaADC|class_C_beta-lactamase_ADC-145 NG_064700:9-1160,0
,atgatagatattaaaaatgagaatataagggttagaactttaaatgataatgattttccattaatgttaaaatggcttaccgatgaaagagtattagaattttatgatggtagagataaaaaatatacattagaaactttaaaagaacattatacagaaccttgggaagatgaagttataagagtaattattgaatataatggtcaacctattggttatggacaaatatataaaatgtatgatgaactatatgatgattatcattaccctagaagtaatgatattgtttatggtatggaccaatttattggtgaagttgattattggagcaaaggcataggaacaaaatatacaaaaatgatttttgaattcttaaaaaaagaaagaaatgcagatgctgtaatattggacccacaccaagataatccaagagcaattagaatgtatcaaaaagcaggatttagaattattgaagatttaccagaacacgaacttcacgaaggtaaaaaagaagattgttatttaatggaatatcgatatgatgataatgaaactaatgttaaagcaataaaatatataattgaacatagttttgatatcaaaataacctctattaaattaattggtaatggtaatgactcgtttgcttatgaagttaatgataatatgatttttaaatttcctagacacgaaaaagcaaatgaaaatttattaaaagaaattgaaatactacaatatttagaaaataaaacaacttttaatatacctaaagttttatatgttaataatgataattcgaattataaatattgtattgcttgttttacaaaaattaatggtgtttctttaagtaaagaaatatatgaaagattaactgatgaagaaaaagataaattagcacaagatttagcaagatttttaaaagaactacatagttccaattataataaataccaagtcgatacaattgagaattacaaaaaagattatgcaagattagttgaattaatttttgataaattagatgataatgaaaaaatggtaattaataatatttataatagcattttatctaatgatgatatgctaacaataaataaatctcttgttcataacgactttagttgtggtaatattttatttgatactacaacaaatagaatttcaggtattattgattttggggattcttgtgtttctgatactgataatgatttttattgtttattagaagattcagatgaagaattaggaagatgttttggtataaaagttttaaattattatggttatgacaacattgaaaaaatgttgagaaaatcagattttcacgaattttattggatgtttgaaaaaataatttatggttatgaatataattataatgattggattactgaaggattatcagagttaaaagaatattgtgaaataagtattaaaaataaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_88,Drugs,MEG_88|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1509794531|WP_122630840.1|NG_062248|1|2|aac(6')-Ie_fam|aac(6')-Ie_fam|bifunctional_AAC(6')-Ie_family_aminoglycoside_N-acetyltransferase/APH(2'')_family_aminoglycoside_O-phosphotransferase NG_062248:101-1552,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccacctcggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctgacccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgttggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcactgcaaccgcacaggatcgccaggctgcccgcgccacagacgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5563,Drugs,MEG_5563|Drugs|betalactams|Class_C_betalactamases|PDC,730535670|WP_034039380.1|NG_049936|1|1|blaPDC-61|blaPDC|class_C_beta-lactamase_PDC-61 NG_049936:1-1194,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccaaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcccatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5669,Drugs,MEG_5669|Drugs|betalactams|Class_C_betalactamases|PDC,1408841616|WP_111672889.1|NG_060545|1|1|blaPDC-300|blaPDC|class_C_beta-lactamase_PDC-300 NG_060545:1-1194,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgggacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgataagcctggtaaatattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaagttgttgctttgtctatgaataaacctttcgatcaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaggaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatacggcgtcaaatccaccttaccggatatgttgagttttattcatgccaatctgaacccacaaaaatattcggcagatattcaacgtgcaattaatgaaacacatcagggtcgctatcaaataaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagagccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgagtgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_600,Drugs,MEG_600|Drugs|betalactams|Class_C_betalactamases|ADC,491270099|WP_005128228.1|NG_055285|1|1|blaADC-155|blaADC|class_C_beta-lactamase_ADC-155 NG_055285:1-1152,0
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagacctgtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_232,Drugs,MEG_232|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1073100721|WP_069985732.1|NG_052506|1|1|aac(6')-Ib11|aac(6')-Ib11|aminoglycoside_N-acetyltransferase_AAC(6')-Ib11 NG_052506:101-655,2
,atgaacattaaagccctcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattctagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggatagtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaacaaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4506,Drugs,MEG_4506|Drugs|betalactams|Class_D_betalactamases|OXA,1044690747|WP_065419572.1|NG_051168|1|1|blaOXA-521|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-521 NG_051168:1-825,0
,atggaaagaaaagggattttcattaaggttttttcctatacgatcattgtcctgctactgcttgtcggtgtaacagcaacactgcttgcacagcaatttgtgtcttatttcagagtgatggaattacagcaaacagtaaaatcctatcagccattggtggaactgattcagaatagcgataggcttgatattcaagaggtggcagggctgtttcactacaataaccaatcctttgagttttatattgaagataaagagggaagcgtactctatgccacaccaaatgccaatacatcaaatagttttagacccgactttctttatgtggtacatagagatgataatatttcgattgttgctcaaaacaaggcaggtgtgggattgctttatcaagggctgacaattcggggaattgttatgattgcgataatggttgtattcagccttttatgcgcgtatatctttgcgcggcaaatgacaacgccgatcaaagccttagcggacagtgcgaataaaatggcaaacctgaaagatgtaccgccgccgctggagcgaaaggatgagcttggcgcactggctcatgatatgcattccatgtatgtcaggctgaaagaaaccatcgcaaggctggaggatgaaatcgcaagggaacatgagttggaggaaacacagcgatatttctttgcggcagcttctcatgagctaaaaacgcccatcgcggctacaagcgttctgttggagggaatgcttgaaaatatcggtgactacaaagatcattctaagtatctgcgcgaatgcatcaaaatgatggataggcagggcaaaatcatttccgaaatactggagcttgtcagcctgaatgatgggagaatcgtacccatagctgaaccgttggacatagggcgcacggttgccgagttgctgcccgattttcaaaccttggcagaggcaaacaaccagcggttcgtcacagatattccagccgggcaaattgtcctgtccgatccgaggctgctccaaaaggcactatccaatgtcatattgaatgcagttcagaacacgccgcagggaggcgaggtacggatatggagtgagcctggtgctgaaaaatgccgcctttttgttttgaacatgggcgttcacattgatgatactgcgcttccaaggctgttcaccccattctatcgcattgatcaggcgcgaagcagaaaaagtgggcgaagcggtttaggacttgccatcgtacaaaaaacgctggatgccatgagcctccagtatgcgctggaaaacacctcggatggcgttttgttctggctggatttaccgctcacatcaacattgtaa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7490,Drugs,MEG_7490|Drugs|Glycopeptides|VanB-type_regulator|VANSB,501574713|WP_012579101.1|NG_048449|1|1|vanS-B|vanS-B|VanB-type_vancomycin_resistance_histidine_kinase_VanS NG_048449:101-1444,5
,atgaatagaataaaagtcgcaatcatcttcggcggttgctcggaggaacatgatgtgtcggtaaaatccgcaatagaaattgctgcgaacattgatacggaaaaattcgatccgcactacatcggaattacaaaaaacggtgtatggaagctatgcaagaagccatgtacggaatgggaagccgatagtctccccgccatattctccccggataggaaaacgcatgggctgcttgtcatgaaagaaagcgaatacgaaacacggcgtattgatgtggctttcccggttttgcatggcaaatgcggggaggatggtgcgatacaggggctgtttgtattgtctggtatcccctatgtgggctgtgatattcaaagctccgcagcttgcatggacaaatcactggcctacattcttacaaaaaatgcgggcatcgccgtccccgaatttcaagtgattgaaaaaggtggcaaaccggaggcgaggacgcttacctaccctgtctttgtgaagccggcacggtcaggttcgtcctttggcgtaaccaaagtaaacagtacggaagaactaaacgctgcgatagaagcagcaggacaatatgatggaaaaatcttaattgagcaagcgatttcgggctgtgaggtcggctgcgcggtcatgggaaacgaggatgatttgattgtcggcgaagtggatcaaatccggttgagccacggtatcttccgcatccatcaggaaaacgagccggaaaaaggctcagagaatgcgatgattatcgttccagcagacattccggtcgaggaacgaaatcgggtgcaagaaacggcaaagaaagtatatcgggtgcttggatgcagagggcttgctcgtgttgatctttttttgcaggaggatggcggcatcgttctaaacgaggtcaataccctccccggttttacatcgtacagccgctacccacgtatgatggccgccgcaggaatcacgcttcctgcactgattgacagcctgattacattggcgttaaagaggtga,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7352,Drugs,MEG_7352|Drugs|Glycopeptides|VanB-type_resistance_protein|VANB,1028100445|WP_063856580.1|NG_048336|1|1|vanB|vanB|D-alanine--(R)-lactate_ligase_VanB NG_048336:1-1029,5
,atgcgatttaaaaaaatttcttgtctacttttatctccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaacgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgctgttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatacggcgtcaaatccaccttaccggatatgttgagttttattaatgccaaccttaacccacaaaaatatccgacagatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaagcctaataaagtgactgctatttcaaaagagccttcagttaagatgtaccataaaactggctcaactaccggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_616,Drugs,MEG_616|Drugs|betalactams|Class_C_betalactamases|ADC,447133954|WP_001211210.1|NG_064708|1|1|blaADC-185|blaADC|class_C_beta-lactamase_ADC-185 NG_064708:1-1152,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagtagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggtggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgtagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_809,Drugs,MEG_809|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502152|WP_071846304.1|NG_052368|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052368:101-892,2
,TCATTATTAGCTAACTTCAATTCAATCTTATAAGTCTTATGAACATTAAAGCCCTCTTACTTATAACAAGCACTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATGAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTCTTAGTTATCCAACAAGGCCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCAGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAGTGGGACGGGCAAAAAAGGCTATTCCCAGAATGGGAAAAGGACATGACCCTAGGCGACGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAATGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACTCCTCAGCAAGAGGCACAATTTGCTTACAAGCTAGCTAATAAAACGCTTCCATTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGCTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAAACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGGAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGAATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGCTTAGAACAATTAGGTATTTTATAGAGTTAGTTTATAGCCCAGTTCACTTTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_5256,Drugs,MEG_5256|Drugs|betalactams|Class_D_betalactamases|OXA,gi|94960148|gb|DQ519087.1|1-890,0
,atgatgaaaaaatccctaagctgcgccctgctgctcagcgttgcctgctctgcttttgccgcaccgatgtcagaaaaacagctggctgacgtcgtggaacgtaccgttacgcccctgatgaaggcgcaggccatacccggaatggccgtggccgtcatttatcagggccagccacactattttactttcggtaaagcagacgtcgcggcgaataagcccgtcacgccgcaaaccttatttgagctgggctccgtcagcaaaaccttcaccggcgtgctgggtggcgatgccattgcccgcaaagagatttcgctggccgacccggtcacgaaatattggcctgaattgacgggcaagcagtggcaaggcattcgcctgctcgacctggcaacctataccgcaggcggattgccgttgcaggtaccggatgatgtcaccgataacgcctctctgctgcgtttctaccagtcctggcagccaaagtgggccccgggtaccacgcgtctgtacgccaacaccagcatcggcctgtttggctcactggccgttaaaccgtccggcatgcgcttcgagcaggccatggcggagcgggtctttaagcccctgaaactcaaccatacgtggataaacgttccacacgctgaagagcccaactacgcatggggttatcgtgagggaaaagcggtccacgtttcgcctggtatgctggatgcagaagcctatggtgtgaaatctaacgtcaaagatatggcgagctgggtgatggccaatatggcacctgagacactcccgcagtccactctgcagcagggtattgcgctggcgcagtctcgctactggcgcgtgggtgccatgtatcaagggttaggctgggagatgctcaactggccggtcgacgccaaaaccgtggtggatggcagcgataataaggttgcactggcgccgttgccggtcgcagaagtgaatcctccggctccgccagtaaaagcctcctgggtgcataaaacgggctctacgggtgggtttggcagctacgtggcgtttattcctgaaaagcagatcggtattgtgatgctcgcaaataaaagttatccgaacccggtacgggtggaaacggcttaccgtattctcgagacgctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1749,Drugs,MEG_1749|Drugs|betalactams|Class_C_betalactamases|CMH,772703496|WP_045295573.1|NG_050719|1|1|blaCMH-3|blaCMH|class_C_beta-lactamase_CMH-3 NG_050719:1-1146,0
,atgaaaaaaagcattccgttttttattatttcgatgttgctaagcccattggcaaacgcccaggatacacaggtaagagattttgtaattgagcctcaaattcaacccaacttttatatttacaaaacattcggagtattcggagggaaagaatattctaccaatgccgtgtatctggtaactaaaaaaggagttgtcctgtttgatgttccatggcagaaaacccaataccaaagtctgatggatacaattcaaaaacgtcatcaccttccggttatagctgtatttgctacccattctcatgaagacagagcgggagatttaagcttttataataagaaaggaatcaaaacctacgctacagcaaaaaccaatgaaattttaaagaaagaaggaaaagcaacttctacagaaattataaaaaccggtaaaccttaccgtattggtggagaagaatttgtagtagactttcttggtgaaggtcatacggcggataatgtagtggtttggtttcccaaatataagatactggacggaggctgtcttgtaaaaagtaaagcagcagccgatcttggctacaccggcgaagccaacgttgcacaatggccaaaaacaatggaaaagttaaaatccaaatacgctcaggcaaccctgattattcccggacatgatgaatggaaaggcggcggccatgtagagcacacacttgatcttttaaataaaaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3401,Drugs,MEG_3401|Drugs|betalactams|Class_B_betalactamases|IND,489069302|WP_002979282.1|NG_051689|1|1|blaCGB-1|blaIND|IND_family_subclass_B1_metallo-beta-lactamase_CGB-1 NG_051689:101-829,0
,ATGAGAATAGTGAATGGACCAATAATAATGACTAGAGAAGAAAGAATGAAGATTGTTCATGAAATTAAGGAACGAATATTGGATAAATATGGGGATGATGTTAAGGCTATTGGTGTTTATGGCTCTCTTGGTCGTCAGACTGATGGGCCCTATTCGGATATTGAGATGATGTGTGTCATGTCAACAGAAGAAGCAGAGTTCAGCCATGAATGGACAACCGGTGAGTGGAAGGTGGAAGTGAATTTTGATAGCGAAGAGATTCTACTAGATTATGCATCTCAGGTGGAATCAGATTGGCCTCTTACACATGGTCAATTTTTCTCTATTTTGCCGATTTATGATTCAGGTGGATACTTAGAGAAAGTGTATCAAACTGCTAAATCGGTAGAAGCCCAAACGTTCCACGATGCGATTTGTGCCCTTATCGTAGAAGAGCTGTTTGAATATGCAGGCAAATGGCGTAATATTCGTGTGCAAGGACCGACAACATTTCTACCATCCTTGACTGTACAGGTAGCAATGGCAGGTGCCATGTTGATTGGTCTGCATCATCGCATCTGTTATACGACGAGCGCTTCGGTCTTAACTGAAGCAGTTAAGCAATCAGATCTTCCTTCAGGTTATGACCATCTGTGCCAGTTCGTAATGTCTGGTCAACTTTCCGACTCTGAGAAACTTCTGGAATCGCTAGAGAATTTCTGGAATGGGATTCAGGAGTGGACAGAACGACACGGATATATAGTGGATGTGTCAAAACGCATACCATTTTGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_981,Drugs,MEG_981|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT4-PRIME,(AGly)AadD:AF181950:3176-3946:771,2
,ATGAATAAATCAATTATTATTATACTGCTGATCACCGTATTAGATGCCATTGGTATCGGGCTTATCATGCCAGTACTCCCTACTCTATTAAATGAATTTGTCAGTGAAAATTCACTGGCAACCCATTACGGTGTGCTATTAGCGCTCTATGCTACCATGCAGGTTATTTTTGCTCCTATTCTAGGACGACTGTCTGATAAATACGGCAGAAAACCCATCTTGCTGTTTTCCCTTTTAGGCGCGGCACTCGACTATCTTTTAATGGCATTCTCAACCACACTTTGGATGCTCTATATTGGGCGCATCATTGCGGGGATCACAGGCGCAACAGGTGCCGTATGTGCATCAGCGATGAGTGATGTGACTCCCGCTAAAAATCGAACTCGCTATTTTGGTTTCTTAGGTGGTGTTTTTGGTGTTGGCCTTATTATCGGCCCAATGCTAGGGGGATTATTAGGTGATATCAGTGCTCATATGCCATTTATTTTTGCCGCTATTTCACACTCGATATTATTAATACTCTCTTTGCTCTTTTTCCGAGAAACACAAAAAAGAGAAGCGCTTGTTGCCAATAGGACACCTGAAAACCAAACTGCCTCAAATACAGTCACTGTTTTTTTTAAGAAAAGCCTCTACTTTTGGTTAGCAACCTATTTTATTATCCAGCTTATCGGGCAAATTCCTGCCACCATCTGGGTGCTGTTTACACAATATCGTTTTGATTGGAACACAACTTCTATCGGTATGTCTTTGGCGGTTCTGGGTGTATTACATATTTTCTTTCAGGCGATTGTCGCTGGGAAATTGGCACAAAAATGGGGCGAAAAAACCACCATTATGATCAGTATGTCTATTGATATGATGGGCTGTTTATTATTAGCGTGGATAGGCCACGTTTGGGTCATCTTACCAGCATTAATTTGCTTAGCGGCAGGAGGTATGGGGCAACCCGCATTACAAGGTTATTTATCAAAATCTGTCGATGATAATGCGCAAGGGAAATTACAAGGTACTCTGGTGAGCCTAACCAATATTACCGGGATCATTGGTCCCCTTTTATTTGCCTTTATTTATAGTTATAGCGTCGCTTATTGGGATGGTCTGTTATGGCTGATGGGGGCAATACTTTATGCTATGTTGCTTATTACCGCTTATTTTCACCAAAGAAAAACCACACCTAAAGCTGTTATTTCAACCCCTTAA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7085,Drugs,MEG_7085|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETH,gi|695209907|ref|NG_035903.1|3048-1846 gi|392871|gb|U00792.1|PMTETRH|716-1918 gi|356596244|gb|CP003022.1|336102-336144,4
,ATAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCAGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6928,Drugs,MEG_6928|Drugs|betalactams|Class_A_betalactamases|TEM,gi|6007798|gb|AF188199.1|AF188199|1-1080 gi|961666360|gb|KT185451.1|87740-87690,0
,atgtcactgtatcgccgtctagttctgctgtcttgtctctcatggccgctgtctggcttttctgccaccgcgctgaccaacctcgtcgcggaaccattcgctaaactcgaacaggactttggcggctccatcggtgtgtacgcgatggataccggctcaggcgcaactgtaagttaccgcgctgaggagcgcttcccactgtgcagctcattcaagggctttcttgctgccgctgtgctggctcgcagccagcagcaggccggcttgctggacacacccatccgttacggcaaaaatgcgctggttccgtggtcacccatctcggaaaaatatctgacaacaggcatgacggtggcggagctgtccgcggccgccgtgcaatacagtgataacgccgccgccaatttgttgctgaaggagttgggcggcccggccgggctgacggccttcatgcgctctatcggcgataccacgttccgtctggaccgctgggagctggagctgaactccgccatcccaggcgatgcgcgcgatacctcatcgccgcgcgccgtgacggaaagcttacaaaaactgacactgggctctgcactggctgcgccgcagcggcagcagtttgttgattggctaaagggaaacacgaccggcaaccaccgcatccgcgcggcggtgccggcagactgggcagtcggagacaaaaccggaacctgcggagtgtatggcacggcaaatgactatgccgtcgtctggcccactgggcgcgcacctattgtgttggccgtctacacccgggcgcctaacaaggatgacaagcacagcgaggccgtcatcgccgctgcggctagactcgcgctcgagggattgggcgtcaacgggcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3483,Drugs,MEG_3483|Drugs|betalactams|Class_A_betalactamases|KPC,1058243982|WP_068981634.1|NG_051469|1|1|blaKPC-26|blaKPC|carbapenem-hydrolyzing_class_A_beta-lactamase_KPC-26 NG_051469:1-882,0
,atgcgttatgttcgcctgtgccttatctccctgattgccgccctgccactggcggtattcgccagccctcagccgcttgagcagattaaaatcagcgaaagtcagctggcgggccgggtgggctatgtggaaatggatctggccagcggccgcacgctggccgcctggcgcgccagtgagcgctttccgctgatgagcacctttaaagtgctgctctgcggcgcggtgctggcccgggtggatgccggcgacgaacagctggatcggcggatccactaccgccagcaggatctggtggactactccccggtcagcgaaaaacaccttgccgacgggatgaccgttggcgaactctgcgccgccgccatcaccatgagcgacaacaccgccggcaatctgctgttgaagatcgtcggcggccccgcgggattgactgcctttttgcgccagatcggtgacaacgtcacccgtcttgaccgctgggaaacggaacttaatgaggcgcttcccggcgacgtgcgcgacaccaccaccccggccagtatggccaccaccctgcgcaagctgctaaccaccccctctctgagcgcccgttcgcagcagcagctgctgcagtggatggttgacgaccgggtggccggcccgttgatccgcgccgtgctgccggcgggctggtttatcgccgataaaaccggggccggtgagcggggctcacgcggcattgtcgccctgctcggcccggacggcaaagcggagcgtatcgtggtgatctatctgcgtgataccccggcgaccatggtcgagcgtaaccagcagatcgccgggataggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4235,Drugs,MEG_4235|Drugs|betalactams|Class_A_betalactamases|OKP,1028105924|WP_063860923.1|NG_049381|1|1|blaOKP-B-5|blaOKP-B|class_A_broad-spectrum_beta-lactamase_OKP-B-5 NG_049381:47-907,0
,AATTCTTGAAGACGAAAGGGCCTCGTGATACGCTTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGGTAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTTCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGCTGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCATTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6923,Drugs,MEG_6923|Drugs|betalactams|Class_A_betalactamases|TEM,gi|48734421|gb|AY628175.1|1-1071,0
,atgaaaacatttgccgcatatgtaattatcgcgtgtctttcaagtacggcattagctggttcaattacagaaaatacgtcttggaacaaagagttctctgccgaagccgtcaatggtgtcttcgtgctttgtaaaagtagcagtaaatcctgcgctaccaatgacttagctcgtgcatcaaaggaatatcttccagcatcaacatttaagatccccaacgcaattatcggcctagaaactggtgtcataaagaatgagcatcaggttttcaaatgggacggaaagccaagagccatgaagcaatgggaaagagacttgaccttaagaggggcaatacaagtttcagcttttcccgtatttcaacaaatcgccagagaagttggcgaagtaagaatgcagaaataccttaaaaaattttcctatggcaaccagaatatcagtggtggcattgacaaattctggttggaaggccagcttagaatttccgcagttaatcaagtggagtttctagagtctctatatttaaataaattgtcagcatctaaagaaaaccagctaatagtaaaagaggctttggtaacggaggcggcacctgaatatctagtgcattcaaaaactggtttttctggtgtgggaactgagtcaaatcctggtgtcgcatggtgggttgggtgggttgagaaggagacagaggtttactttttcgcctttaacatggatatagacaacgaaagtaagttgccgctaagaaaatccattcccaccaaaatcatggaaagtgagggcatcattggtggctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4417,Drugs,MEG_4417|Drugs|betalactams|Class_D_betalactamases|OXA,1509794550|WP_122630859.1|NG_062272|1|1|blaOXA-677|blaOXA-10_like|OXA-10_family_class_D_beta-lactamase_OXA-677 NG_062272:1-801,0
,atgaaaaacacaatacatatcaacttcgctatttttttaataattgcaaatattatctacagcagcgccagtgcatcaacagatatctctactgttgcatctcaattatttgaaggaactgaaggttgttttttactttacgatgcatccacaaacgctgaaattgctcaattcaataaagcaaagtgcgcagcgcaaatggcaccagattcaactttcaagatcgcattatcacttatggcatttgatgcggaaataatagatcagaaaaccatattcaaatgggataaaatcccaaaaggaatggaaatttggaacagcaatcatacaccaaagacgtggatgcaattttctgttgtttgggtttcgcaagaaataacccaaaaaattggattaaataaaatcaaaaattatctcaaagattttgattatggaaatcaagacttctctggagataaagaaagaaacaacggattaacagaagcatggctcgaaagtagcttaaaaatttcaccggaagaacaaattcaattcctgcgtaaaattattaatcacaatcttccagttagaaattcagccatagaaaacaccatagataacatgtatctacaagatctggagaatagtacaaaactgtatgggaaaactggtgcaggattcacagcaaatagaaccctacaaaacggatggtttgaagggtttattataagcaaatcaggacataaatatgtttttgtgtccgcacttacaggaaacttggggtcgaatttaacatcaagcataaaagccaagaaaaatgcaatcaccattctaaacacactaaatttataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4408,Drugs,MEG_4408|Drugs|betalactams|Class_D_betalactamases|OXA,695263578|WP_032490448.1|NG_064747|1|1|blaOXA-392|blaOXA-1_like|OXA-1_family_class_D_beta-lactamase_OXA-392 NG_064747:101-931,0
,atgaaaacatttaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_106,Drugs,MEG_106|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1102724734|WP_071593230.1|NG_052059|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052059:101-655,2
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgttcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacattacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggctattcccagaatgggaaaagaacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4491,Drugs,MEG_4491|Drugs|betalactams|Class_D_betalactamases|OXA,1509794598|WP_122630907.1|NG_062327|1|1|blaOXA-705|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-705 NG_062327:26-850,0
,TTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATAAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCATTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCT,beta-lactamase,antibiotic inactivation,betalactams,MEG_6927,Drugs,MEG_6927|Drugs|betalactams|Class_A_betalactamases|TEM,gi|58200708|gb|AY874537.1|1-1149 gi|479327147|gb|KC354802.1|11791-11985,0
,atgaaaaactactttgacagccctttcaaaggggaactactttctgagcaagtgaaaaatcaaaatatcagagtaggccggtatagctattactctggctactatcatgggcactcatttgatgattgcgcgcgatacttgcgtccagatcgtgatgacgttgataaattgatcattggcagcttttgttctataggaagcggggcttccttcatcatggctggcaatcaggggcatcggcatgactgggcatcatccttccccttcttttatatgcaagaggagcctgctttctcaagcgcactcgacgccttccaaagagcaggtgataccgccattggcaatgatgtctggataggctcggaggcaatgattatgcccggcatcaaaattggagacggtgccgtaataggcagtcgctcgttggtgacaaaagatgtagagccttatgccatcatcggaggaaatcccgcaaagcaaattaagaagcgcttctccgatgaggaaatatcattgctcatggagatggagtggtggagctggccactagataaaattaagacagcaatgccgctgctgtgctcgtcaaatatttttggtctgcataagtattggcgcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1597,Drugs,MEG_1597|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,920256382|WP_052972810.1|NG_047619|1|1|catB8|catB8|type_B-3_chloramphenicol_O-acetyltransferase_CatB8 NG_047619:101-733,6
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgccttgtaagtattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcaatttccagatgaagtaaaaacagatcagcaagttttaacattttttaaagactggaaacctaaaaactcaatcggtgaatatcgacaatattcaaacccaagcattggtttatttggaaaagttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagggtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaactaccggtttcggaacatatgtggtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_577,Drugs,MEG_577|Drugs|betalactams|Class_C_betalactamases|ADC,691150664|WP_032062810.1|NG_064697|1|1|blaADC-141|blaADC|class_C_beta-lactamase_ADC-141 NG_064697:101-1252,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagtgcttcaaaatctgatgacaaagcagagaaaattaaaaatttatttaacgaagcacacactacaggtgttttagttatccatcaaggtcaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacacaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagcttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4473,Drugs,MEG_4473|Drugs|betalactams|Class_D_betalactamases|OXA,1509794607|WP_122630916.1|NG_062336|1|1|blaOXA-708|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-708 NG_062336:20-844,0
,atgcgttttatactgctcgccttcgccctggccgtcgctcttccggccgtccacgccagcgccgccgaggcaccgctgccacaactgcgggcctataccgtggatgcgtcctggctgcagccgatagcgccgctgcaggttgccgaccacacctggcagatcggcaccgaggacctgaccgcgctgctggtgcagaccgccgagggcgcagtactgctggatggcggcatgccacagatggccggtcacctgctggacaacgtgaagctgcgcggcgtggccccgcaggacctgcgattgatcctgctcagccatgcgcatgccgaccacgccggcccggtcgccgagctcaagcgtcgcaccggcgcgcatgtggcggccaatgcagaaacggcggtgctgctggcgcgcggcggcagcaacgacctgcactttggcgacggcatcacctatccgccggccagcgccgaccgcatcatcatggatggcgaagtggtcacggtgggcggcatcgcgttcaccgcgcacttcatgccagggcacaccccgggcagcaccgcctggacctggaccgacacccgcgatggcaagccggtgcgcatcgcctacgccgacagcctcagcgcaccgggttaccagctgaagggcaatccccgttatccgcgcctgatcgaggactacaagcgcagcttcgcaacggtgcgggcgctgccctgcgatctgctgctcaccccgcatccgggcgccagcaactggaactacgccgccggcagcaaggccagcaccgaggcactgacctgcaacgcctacgcggatgcggccgagaagaagttcgacgcgcagttggccagggaaacggccgggacccgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3531,Drugs,MEG_3531|Drugs|betalactams|Class_B_betalactamases|L1,1028083731|WP_063842699.1|NG_047517|1|1|blaL1|blaL1|L1_family_subclass_B3_metallo-beta-lactamase NG_047517:101-973,0
,ATGACGCCATTACTGTATAAAAAAACAGGTACAAATATGGCTCTGGCACTCGTTGGCGAAAAAATTGACAGAAACCGTTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCGATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGCGGATTTTCGCAATGCCAGTGCGCTGGGCATTGAAATTCGCCACTGCCGCGCACAAGGCGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACCACGCGCACCTGGTTTTGTAGCGCATATATCACGAATACCAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGTTGGAAAAGTGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTCTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCGAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGGGCGTTGATTTACAAGGCGTTAAGCTGGACAACTACCAGGCGTCGTTGCTCATGGAGCGGCTTGGCATCGCGGTGATTGGTTAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5999,Drugs,MEG_5999|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,gi|805300607|gb|KP339254.1|135-815 gi|686483900|gb|KM111270.1|3479-2799 gi|672605144|gb|CP009116.1|69546-70226 gi|347311572|gb|JF775514.1|8374-7694 gi|293628003|gb|GU723682.1|3366-2686 gi|293627996|gb|GU723680.1|3368-2688 gi|284019459|gb|GU295959.1|3405-2725 gi|226536677|gb|FJ851186.1|3397-2717 gi|197092208|gb|EU908090.1|6603-7283 gi|695213227|ref|NG_036578.1|3509-2829,3
,atggaaaatggttttttgtttttagatgaaatgttgcatggcgtccgttgggatgccaagtacgccacatgggataacttcacaggaaaaccggtggatgggtatgaggtgaatcgcatcatcggcacaaaggccgtggcgtttgctctgcgcgaggcacaaatccatgcggctgcgcttggctatggcttgcttttatgggatggatatcggccaagaactgcggtggactgcttcctgcgttgggcagcgcaaccggaggacaagctcacaaaagaaaaattttaccccaatatagagcgagccgagttgattacaaagggttatgtggcctcacaatccagccatagccgtggaagcgcaattgatcttacgctctaccacctggatacaggggaacttgtttcaatgggaagtaacttcgattttatggacgaacggtcgcatcatacagcaaaagggataggggatgcagaggcacaaaatcgaagatgcttgcgtaaaatcatggaaagcagcggatttcagtcttatcgctttgaatggtggcactataagttgattgatgagccataccccgatacctattttaattttgccgtttcataa,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7560,Drugs,MEG_7560|Drugs|Glycopeptides|VanB-type_resistance_protein|VANXB,1028100637|WP_063856772.1|NG_048485|1|1|vanX-B|vanX-B|D-Ala-D-Ala_dipeptidase_VanX-B NG_048485:101-709,5
,atgaacgagaaaaatataaaacacagtcaaaactttattacttcaaaacataatatagataaaataatgacaaatataagattaaatgaacatgataatatctttgaaatcggctcaggaaaagggcattttacccttgaattagtacagaggtgtaatttcgtaactgccattgaaatagaccataaattatgcaaaactacagaaaataaacttgttgatcacgataatttccaagttttaaacaaggatatattgcagtttaaatttcctaaaaaccaatcctataaaatatttggtaatataccttataacataagtacggatataatacgcaaaattgtttttgatagtatagctgatgagatttatttaatcgtggaatacgagtttgctaaaagattattaaatacaaaacgctcattggcattatttttaatggcagaagttgatatttctatattaagtatggttccaagagaatattttcatcctaaacctaaagtgaatagctcacttatcagattaaatagaaaaaaatcaagaatatcacacaaagataaacagaagtataattatttcgttatgaaatgggttaacaaagaatacaagaaaatatttacaaaaaatcaatttaacaattccttaaaacatgcaggaattgacgatttaaacaatattagctttgaacaattcttatctcttttcaatagctataaattatttaataagtaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2814,Drugs,MEG_2814|Drugs|MLS|23S_rRNA_methyltransferases|ERMC,446926004|WP_001003260.1|NG_055988|1|1|erm(C)|erm(C)|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(C) NG_055988:101-835,7
,ATGAGCGAACCCTACCTGAGCCGCTGGCGATTGCGGCGTGATGGCCCGGCCATCCGTACGCCCCACGCCCGGCTCTGGCCGGTGCTGACCGCTGCGGGCGAGCCAGCGATGCTGAAGATCAGCAGCGAGACCGAGGAGCAGAACAGCCATCGCCTGCTACGCTGGTGGAACGGCGATGGCGCCGCCCGCCTGCTGGCCCACGAGGGGCCTGCGATCCTGATCGAGCGTGCCCGCGGTGACTCGCTGCGGCAACGCTCGATCGAGGGCGACGATGACGCCTGCACCGCGATCCTGTGCCAGGTCCTGCAGCGGCTGCACCGGCCACGGAGCGCGCCGCCAGCGGAACTGGTCTGCCTGCGTAGATGGTTCGCCGACCTGCTGCAGCCAAGGGCTGTGCTGCCGCCACTGCTGGAACAGTGCAGATCACTGGCGGAGGGGCTGCTGCGTGACGAACAGGAGATCCGGCCGCTGCACGGCGACCTGCATCATGACAATGTGCTGGATTTCGGCCCGCGCGGCTGGTTGGCGATCGACCCGAAGCGACTGCTGGGGGACCGTGCGTTCGATTACGCGACGATGTTCAGCAACCCGGACCTCTGTGGTCCGGGCATCCACGTTGCGACGCGGCCCGAGCGGTTTGCGATCCGCCTTGAGCAGGTCTGTGCGCTGGCCGAACTGGAACGCACACGCCTGCTGCGCTGGATCGCGGCCAGCACTGCGCTGTCGGCAGTGTGGTTCAGGGATGACGGCGACCCGGCCGATATCGACGAGACAGTCGCCCGGATGGCCCTGGAGGCGCTGGCGGAAGCGTGA,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1052,Drugs,MEG_1052|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,gi|312191072|gb|HQ424461.1|18-830,2
,GTGACCATCGAAATTTCGAACCAACTATCAGAGGTGCTAAGCGTCATTGAGCGCCATCTGGAATCAACGTTGCTGGCCGTGCATTTGTACGGCTCCGCAGTGGATGGCGGCCTGAAGCCATACAGCGATATTGATTTGTTGGTTACTGTGGCCGTAAAGCTTGATGAAACGACGCGGCGAGCATTGCTCAATGATCTTATGGAGGCTTCGGCTCTCCCTGGCGAGAGCGAGACGCTCCGCGCTATAGAAGTCACCCTTGTCGTGCATGACGACATCATCCCGTGGCGTTATCCGGCTAAGCGCGAGCTGCAATTTGGAGAATGGCAGCGCAATGACATTCTTGCGGGTATCTTCGAGCCAGCCATGATCGACATTGATCTAGCTATCCTGCTTACAAAAGCAAGAGAACATAGCGTTGCCTTGGTAGGTCCGGCAGCGGAGGAATTCTTTGACCCGGTTCCTGAACAGGATCTATTCGAGGCGCTGAGGGAAACCTTGAAGCTATGGAACTCGCAGCCCGACTGGGCCGGCGATGAGCGAAATGTAGTGCTTACGTTGTCCCGCATTTGGTACAGCGCAATAACCGGCAAAATCGCGCCGAAGGATGTCGCTGCCGACTGGGCAATAAAACGCCTACCTGCCCAGTATCAGCCCGTCTTACTTGAAGCTAAGCAAGCTTATCTGGGACAAAAAGAAGATCACTTGGCCTCACGCGCAGATCACTTGGAAGAATTTATTCGCTTTGTGAAAGGCGAGATCATCAAGTCAGTTGGTAAATGA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_959,Drugs,MEG_959|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,gi|695207935|ref|NG_035452.1|1709-2488,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5576,Drugs,MEG_5576|Drugs|betalactams|Class_C_betalactamases|PDC,1408841630|WP_111672903.1|NG_060561|1|1|blaPDC-291|blaPDC|class_C_beta-lactamase_PDC-291 NG_060561:1-1173,0
,ATTACTCGCTGCGCTCCTAATTTGCCGGTGAGCGTGGCGTTGGGCGTCAAGGAAAACTTAATGGCAATCCGAATCTTTGCAATACTTTTCTCCACTTTTGTTTTTGGCACGTTCGCGCATGCACAAGAAGGCATGCGCGAACGTTCTGACTGGCGGAAGTTTTTCAGCGAATTTCAAGCCAAAGGCACGATAGTTGTGGCAGACGAACGCCAAACAGATCGTGTCATATTGGTTTTTGATCAGGTGCGGTCAGAGAAACGCTACTCGCCGGCCTCGACATTCAAGATTCCACATACACTTTTTGCACTTGACGCAGGCGCTGCACGTGATGAGTTTCAAGTTTTCCGATGGGACGGCATCAAAAGAAGCTTTGCAGCTCACAACCAAGACCAAGACTTGCGATCAGCAATGCGGAATTCTACTGTCTGGATTTATGAGCTATTTGCAAAAGAGATCGGTGAAGACAAGGCTCGACGCTATTTGAAGCAAATCGACTATGGCAACGCCGATCCTTCGACAAGTAATGGCGATTACTGGATAGATGGCAATCTTGCTATCGCGGCACAAGAACAGATTGCATTTCTCAGGAAGCTCTATCATAACGAGTTGCCCTTTCGGGTAGAACATCAGCGCTTGGTCAAGGACCTCATGATTGTGGAAGCCGGTCGCAACTGGATACTGCGCGCAAAGACGGGCTGGGAAGGCCGCATTGGTTGGTGGGTAGGATGGGTTGAGTGGCCGACTGGCCCCGTATTCTTCGCACTGAATATTGATACGCCAAACAGGATGGATGACCTTTTCAAAAGGGAGGCAATAGTGCGGGCAATCCTTCGCTCTATCGAAGCGTTGCCGCCCAACCCGGCAGTCAACTCGGACGCAGCGCGATAAAGCCGCGACAGC,beta-lactamase,antibiotic inactivation,betalactams,MEG_5249,Drugs,MEG_5249|Drugs|betalactams|Class_D_betalactamases|OXA,gi|784887|gb|L07945.1|PSEBLAOXA3|1-900,0
,atgaatgtcatcctgaaccgtcgaacgtttttattggctagcgctgtggtgtctgcgtcttattcgctaggtacgctggctggcgctaatcgggatgatgcttcctttcaagatcggctggctaagttagagcagaagctgaacggacggcttggggtatgcgccatcgataccgcagatggagcacagttgggctatcgcgccaatgagcggtttgccatgaacagcacgttcaaggtcatgctcgcttcagcgtttctcgcccaaagccaagacgaaccggggctcctcgaagagcggctcacgtacacccgggccgatctggtcacatactctccagtgacggaaaagcacgttgccactgggatgaccgttgccgagttgtgcgccgcaggcattcagtacagtgataacaccgcggccaatgtgctcatgaaaaagctggggggccctgaagcggtcaccgcatttgcccgctcgataggagatacgcattttcgcctcgatcgatgggaaaccgaactcaattcggctattccgggagatcctcgtgatacgagtacccctcaggccatggcaatgagtctgcaacgtctggcattgggtgacatgctggctgcggataaacagcatcagttgcaggcgtggttgaaaggcaataccacgggtggcaagcgtatccgggccggggtaccggctggctggcaggtaggcgataagacaggtacgggtgattacggctcggccaacgacgtggctatcctctggccgcctcgccgtgcacccgttgtgctggctctctattccgctcttgaaaaccagcaggcggaagcgcgcaatgacgtactggccgatgcggcacgcattgtggctgaatgggtgacaggctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3652,Drugs,MEG_3652|Drugs|betalactams|Class_A_betalactamases|LUT,1028105806|WP_063860831.1|NG_049288|1|1|blaLUT-5|blaLUT|class_A_beta-lactamase_LUT-5 NG_049288:1-891,0
,atggtatttgaaaaaattgataaaaatagttggaacagaaaagagtattttgaccactactttgcaagtgtaccttgtacatacagcatgaccgttaaagtggatatcacacaaataaaggaaaagggaatgaaactatatcctgcaatgctttattatattgcaatgattgtaaaccgccattcagagtttaggacggcaatcaatcaagatggtgaattggggatatatgatgagatgataccaagctatacaatatttcacaatgatactgaaacattttccagcctttggactgagtgtaagtctgactttaaatcatttttagcagattatgaaagtgatacgcaacggtatggaaacaatcatagaatggaaggaaagccaaatgctccggaaaacatttttaatgtatctatgataccgtggtcaaccttcgatggctttaatctgaatttgcagaaaggatatgattatttgattcctatttttactatggggaaaattataaagaaggataacaaaattatacttcctttggcaattcaagttcatcacgcagtatgtgacggatttcacatttgccgttttgtaaacgaattgcaggaattgataatagttactcaggtttgtctgtaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1631,Drugs,MEG_1631|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATP|RequiresSNPConfirmation,1028084265|WP_063843233.1|NG_047622|1|1|catD|catD|type_A-11_chloramphenicol_O-acetyltransferase_CatD NG_047622:91-729,6
,ATGTATAAGCTTAAAATTGCAGTCCTGTTTGGAGGCTGCTCAGAGGAACATGATGTTTCAGTGAAATCTGCGATGGAGGTTGCAGCAAATATAAACAAGGAAAAATACCAGCCGTTTTATATTGGAATCACAAAATCCGGCGCATGGAAACTATGCGATAAGCCCTGCCGGGACTGGGAAAACTATGCGGGATACCCGGCTGTGATTTCTCCGGACAGAAGGACCCATGGCCTGCTGATACAAAAGGATGGCGGATATGAGAGCCAGCCTGTAGACGTGGTGCTTCCGATGATTCATGGAAAATTTGGCGAGGACGGAACCATACAGGGTCTGCTTGAGCTGTCCGGCATTCCTTATGTGGGATGCGACATTCAAAGTTCTGTAACCTGTATGGATAAGTCGCTCGCTTATATGGTTGTGAAAAATGCGGGAATTGAGGTACCTGGGTTTCGAGTTCTACAAAAGGGGGACAGCCTGAAAGCAGAGACACTCTCGTACCCGGTCTTTGTAAAACCTGCCCGTTCCGGCTCCTCTTTTGGCGTGAATAAGGTATGCCGGGCAGAGGAACTGCAGGCAGCGGTCACAGAGGCGGGCAAGTATGACTGCAAAATATTGGTTGAGGAGGCCGTTTCCGGGAGTGAGGTAGGCTGTGCCATACTGGGAAATGAAAATGCTCTCATGGCTGGCGAGGTGGATCAGATTGAGCTGAGACACGGTTTTTTTAAGATTCATCAGGAAGCACAGCCGGAGAAAGGTTCTGAAAATGCAGTTATCAGAGTTCCAGCTGTCTTACCGGATGAGGTAAGAGAACGGATTCAGAAAACAGCAATGAAGATTTACCGGATACTTGGCTGCCGAGGATTGGCTCGTATTGATCTGTTTTTGCGGGAGGACGGCTGCATTGTGCTGAATGAAGTGAATACCATGCCGGGTTTTACTTCCTACAGCCGTTATCCCCGCATGATGACAGCAGCCGGTTTTACGCTTACTGAAATACTGGATCGCTTGATTGAACTTTCACTTAGGAGGTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7388,Drugs,MEG_7388|Drugs|Glycopeptides|VanD-type_resistance_protein|VAND,gi|40021670|gb|AY489045.1|4010-5041,5
,atgaaaaaaataataattgctctactcattttgatagttgcagctgccggcgttggtacatatttttatgcttcaaaagataaaaaaattaatgaaactgttgatgcaattgaagataaaaatttcaaacaagtttataaagatagcacttatcgttctaaaaatgataacggcgaagtagaaatgactgaccgcccgataaaaatttatgaaagtttaggcgttaaagatataaatattcaggatcgtaaaataaagaaagtatctaaaaataaaaagcaagttgatgctcaatataaaatcaaaacaaactacggtaccatcgaccgcaatgttcgatttaatttcgttaaagaagatggtaaatggaaattagattggaatcaaagcgtcattattccagacatgcagaaagatcaaagcattcatatcgaaccagttaagtcggaacgcggtaaaattttagacagaaacaacgtagaattggccaatacaggaacagcacatgagataggcattgttccaacgagtgtgtctaaagaagactataaagcaatcgctcaaaaactaagtatttcagaagatcatattaaccaacaaatgaaccaagattgggttcaagatgatacattcgttccacttaagaccgttaaaacaatggataaagatttaagtgatttcgtaaaaaaacatcatcttacaactaatgaaacagaaagtcgcaactatcctctagaaaaagcgacgtcacatttattaggttatgttggcccaattaactctgaagaattaaagaagaaagaatttaaaggttatgaagatgatgctgtcgttggtaaaaaaggactcgaaaaactttatgataaaaagctccaacataaagatggctatcgtgtcactatcatggacgataatagcaataaagtcgcacatacattagtagagaaaaagaaaaaagatggcaaagatattcaactgactattgatgctaacgttcaaaaaagcatttataacaacatgaaaaatgattatggctcaggtactgctattcacccacaaacaggagaattgttagcacttgtaagcacgccttcatacgacgtatatccatttatgaatggtatgagcgacgaagcatataaaaaattaaccgaagataaaaaagaaccactgctcaacaagttccagatcacaacttcaccaggctcaactcaaaaaatattaacagcaatgattggattaaataacaaaacattagacgatcaaacaaattataagattaatggtaaaggctggcaaaaagataaatcttggggtgattataacgttacaagatatgaagtggtaaatggtaatatcgacttaaaacaagcaatagaatcatcagataacattttctttgctagagtagcactcgaattaggaagtaagcaatttgaaaaaggcatgaaaaaactaggtgttggtgaagacataccaagtgattacccattctataatgcacaaatttcaaacaaagatttagataatgaaatattgttagcagattcaggttacggacaaggtgaaatactgattaacccagtacaaatcctttcaatctatagcgcattagaaaataacggcaatattaacgcaccacacgtattaaaagacacgaaaaacaaagtttggaagaaaaatattatttccgcggaaaatatcaatctattaacagacggcatgcaacaagtcgtaaacaaaacacatagagaagatatttatagaccatacgcaaacttagttggtaaatccggaacagcagaactcaaaatgaaacaaggcgaaacaggcagacagattggttggtttatatcttatgataaagacaatccaaatatgatgatggccattaatgttaaagatgtacaagataaaggcatggcgagttacaacgccaaaatctcaggtaaagtttatgatgacctatacgagaacggtgataaaaaattcgatatagataaataa,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3766,Drugs,MEG_3766|Drugs|betalactams|Penicillin_binding_protein|MECA,1028095812|WP_063852700.1|NG_047952|1|1|mecA2|mecA2|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA2 NG_047952:101-2107,0
,atgatgagaaaaagcgtaagtcgggcgatattaatgacgacagcctgtgtttcgctgctgttggccagtgtgccgctgtatgcccaggcgaacgatattcagcaaaagctggcggcgctggagaaaagcagcgggggacgactgggtgtggcgttgattaacaccgccgataacacgcagacgctctaccgcgccgacgagcgttttgctatgtgcagcaccagtaaagtgatggcggcggcggcggtgcttaagcaaagtgaaacgcaaaaagacttactgagtcagcgggttgaaattaagtcctcagacttgattaactacaacccaatcgctgaaaagcacgtcaatggcacgatgacactcggggagctgagcgcggcggcgctgcagtacagcgataatactgccatgaataagctgattgcccatctcggggggccgggtaaagtgacggcatttgctcgcgtgattggcgatgacactttccggctcgatcgtaccgagccgacgctcaacaccgcgatccccggcgacccgcgcgataccaccacgccgttagcgatggcgcagactctacgcaatctcacattgggcaatgccctgggtgacactcagcgtgcgcagctggtgacgtggctgaaaggcaacaccaccggcgctgccagcattcaggcagggctacccacatcgtgggttgtcggggataaaaccggcagcggcgattatggtacgacgaatgatatcgcggttatttggccggaaggtcgcgcgccgctcgttctggtgacttacttcacccagccgaagccgaaggcagagagccgtcgtgacgtgctcgctgctgccgccagaattgtcaccgacggttattag,beta-lactamase,antibiotic inactivation,betalactams,MEG_2173,Drugs,MEG_2173|Drugs|betalactams|Class_A_betalactamases|CTX,1040476835|WP_065102278.1|NG_050944|1|1|blaCTX-M-185|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-185 NG_050944:1-876,0
,atgaatgtcattataaaagctgtagttactgcctcgacgctactgatggtatcttttagttcattcgaaacctcagcgcaatccccactgttaaaagagcaaattgaatccatagtcattggaaaaaaagccactgtaggcgttgcagtgtgggggcctgacgatctggaacctttactgattaatccttttgaaaaattcccaatgcaaagtgtatttaaattgcatttagctatgttggtactgcatcaggttgatcagggaaagttggatttaaatcagaccgttatcgtaaacagggctaaggttttacagaatacctgggctccgataatgaaagcgtatcagggagacgagtttagtgttccagtgcagcaactgctgcaatactcggtctcgctcagcgataacgtggcctgtgatttgttatttgaactggttggtggaccagctgctttgcatgactatatccagtctatgggtataaaggagaccgctgtggtcgcaaatgaagcgcagatgcacgccgatgatcaggtgcagtatcaaaactggacctcgatgaaaggtgctgcagagatcctgaaaaagtttgagcaaaaaacacagctgtctgaaacctcgcaggctttgttatggaagtggatggtcgaaaccaccacaggaccagagcggttaaaaggtttgttaccagctggtactgtggtcgcacataaaactggtacttcgggtatcaaagccggaaaaactgcggccactaatgatttaggtatcattctgttgcctgatggacggcccttgctggttgctgtttttgtgaaagactcagccgagtcaagccgaaccaatgaagctatcattgcgcaggctgctcagactgcgtatcaatttgaattgaaaaagctttctgccctaagcccaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_5757,Drugs,MEG_5757|Drugs|betalactams|Class_A_betalactamases|PER,1343491215|WP_104009831.1|NG_056387|1|1|blaPER-11|blaPER|class_A_extended-spectrum_beta-lactamase_PER-11 NG_056387:101-1027,0
,atgaaaaaaaacagaaaaaagcaaatcgtagttttgtgtatagctttagtttgcatcttcatcttggtgttctcattgtcccataaatcagctacaaaaggtagcgcgaatcctccattaacagatgttttgactgatagcatttctcagattgtctcggcttgtcctggtgaaattggtgtggcggttattattaataacacagatacggttagtgttaataataaaagcatttatcctatgatgagtgtatttaaggttcatcaggcattagctctttgcaatgattttgacaaaaaaggcctttcccttgataccttggtaaagataaatagggaaaaacttgatccaaagacatggagccctatgatgaaagattattcagcaccagttatatcgttgacagtaagagatctgttgcgctatactctttcccagagcgacaataatgcaagcaatatcatgtttaagaatatgctcaatactgcacaaacagacagttttatagcgaaactcataccacgttcgagttttcagatagcttatacagaagaggaaatgtccgctgaccatgacaaagcttactctaattacacatctcctcttggtgctgcaatgttgatgaatcgtttgtttacagaaagtcttatcagtaatgagaaacaagatttcattaagaatgcattgaaagaatgtaaaacaggtatagataggatagtagctccacttcttgataaagaaggggttgtaatagcacataagacaggttctggtaatgtcaatgaaaatggtattcttgcagctcagaatgatgtagcctatatatgtctgcctaataaggtctgctataccttagctgtatttgttaaggatttcaagggaaatgaatcacaagcgtcacaatttgttgcgcatatatcagcggtagtatattctttattaatcaatactgcgttaaattaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1686,Drugs,MEG_1686|Drugs|betalactams|Class_A_betalactamases|CFX,1469324127|WP_117664257.1|NG_064793|1|1|cfxA6|cfxA6|class_A_broad-spectrum_beta-lactamase_CfxA6 NG_064793:101-1063,0
,atgaaaaatacattattaaaattaggggtatgtgttagtttactaggaataactccatttgttagtacaatttcttctgtacaagcagaacgaaaggtagagcataaagtaataaaaaatgagacaggaactatttcaatttctcagttaaacaaaaatgtttgggttcatacggagttaggttattttaacggagaagcagttccttcgaacggtttaatccttaatacttctaaaggattagtacttgtcgattcttcttgggatgataagttaacgaaggaattaatagagatggcagaaaagaaatttaagaagagtgtaacggatgttattattacacatgcacacgctgatcggattggtggaataaaaacgttgaaagaaagaggcattaaagcgcatagtacaacgttaactgcggaactagcaaagaaaaatggatatgaagaaccacttggagacttacaagcaattacgaaattgaagtttggaaatatgaaagtagaaacgttttatccagggaaaggacatacagaagataatatcgtcgtatggttaccacaatacaacatgttagttggaggctgtttagtgaagtctgcgtccgcgaaagatttaggaaatattactgatgcttatgtaaatgaatggtctacatcgattgagaatgtgctgaagcgatatgaaaatataaattttgtagtacctggtcatggagaagtaggggacaaaggattacttttacatacattggatttgttaaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1204,Drugs,MEG_1204|Drugs|betalactams|Class_B_betalactamases|BCII,446721910|WP_000799223.1|NG_047220|1|1|BcII|BcII|BcII_family_subclass_B1_metallo-beta-lactamase NG_047220:101-871,0
,atgagaaattttgttacactattttttctgttagtttgtttgagcttgaatgctcaggtcgtaaaagaacctgagaatatgccaaaagaatggaaccagacttatgaaccattcagaattgcaggtaatttatattacgtaggaacctatgatttggcgtcctaccttattgtgacagacaaaggcaatattctcattaatacaggaacggcagaatcatttccaataataaaaggaaatattcaaaagctggggtttaattataaagacattaagatcttgctgcttactcaggctcattatgaccatacaggcgcgttacaggattttaaaacggaaaccggtgcgaaattttatgccgataaagcagatgctgatgtcctgagaacaggcggaaaatctgattatgaattaggtaaatatggtgtgacatttaaacctgttaccccagacaaaacattgaaggatcaggataaaataacattgggaaatacaaccctgactttgcttcaccatccgggacatacaaaaggttcctgcagttttatttttgaaacaaaagatgaaaacaggaaatacaagattttaatagctaatatgccttccattattgttgataagaaattttctgaagttacagcatatccaggtattcagtccgattacgcatatactttcaaagcgatgaagaatctggattttgatatctgggttgcctcgcatgcaagtcagttcgatttgcataccaaacgcaaagaaggtgactcttacaatccacagttgtttatggataaagagaattattttaaaaggctcgagcgtttggaaaataattattttgaaaagattaaagaagattcaaaggataaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3145,Drugs,MEG_3145|Drugs|betalactams|Class_B_betalactamases|GOB,736866358|WP_034866180.1|NG_050655|1|1|blaGOB-7|blaGOB|subclass_B3_metallo-beta-lactamase_GOB-7 NG_050655:101-973,0
,atgaccaactattttgaaagtccatttaaaggcaaactgctggccgaccaggtaaagaacccgaacatcaaagtcggacggtatagctattattccggctattaccatggccattcgtttgacgagtgcgctcgctttctcttgccagatcgcaatgacatcgaccaactgatcgttggtagcttctgttccatcggcacgggcgcctccttcatcatggccggaaatcaggggcaccgttatgactgggcgtcttcttttcccttcttctacatgaaagaggagccagcattctcgggcgcacttgatgcattccaaaaagccggtgacacagtcatcggaagtgatgtctggataggctctgaggccatgatcatgcccggcatcaacgtcggtcatggcgctgtgattggaagccgcgctttggtcacgaaagatgtggagccgtacactatcgttggcggaaatcccgccaaaccgatcaagaaacgcttctccgacgaggagatcgccatgcttttgaaaatgaattggtgggattggccaactgaaaaaattgaggaagcaatgcctttgctatgctcatccaacatcgttgggctgcatcgatactggcaaggctttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1617,Drugs,MEG_1617|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,730732758|WP_034085125.1|NG_052134|1|1|catB10|catB10|type_B_chloramphenicol_O-acetyltransferase_CatB10 NG_052134:101-733,6
,CTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGAATTGTCGCCCTGCTTGGCCCGGATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCC,beta-lactamase,antibiotic inactivation,betalactams,MEG_6340,Drugs,MEG_6340|Drugs|betalactams|Class_A_betalactamases|SHV,gb|EU477409|+|0-308|ARO:3001161|SHV-112 [Klebsiella pneumoniae] Partial,0
,CGCACAATAAGGCTCCTTGCAGAGTTGCTTGAAAGTTGTTACGATTCAAATTCAATCATGAGATAGTCAGCAGATGAGCACTTCCAAGAACGCAGACAAGTAAGCCGCAGCAACCTCATTTTTCGGTTGTTGCGGCGTTCTCATGAATCCTTTTGCTCTACGGGAGCGCCGCCAAATCCTTTGTTCAAGGAGATGGTTTCGTGAGCTCAAAAAACTTTAGTTGGCGGTACTCCCTTGCCGCCACGGTGTTGTTGTTATCACCGTTCGATTTATTGGCATCACTCGGCATGGACATGTACTTGCCAGCAGTGCCGTTTATGCCAAACGCGCTTGGTACGACAGCGAGCACAATTCAGCTTACGCTGACAACGTACTTGGTCATGATTGGTGCCGGTCAGCTCTTGTTTGGACCGCTATCGGACCGACTGGGGCGCCGCCCCGTTCTACTGGGAGGTGGCCTCGCAAACGTTGTGGCGTCAATGGGCCTCGCTCTTACGTCATCGGCTGAAGTCTTTCTGGGGCTTCGGATTCTTCAGGCTTGTGGTGCCTCGGCGTGCCTTGTTTCCACATTTGCAACAGTACGTGACATTTACGCAGGTCGCGAGGAAAGTAATGTCATTTACGGCATACTCGGATCCATGCTGGCCATGGTCCCGGCGGTAGGCCCATTGCTCGGAGCGCTCGTCGACATGTGGCTTGGGTGGCGGGCTATCTTTGCGTTTCTAGGTTTGGGCATGATCGCTGCATCTGCAGCAGCGTGGCGATTCTGGCCTGAAACCCGGGTGCAACGAGTTGCGGGCTTGCAATGGTCGCAGCTGCTACTCCCCGTTAAGTGCCTGAACTTCTGGTTGTACACGTTGTGTTACGCCGCTGGAATGGGTAGCTTCTTCGTCTTTTTCTCCATTGCGCCCGGACTAATGATGGGCAGGCAAGGTGTGTCTCAGCTTGGCTTCAGCCTGCTGTTCGCCACAGTGGCAATTGCCATGGTGTTTACGGCTCGTTTTATGGGGCGTGTGATACCCAAGTGGGGCAGCCCAAGTGTCTTGCGAATGGGAATGGGATGCCTGATAGCTGGAGCAGTATTGCTTGCCATCACCGAAATATGGGCTTTGCAGTCCGTGTTAGGCTTTATTGCTCCAATGTGGCTAGTGGGTATTGGTGTCGCCACAGCGGTATCTGTGGCGCCCAATGGCGCTCTTCGAGGATTCGACCATGTTGCTGGAACGGTCACGGCAGTCTACTTCTGCTTGGGCGGTGTACTGCTAGGAAGCATCGGAACGTTGATCATTTCGCTGTTGCCGCGCAACACGGCTTGGCCGGTTGTCGTGTACTGTTTGACCCTTGCAACAGTCGTGCTCGGTCTGTCTTGTGTTTCCCGAGTGAAGGGCTCTCGCGGCCAGGGGGAGCATGATGTGGTCGCGCTACAAAGTGCGGGAAGTACATCAAATCCCAATCGTTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Phenicol,MEG_1768,Drugs,MEG_1768|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA,gi|114421723|emb|AJ487033.2|1399-2858,6
,atgaaaattattaatattggagttttagctcatgttgatgcaggaaaaactaccttaacagaaagcttattatataacagtggagcgattacagaattaggaagcgtggacaaaggtacaacgaggacggataatacgcttttagaacgtcagagaggaattacaattcagacaggaataacctcttttcagtgggaaaatacgaaggtgaacatcatagacacgccaggacatatggatttcttagcagaagtatatcgttcattatcagttttagatggggcaattctactgatttctgcaaaagatggcgtacaagcacaaactcgtatattatttcatgcacttaggaaaatggggattcccacaatcttttttatcaataagattgaccaaaatggaattgatttatcaacggtttatcaggatattaaagagaaactttctgccgaaattgtaatcaaacagaaggtagaactgtatcctaatatgtgtgtgacgaactttaccgaatctgaacaatgggatacggtaatagagggaaacgatgaccttttagagaaatatatgtccggtaaatcattagaagcattggaactcgaacaagaggaaagcataagatttcagaattgttctctgttccctctttatcatggaagtgcaaaaagtaatatagggattgataaccttatagaagttattactaataaattttattcatcaacacatcgaggtccgtctgaactttgcggaaatgttttcaaaattgaatatacaaaaaaaagacaacgtcttgcatatatacgcctttatagtggagtactacatttacgagattcggttagagtatcagaaaaggaaaaaataaaagttacagaaatgtatacttcaataaatggtgaattatgtaagattgatagagcttattctggagaaattgttattttgcataatgagtttttgaagttaaatagtgttcgtggagatacaaaactattgccacagagaaaaaagattgaaaatccgcaccctctactacaaacaactgttgaaccgagtaaacctgaacagagagaaatgttgcttgatgcccttttggaaatctcagatagtgatccgcttctacgatattacgtggattctacgacacatgaaattatactttctttcttagggaaagtacaaatggaagtgattagtgcactgttgcaagaaaagtatcatgtggagatagaaataacagagcctacagtcatttatatggagagaccgttaaaaaatgcagaatataccattcacatcgaagtgccgccaaatcctttctgggcttccattggtctatctgtatcaccgcttccgttgggaagtggaatgcagtatgagagctcggtttctcttggatacttaaatcaatcgtttcaaaatgcagttatggaggggatacgctatggctgtgaacaaggattgtatggttggaatgtgacggactgtaaaatctgttttaagtatggcttatactatagccctgttagtaccccagcagattttcggatgcttgctcctattgtattggaacaagtcttaaaaaaagctggaacagaattgttagagccatatcttagttttaaaatttatgcgccacaggaatatctttcacgagcatacaacgatgctcctaaatattgtgcgaacatcgtagacactcaattgaaaaataatgaggtcattcttagtggagaaattcctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7127,Drugs,MEG_7127|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETM,1028100159|WP_063856390.1|NG_048226|1|1|tet(M)|tet(M)|tetracycline_resistance_ribosomal_protection_protein_Tet(M) NG_048226:101-2020,4
,atgcgcttcattcacgcactattactggcagggatcgctcactctgcatatgcgtcggaaaaattaaccttcaagaccgatcttgagaagctagagcgcgaaaaagcagctcagatcggtgttgcgatcgtcgatccccaaggagagatcgtcgcgggccaccgaatggcgcagcgttttgcaatgtgctcaacgttcaagtttccgctagccgcgctggtctttgaaagaattgactcaggcaccgagcggggggatcgaaaactttcatatgggccggacatgatcgtcaaatggtctcctgccacggagcggtttctagcatcgggacacatgacggttctcgaggcagcgcaagctgcggtgcagcttagcgacaatggggctactaacctcttactgagagaaattggcggacctgctgcaatgacgcagtattttcgtaaaattggcgactctgtgagtcggctagaccggaaagagccggagatgagcgacaacacacctggcgacctcagagatacaactacgcctattgctatggcacgtactgtggctaaagtcctctatggcggcgcactgacgtccacctcgacccacaccattgagaggtggctgatcggaaaccaaacgggagacgcgacactacgagcgggttttcctaaagattgggttgttggagagaaaactggtgcctgcgccaacgggggccggaacgacattggtttttttaaagcccaggagagagattacgctgtagcggtgtatacaacggccccgaaactatcggccgtagaacgtgacgaattagttgcctctgtcggtcaagttattacacaactcatcctgagcacggacaaatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_3088,Drugs,MEG_3088|Drugs|betalactams|Class_A_betalactamases|GES,1188444917|WP_085562419.1|NG_054709|1|1|blaGES-33|blaGES|class_A_beta-lactamase_GES-33 NG_054709:1-864,0
,atgttcaaaacgacgctctgcgccttattaattaccgcctcttgctccacatttgctgcccctcaacaaatcaacgatattgtgcatcgcacaattaccccgcttatagagcaacaaaagatccccggtatggcggtggcggtaatttatcagggtaaaccttattactttacctggggctatgcggacatcgccaaaaagcagcccgtcacacagcaaacgttgtttgagttaggttcggtcagcaaaacatttacgggcgtgcttggtggcgacgctattgctcgaggggaaatcaagttaagcgatcccgcaacaaaatactggcctgaacttaccgctaaacagtggaatgggatcacactattacatcttgcgacctacaccgctggcggcctgccattgcaggtgccggatgaagtgaaatcctcaagcgacttgctgcgcttctatcaaaactggcagcctgcatgggctccaggaacacaacgtctgtatgccaactccagtatcggtttgttcggcgcactggctgtgaagccgtctggtttgagttttgagcaggcgatgcaaactcgtgtcttccagccactcaaactcaaccatacgtggattaatgtacctcccccagaagaaaagaattacgcctggggatatcgcgaaggtaaggcagtgcatgtttcgccaggggcgttagatgctgaagcttatggtgtgaagtcgaccattgaagatatggcccgctgggtacgaagcaatatgaatccccgtgatatcaacgacaaaacacttcagcaagggatacaactggcacaatctcgctactggcaaaccggcgatatgtatcagggcctgggctgggaaatgctggactggccggtaaatcctgacagcatcattaacggcagtggcaataaaattgcactggcagcaccccctgtaaaagcgattacgcccccaactcctgcagtacgcgcatcatgggtacataaaacaggggcaaccggcggatttggtagctatgtcgcgtttattccagaaaaagagctgggtatagtgatgctggctaacaaaaactatcccaatccagcgagagtcgccgccgcctggcagattctcaacgctctacagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1282,Drugs,MEG_1282|Drugs|betalactams|Class_C_betalactamases|BLAEC,1027667609|WP_063610930.1|NG_049081|1|1|blaEC-15|blaEC|class_C_extended-spectrum_beta-lactamase_EC-15 NG_049081:101-1234,0
,GTGAAACCCAACAGACCCCTGATCGTAATTCTGAGCACTGTCGCGCTCGACGCTGTCGGCATCGGCCTGATTATGCCGGTGCTGCCGGGCCTCCTGCGCGATCTGGTTCACTCGAACGACGTCACCGCCCACTATGGCATTCTGCTGGCGCTGTATGCGTTGATGCAATTTGCCTGCGCACCTGTGCTGGGCGCGCTGTCGGATCGTTTCGGGCGGCGGCCGGTCTTGCTCGTCTCGCTGGCCGGCGCTGCTGTCGACTACGCCATCATGGCGACGGCGCCTTTCCTTTGGGTTCTCTATATCGGGCGGATCGTGGCCGGCATCACCGGGGCGACTGGGGCGGTAGCCGGCGCTTATATTGCCGATATCACTGATGGCGATGAGCGCGCGCGGCACTTCGGCTTCATGAGCGCCTGTTTCGGGTTCGGGATGGTCGCGGGACCTGTGCTCGGTGGGCTGATGGGCGGTTTCTCCCCCCACGCTCCGTTCTTCGCCGCGGCAGCCTTGAACGGCCTCAATTTCCTGACGGGCTGTTTCCTTTTGCCGGAGTCGCACATTGGCGAACGCCGGCCGTTACGCCGGGAGGCTCTCAACCCGCTCGCTTCGTTCCGGTGGGCCCGGGGCATGACCGTCGTCGCCGCCCTGATGGCGGTCTTCTTCATCATGCAACTTGTCGGACAGGTGCCGGCCGCGCTTTGGGTCATTTTCGGCGAGGATCGCTTTCACTGGGACGCGACCACGATCGGCATTTCGCTTGCCGCATTTGGCATTCTGCATTCACTCGCCCAGGCAATGATCACCGGCCCTGTAGCCGCCCGGCTCGGCGAAAGGCGGGCACTCATGCTCGGAATGATTGCCGACGGCACAGGCTACATCCTGCTTGCTTTCGCGACACGGGGATGGATGGCGTTCCCGATCATGGTCCTGCTTGCTTCGGGTGGCATCGGAATGCCGGCGCTGCAAGCAATGTTGTCCAGGCAGGTGGATGAGGAACGTCAGGGGCAGCTGCAAGGCTCACTGGCGGCGCTCACCAGCCTGACCTCGATCGTCGGACCCCTCCTCTTCACGGCGATCTATGCGGCTTCTATAACAACGTGGAACGGGTGGGCATGGATTGCAGGCGCTGCCCTCTACTTGCTCTGCCTGCCGGCGCTGCGTCGCGGGCTTTGGAGCGGCGCAGGGCAACGAGCCGATCGCTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7028,Drugs,MEG_7028|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETA,gi|16945309|emb|AJ419171.1|2832-4031,4
,ATGAGCAACTCTATACACACCGGAATCTCAAGACAGCTTTCACAGGCACGCGATGTAATTAAACGCCATTTGGCATCAACGCTGAAAGCCATACACTTGTATGGTTCTGCAATTGATGGTGGCCTCAAACCATATAGCGACATTGATCTGCTGGTTACCGTGGATGCACGCTTGGATGAAGCTACCAGACGCTCCCTGATGCTCGATTTCTTGAATATCTCGGCACCACCATGCGAAAGCTCAATACTCCGGCCGCTAGAGGTAACTGTTGTTGCATGCAACGAAGTAGTGCCTTGGCGTTATCCGGCACGACGAGAACTGCAGTTCGGGGAGTGGCTGCGGGAGGATATTCTTGAAGGTGTCTTCGAGCCAGCCGCCTTGGACGCCGACCTTGCAATTCTAATAACGAAAGCTAGGCAACACAGCATCGCTTTAGTAGGTCCAGTGGCTCAAAAAGTCTTCATGCCGGTGCCAGAGCATGACTTTCTCCAGGTGCTTTCCGATACCCTTAAGCTGTGGAATACTCATGAGGATTGGGAAAATGAGGAGCGGAACATCGTACTCACGTTAGCTCGGATCTGGTATAGCACTGAAACTGGAGGAATCGTCCCCAAGGATGTGGCCGCCGAATGGGTTTTAGAGCGCTTGCCAGCTGAGCATAAGCCAATACTGGTTGAGGCGCGGCAAGCCTATCTTGGGCTTTGCAAGGATAGTCTTGCTTTGCGTGCAGATGAGACTTCGGCGTTCATTGGCTATGCAAAGTCTGCGGTCGCTGATTTGCTCGAAAAGCGAAAATCTCAAACTTCGCATATTTGCGATGGCGCCAAGAACGTCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_924,Drugs,MEG_924|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,(AGly)AadA9:AJ420072:26773-27609:837,2
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacagttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacaacaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1816,Drugs,MEG_1816|Drugs|betalactams|Class_C_betalactamases|CMY,1132963063|WP_075985683.1|NG_052648|1|1|blaCMY-146|blaCMY|class_C_beta-lactamase_CMY-146 NG_052648:1-1146,0
,atgaaaataatcaatattggaattcttgcccatgtagacgctggaaagacgaccttgacggagagcctgctatatgccagcggagccatttcagaaccggggagcgtcgaaaaagggacaacgaggacggacaccatgtttttggagcggcagcgtgggattaccattcaagcggcagtcacttccttccagtggcacagatgtaaagtcaacattgtggatacgcccggccacatggattttttggcggaggtgtaccgctctttggctgttttagatggggccatcttggtgatctccgctaaagatggcgtgcaggcccagacccgtattctgttccatgccctgcggaaaatgaacattcccaccgttatctttatcaacaagatcgaccaggctggcgttgatttgcagagcgtggttcagtctgttcgggataagctctccgccgatattatcatcaagcagacggtgtcgctgtccccggaaatagtcctggaggaaaataccgacatagaagcatgggatgcggtcatcgaaaataacgataaattattggaaaagtatatcgcaggagaaccaatcagccgggaaaaacttgtgcgggaggaacagcggcgggttcaagacgcctccctgttcccggtctattatggcagcgccaaaaagggccttggcattcaaccgttgatggatgcggtgacagggctgttccaaccgattggggaacaggggagcgccgccctatgcggcagcgttttcaaggtggagtatacagattgcggccagcggcgtgtctatctacggctatacagcggaacgctgcgcctgcgggatacggtggccctggccgggagagaaaagctgaaaatcacagagatgcgtattccatccaaaggggaaattgttcggacagacaccgcttatccgggtgaaattgttatccttcccagcgacagcgtgaggttaaacgatgtattaggggacccaacccggctccctcgtaaaaggtggcgtgaggaccccctccccatgctgcggacgtcgattgcgccgaaaacggcagcgcaaagagaacggctgctggacgctcttacgcaacttgcggatactgacccgcttttgcgctgcgaggtggattccatcacccatgagatcattctttcttttttgggccgggtgcagttggaggttgtttccgctttgctgtcggaaaaatacaagcttgaaacagtggtaaaggaacccaccgtcatttatatggagcggccgctcaaagcagccagccacaccatccatatcgaggtgccgcccaacccgttttgggcatccataggactgtctgttacaccactctcgcttggctccggtgtacaatacgagagccgggtttcgctgggatacttgaaccagagttttcaaaacgctgtcagggatggtatccgttacgggctggagcagggcttgttcggctggaacgtaacggactgtaagatttgctttgaatacgggctttattacagtccggtcagcacgccggcggacttccgctcattggccccgattgtattggaacaggcattgaaggaatcagggacgcaactgctggaaccttatctctccttcaccctctatgcgccccgggaatatctttccagggcttatcatgatgcaccgaaatactgtgccaccatcgaaacggtccaggtaaaaaaggatgaagttgtctttactggcgagattcccgcccgctgtatacaggcataccgtactgatctggccttttacaccaacgggcggagcgtatgccttacagagctgaaaggatatcaggccgctgtcggtcagccggtcatccagccccgccgtccaaacagccgcctggacaaggtgcgccatatgtttcagaaggtaatgtaa,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7216,Drugs,MEG_7216|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETW,1028100283|WP_063856418.1|NG_048290|1|1|tet(W)|tet(W)|tetracycline_resistance_ribosomal_protection_protein_Tet(W) NG_048290:101-2020,4
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgtctgctaatccaaatcacagtgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtaaacccacaagtaggctggttaactggatgggttgttcagcctcatgggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4713,Drugs,MEG_4713|Drugs|betalactams|Class_D_betalactamases|OXA,1188444909|WP_085562411.1|NG_054701|1|1|blaOXA-557|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-557 NG_054701:1-825,0
,atgatgaaaaaatcgttatgctgcgcgctgctgctgacagcctctttccccacgtttgctgccgcaaaaacagaacaacaaattgccgatatcgttaaccgcaccatcacaccactgatgcaggagcaggctattccgggtatggccgtggcgattatctacgaggggaaaccttattactttacctggggtaaagccgatatcgccaataaacacccagtcacgcagcaaacgctgtttgagctagggtcggtcagtaagacgtttaacggcgtgttgggcggcgacgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcggggtatcagcctgctgcacttagccacctatacagcgggtggcctgccgctgcagatccccgatgacgttacggataaagccgaattactgcgcttttatcaaaactggcaaccacaatggactccgggcgctaagcgtctttacgctaactccagcattggtctgtttggtgcgctggtggtaaaaccttcaggtatgagctacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcaaagcgaacaaaaaaattatgcctggggctatcgcgaagggaagcctgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttatcgatatggcccgctgggttcaggccaacatggacgccagccacgttcaggagaaaacgctccagcagggcattgagcttgcgcagtctcgctactggcgtattggtgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgccagtacctgccgtgaaagcctcatgggtgcataaaacgggatccacaggtggatttggcagctacgttgccttcgttccagaaaaaaaccttggcatagtgatgctggcaaacaaaagctatcctaaccctgtccgcgtcgaggcggcctggcgcattcttgaaaaactgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1807,Drugs,MEG_1807|Drugs|betalactams|Class_C_betalactamases|CMY,1028104570|WP_063859891.1|NG_048886|1|1|blaCMY-89|blaCMY|class_C_beta-lactamase_CMY-89 NG_048886:1-1146,0
,atggctctggcactcgttggcgaaaaaattgacagaaaccgcttcaccggtgagaaaattgaaaatagtacattttttaactgtgatttttcaggtgccgacctgagcggcactgaatttatcggctgtcagttctatgatcgtgaaagccagaaagggtgcaattttagtcgtgcgatgctgaaagatgccatttttaaaagctgtgatttatccatggcggattttcgcaatgccagtgcgcttggcattgaaattcgccactgtcgtgcgcaaggcgcagatttccgcggcgcaagctttatgaatatgatcactactcgcacctggttttgcagcgcatatatcactaacacaaatctaagctacgccaatttttcgaaagtcgtgttggaaaaatgtgagctgtgggaaaaccgttggatgggtgcccaggtactgggcgcgacgttcagtggttcagatcttgccggcggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttgggtgacttagatattcggggcgttgatttacaaggcgttaagttggacaactaccaggcatcgctgctcatggaacgtcttggcatcgcggtaattggttaa,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5890,Drugs,MEG_5890|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028111891|WP_063866099.1|NG_050506|1|1|qnrB43|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB43 NG_050506:37-681,3
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactactaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtgggatggtaaaaaaaggttattcccagaatgggaaaaggacatgaccctaggcgatgccatgaaagcttccgctattccagtttatcaagatttagctcgtcgtattggacttgagctcatgtctaaggaagtgaagcgtgttggttatggcaatacagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacagtttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttgggggtgggatgtaaacccacaagtaggctggttaactggatggattgttcagcctcaagggaatattgtagcgttctcctttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4443,Drugs,MEG_4443|Drugs|betalactams|Class_D_betalactamases|OXA,1559613001|WP_128268266.1|NG_063871|1|1|blaOXA-767|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-767 NG_063871:37-861,0
,ATGACCAAACTGGACAAGGGCACCGTGATCGCGGCGGGCCTAGAGCTGTTGAACGAGGTTGGCATGGACAGCCTGACGACGCGGAAGCTCGCTGAACGCCTCAAGGTTCAGCAGCCTGCGCTTTACTGGCATTTCCAGAACAAACGAGCGCTGCTTGATGCGCTGCCCGAGGCGATGCTGCGGGAACGCCATACCCGCTCGCTACCCGAAGAGAATGAGGACTGGCGGGTGTTCCTGAAAGAGAATGCCCTGAGCTTCAGAACGGCGTTGCTCTCTTATCGGGACGGCGCGCGTATCCATGCCGGCACTCGACCGACAGAACCGAATTTTGGCACCGCCGAGACGCAAATACGCTTTCTCTGCGCGGAGGGCTTTTGTCCGAAGCGCGCCGTTTGGGCGCTCCGGGCGGTCAGTCACTATGTGGTCGGTTCCGTTCTCGAGCAGCAGGCATCTGATGCCGATGAGAGAGTTCCGGACAGGCCAGATGTGTCCGAGCAAGCACCGTCGTCCTTCCTGCACGTACTGTTTCACGAGTTGGAAACAGACGGCATGGATGCTGCGTTCAACTTCGGACTCGACAGCCTCATCGCTGGTTTCGAGCGGCTGCGTGCTGCAGTGCTAGCGACAGATTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic target alteration,Tetracyclines,MEG_7186,Drugs,MEG_7186|Drugs|Tetracyclines|Tetracycline_transcriptional_repressor|TETR,(Tet)TetR(G):S52438:113-745:633,4
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgttcaccttatatagtgactgctaatccaaatcacagcacttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4481,Drugs,MEG_4481|Drugs|betalactams|Class_D_betalactamases|OXA,1559612999|WP_128268264.1|NG_063869|1|1|blaOXA-765|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-765 NG_063869:14-838,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggtctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccaatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcagccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5633,Drugs,MEG_5633|Drugs|betalactams|Class_C_betalactamases|PDC,518315006|WP_019485213.1|NG_049886|1|1|blaPDC-16|blaPDC|class_C_beta-lactamase_PDC-16 NG_049886:1-1194,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctagccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5461,Drugs,MEG_5461|Drugs|betalactams|Class_C_betalactamases|PDC,514414236|WP_016562272.1|NG_049903|1|1|blaPDC-31|blaPDC|class_C_beta-lactamase_PDC-31 NG_049903:1-1194,0
,ATGAGCGAAAAAAATACTGCGGCGCGTTTAACGCGTGAAACGGTCCTGCGCGGGGCGCTGGCGTTACTGGATGACATCGGCATCGATGCCCTGAGCACCCGCCGCCTGGCGCAGCATCTGGGCGTGCAATCCCCCACGCTCTATTGGCACTTCAAAAACAAGGCCGAGCTGCTGAAGGCGATGGCGGAAACCATCATGTTGGACCACCGCGAAGAGGTGCCCGCCGACATGCCCTGGCAGGCCTGGGTGACCGCCAATGCGATCAATTTCCGCCGCGCGTTGCTGGCTTACCGCGACGGGGCGCGCCTGCACGCCGGCACCCGGCCGCAGGAACCGCAATTCGCCATCATCGAGGCCAAGGTGGCGCTGCTGTGCCGGGCGGGCTTTACGCCGGAACACGCCGTTAATCTGCTGTTCGCCGTCGGGCGTTTTGTGGTGGGTTGGGTGCTGGAAGAGCAGCAAATGCAGCCCGATGATGCGCTGAACGAAGCCGATCGCCGGCGCTACCCGCTGCTGTGTGGAGGCTGGGAAAAGCTGCAGGACAAGGGGGCAGACGCGTTGTTCGAAGCCGGCCTCCGGCTGTTGGTTGACGGCGCCGAGGCCGCGTTGACGAACGCCAATAATCACGGCGCGCAATCATAA,tetR,antibiotic target alteration,Tetracyclines,MEG_7187,Drugs,MEG_7187|Drugs|Tetracyclines|Tetracycline_transcriptional_repressor|TETR,gi|117380087|gb|AY264780.2|3071-3712,4
,atgaaaaagataaaaattgttccactcattttaatagttgcagctgccggcgttggtacatatttttatgcttcaaaagataaaaaaattaatgaaactgttgatgcaattgaagataaaaatttcaaacaagtttataaagatagcacttatcgttctaaaaatgataacggcgaagtagaaatgactgaccgcccgataaaaatttatgaaagtttaggcgttaaagatataaatattcaggatcgtaaaataaagaaagtatctaaaaataaaaagcaagttgatgctcaatataaactcaaaacaaactacggtaccatcgaccgcaatgttcgatttaatttcgttaaagaagatggtaaatggaaattagattggaatcaaagcgtcattattccagacatgcagaaagatcaaagcattcatatcgaaccagttaagtcggaacgcggtaaaattttagacagaaacaacgtagaattggccaatacaggaacagcacatgagataggcattgttccaacgagtgtgtctaaagaagactataaagcaatcgctcaaaaactaagtatttcagaaggtcatattaaccaacaaatgaaccaagattgggttcaagatgatacattcgttccacttaagaccgttaaaacaatggataaagatttaagtgatttcgtaaaaaaacatcatcttacaactaatgaaacagaaagtcgcaactatcctctagaaaaagcgacgtcacatttattaggttatgttggcccaattaactctgaagaattaaagaagaaagaatttaaaggttatgaagatgatgctgtcgttggtaaaaaaggactcgaaaaactttatgataaaaagctccaacataaagatggctatcgtgtcactatcatggacgataatagcaataaagtcgcacatacattagtagagaaaaagaaaaaagatggcaaagatattcaactgactattgatgctaacgttcaaaaaagcatttataacaacatgaaaaatgattatggctcaggtactgctattcacccacaaacaggagaattgttagcacttgtaagcacgccttcatacgacgtatatccatttatgaatggtatgagcgacgaagcatataaaaaattaaccgaagataaaaaagaaccactgctcaacaagttccagatcacaacttcaccaggctcaactcaaaaaatattaacagcaatgattggattaaataacaaaacattagacgatcaaacaaattataagattaatggtaaaggctggcaaaaagataaatcttggggtgattataacgttacaagatatgaagtggtaaatggtaatatcgacttaaaacaagcaatagaatcatcagataacattttctttgctagagtagcactcgaattaggaagtaagcaatttgaaaaaggcatgaaaaaactaggtgttggtgaagacataccaagtgattacccattctataatgcacaaatttcaaacaaagatttagataatgaaatattgttagcagattcaggttacggacaaggtgaaatactgattaacccagtacaaatcctttcaatctatagcgcattagaaaataacggcaatattagcgcaccacacgtattaaaagacacgaaaaacaaagtttggaagaaaaatattatttccgaggaaaatatcaatctattaacagacggcatgcaacaagtcgtaaacaaaacacatagagaagatatttatagaccatacgcaaacttagttggtaaatccggaacagcagaactcaaaatgaaacaaggcgaaacaggcagacagattggttggtttatatcttatgataaagacaatccaaatatgatgatggccattaatgttaaagatgtacaagataaaggcatggcgagttacaacgccaaaatctcaggtaaagtttatgatgacctatacgagaacggtaataaaaaatacgatatagatgaataa,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3769,Drugs,MEG_3769|Drugs|betalactams|Penicillin_binding_protein|MECA,1028095806|WP_063852694.1|NG_047951|1|1|mecA2|mecA2|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA2 NG_047951:1-2007,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5632,Drugs,MEG_5632|Drugs|betalactams|Class_C_betalactamases|PDC,896379876|WP_049321692.1|NG_055487|1|1|blaPDC-123|blaPDC|class_C_beta-lactamase_PDC-123 NG_055487:1-1194,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAGCAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1397,Drugs,MEG_1397|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_38_NZ_JEMM01000040,0
,atgttcaaatttttgagtaagttattggtctatttgaccgcgtctatcatggctattgcgagtccgctcgctttttccgtagattctagcggtgagtatccgacagtcagcgaaattccggtcggggaggtccggctttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcagtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgagaagcaaattggacttcctgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagccgaggtagaggggaacgagattcccacgcactctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagaactcttctatcctggtgctgcgcattcgaccgacaacttagttgtgtacgtcccgtctgcgagtgtgctctatggtggttgtgcgatttatgagttgtcacgcacgtctgcggggggcgtggccgatgccgatctggctgaatggcccacctccattgagcggattcaacaacactacccggaagcacagttcgtcattccggggcacggcctgccgggcggtctagacttgctcaagcacacaacgaatgttgtaaaagcgcacacaaatcgctcagtcgttgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7718,Drugs,MEG_7718|Drugs|betalactams|Class_B_betalactamases|VIM,1409436280|WP_111772163.1|NG_060588|1|1|blaVIM-58|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-58 NG_060588:1-801,0
,ttgaaaattattaatatcggtatcttagcacatgttgatgcaggaaaaactactttgacagaaagcttactatacagtagcggagcaattaaagagttaggaagtgtagatagcggtacaacgaaaacggatactatgtttttggaacgccagagaggtattactattcagaccgcaataacatcttttcaacgggaaaatgttaaagtaaatattgtagatactcctggacacatggattttttggcagatgtataccgttcattatctgttttggatggagctattttgctaatctctgcaaaagatggagtacagtcacaaactcgtatactattccatgcacttagaaagatgaacatacctataatattttttattaacaaaattgatcaaaatggaataaatttgccagatgtttatcaagatattaaggacaaactttctgacgacatcataattaagcagactgtgaatctaaatttgaaaccttatgtaatagattatactgaaccagaacaatgggagacagtaattgtgggaaatgattatttattagaaaaatataccattgggaaaacattgaatattgcagaacttgaaaaggaggaaaacgaaagaattcaaagttgctccttatatcctgtttatcacggaagtgcaaagaataatattggaattaaacaacttatagaggtaattactagcaaattattttcacccacacaactcaattcagataaactttgtggaaatgtttttaaagtagaatattcagatgatggtcaacggcttgtctatgtacgtctttatagtggaacgctacatttgcgagactcagtcaatatatcagaaaaggaaaaaataaaagttacagaaatgtatacttcaataaatggagaattacgccagatagataaggcagagcctggtgagattattattttaaaaaatgagcttttaaaactaaataacgtacttggagataaaaaaagattaccacatagagaaattcttgagaatcctcttcctatgttacaaacaacaattgaaccatgtaaatcagtacaaagagaaaagttactagatgcactttttgaaatatccgatagtgatccccttctacaatattatgtagatacagtaactcacgaaattgtgctatcttttttaggtgaggtccaaatggaggtaacttgtactctgattcaagaaaaatatcatattgagatagaaacaagaaaaccaactgtcatttatatggaaagaccattaaaaaaatctgaatttaccattgatatcgaagtacctccaaatcctttctgggcttctattggtttatctgtaacaccacttcctttgggtagtggcattcagtatgagagcctggtttctctaggttatttaaatcaatcatttcaaaatgcagttatggaaggtatacgctatgggtgtgaacaaggattgtacggttggaaattaacagactgtaagatctgttttaagtatggtctatattacagccctgtcagtacgccagcagatttccgaatgcttgcgcctattgtactagagcaggcttttagaaagagtggtacagagttattagagccatatcttagcttcgaaatttatgtaccacaagaatatctttcgagagcatataatgatgcttccaaatattgtgcaaatattttaaatactaagttaaaaggtaacgaggtcattctcattggtgaaatccctgctcggtgtattcaagaatatcgtagtgatttaactttctttacaaatggacgtagtgtttgtttaacagagttaaaagggtaccatgttactaccggtgaacctgtttgccagccccgtcgtccaaatagtcggatagataaagtacgatatatgttcaataaaataacttag,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7198,Drugs,MEG_7198|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETS,1391850598|WP_109544237.1|NG_048275|1|1|tet(S)|tet(S)|tetracycline_resistance_ribosomal_protection_protein_Tet(S) NG_048275:101-2020,4
,atgagtgatcaccccgggccgggggccgtcacgccggagctgttcggcgtgggcggcgactggctggccgtcaccgcgggcgaatcgggcgcctccgtctttcgcgccgcggacgccacccggtacgccaagtgcgtgcccgccgcggacgcggccggtcttgaggcggaacgcgaccggatcgcctggctgagcgggcagggcgtaccgggcccccgcgtcctcgactggtacgccggtgacgcgggcgcctgcctggtcacccgtgccgtccccggcgtacccgctgatcgggtgggcgccgatgaccttcgcactgcctggggggccgtcgcggacgcggtccgtcggctgcacgaggtacccgtggcctcgtgtccgttccgccgggggctggactccgtggtcgacgccgcccgtgacgtggtggcccgtggcgcggtgcatccggagttcctgccggtggagcagcggctcgctcccccggcggagctgctggcccggctcaccggggagctcgcccgtcggcgcgatcaggaggccgccgacacggtcgtctgccacggtgatctctgcctgcccaacatcgtcctccatccggagaccctggaggtgtcgggcttcatcgacctgggacggctcggggcggccgaccgccacgccgacctggcgctgctgctggccaacgcgcgcgagacctgggtggacgaggagcgggcgcggttcgccgacgcggcgttcgccgagcgctacggcatcgccccggacccggaacggctgcgcttctacctccatctcgatccgctcacctggggctag,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1033,Drugs,MEG_1033|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,501346013|WP_012377648.1|NG_047411|1|1|aph(3'')-Ia|aph(3'')-Ia|aminoglycoside_O-phosphotransferase_APH(3'')-Ia NG_047411:101-919,2
,atgatgaaaaaaacactctgctgcgcgctggttctgagcgcctccttctccgcctttgccgcccaaaaaacattgagtgacaaacagttagaagacgtcgtcaatcaaacgcttaaaccgatgatcacagcgcaggctattcccggcatggcagtggcggtgatttatcagggcaagccgcactactttacctacggcgtggccgacattgcgaaaaagcagccggtgacaacgcagacgatttttgagctgggctccgtgagtaaaactttcaccggcgtgctgggcggcgatatcgtggcgcgcggggaagtgaagctgagtgacccggcgacgaaatactggccagagctgacgggcaagcagtggcagggcatcacgctgctggatctggcgacctacaccgccggtggcttgccgttgcaggtgccggatgaggttgataatcaggccgcgctgctgaagttttaccagaactggcagccggcctgggcaccgggcacgcgtcgtcagtacgccaactcgagcattggcctgtttggtgcgctggcggtgaaaccgtccgggatgacgtttaacgatgcgatgcgccagcgcgttctgcaaccgctgaacctgaaacatacctggctcaccgttccggccagtgaagaaaatcattacgcctggggctatcgtgatggcaaagccatgcacgttgggccgggcatgctggataccgaagcctacggcgtcaaatccaccatcgaagatatggcgagctgggtgcaatacaacatgaacccgcagcaggtaaaacagccgacgctgcaaaaagggctggagcttgcgcagtcgcgctactggcgcagcggcagtatgtatcagggcttaggctgggaaatgctgaactggccggttgcggcggcgaccgtcattaacggcagcgataacaaagtggcgctggcggcttcgcccgtgacggccattgaaccgccggttgcgccggtaaaagcctctctggtgcataaaaccgggtcgaccaacggcttcggcgcgtacgtggcgttcattcctgaaaaacagatcggcatcgtgatgctggccaacaaaatgtacccgaataccgagcgggtcaaagcggcaaacacccttcttaacacgctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1480,Drugs,MEG_1480|Drugs|betalactams|Class_C_betalactamases|BUT,1349894760|WP_104531863.1|NG_056480|1|1|blaBUT-1|blaBUT|class_C_beta-lactamase_BUT-1 NG_056480:101-1252,0
,ATGATGAAAAAATCGTTATGCTGCGCACTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACATTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTAGCGGTGAAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGTACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1939,Drugs,MEG_1939|Drugs|betalactams|Class_C_betalactamases|CMY,gb|KM087840|+|0-1146|ARO:3002127|CMY-116 [Citrobacter freundii] ,0
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGCATGGCCGTGGCAATTATCTACGAGGGGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAGTTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGACCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTACACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGAAGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGCAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGCGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCAAACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGTGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1904,Drugs,MEG_1904|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JQ711185|+|1027-2173|ARO:3002080|CMY-67 [Citrobacter freundii] ,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtggccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggttcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagtctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccagcccgctggatgccgaaagctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5680,Drugs,MEG_5680|Drugs|betalactams|Class_C_betalactamases|PDC,1035157539|WP_064511504.1|NG_050827|1|1|blaPDC-154|blaPDC|class_C_beta-lactamase_PDC-154 NG_050827:1-1194,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtaccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattgatcaagttaacttacttcaactcgcgacgtatacaagtggcaacctcgctttacaatttccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggcaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtggctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccacttgatgccccagcatccccagcatacggcgtcaaatcgacactacccgacatgttgagttttattcatgccaaccttaccccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaagggttctatcaagtcggcaccatgtatcaggcacttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaccggtttcggaacatatgtggtctttattcctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_593,Drugs,MEG_593|Drugs|betalactams|Class_C_betalactamases|ADC,951242095|WP_057691114.1|NG_063833|1|1|blaADC-182|blaADC|class_C_beta-lactamase_ADC-182 NG_063833:1-1161,0
,ATGCGCCTTTGCCTGACGACCCTTGCCCTGACTGCCACACTTGCCTTTGATGTGACTGCCGCCGACGCACCGCTGCCGCAGCTGCAGGCCTACACCGTGGACGCCTCATGGCTGCAGCCGATGGCACCGCTGCAGATTGCCGACCACACCTGGCAGATCGGCACCGAGGACCTGACCGCGCTGCTGGTGCAGACCGCCGACGGTGCGGTACTGCTCGACGGCGGCATGCCGCAGATGGCCGGTCACCTGCTGGACAACATGAAGGCACGCGGGGTGGCAGCACAGGATCTACGGCTGATCCTGCTCAGCCATGCGCATGCCGACCATGCCGGCCCGGTGGCGGAGCTGAAGCGCCGTACCGGCGCCAGCGTAGCGGCCAACGCCGAATCGGCGGTGCTGCTGGCGCGCGGCGGCAGCAACGACCTGCACTTTGGCGACAGCATCACCTTTCCGCCGGCCAGCGCCGACCGCATCCTCATGGATGGCGAAGGGGTCACCGTAGGCGGCATCGCGTTCACCGCGCACTTCATGCCGGGGCACACCCCAGGCAGCACCGCCTGGACCTGGACCGATACCCGCGATGGCCAGCCGGTGCGCATCGCCTACGCCGACAGCCTGAGTGCGCCGGGCTACCAGCTGCAGGGCAACGCCCGTTATCCACGCCTGGTCGAGGACTACCGGCGCAGCTTCGCTACGGTGCGCGCCCTGCCCTGCGACCTGCTGCTGACGCCGCATCCGGGCGCCAGCAACTGGAACTATGCCGCGGGTGCAGAGGCCGGAGCCAACGCCCTGACCTGCAAGGCCTACGCGGATGCGGCCGAGAAGAAGTTCGACGCACAGCTGGCCAGGGAAGCAGCCACGGCACGCTGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3534,Drugs,MEG_3534|Drugs|betalactams|Class_B_betalactamases|L1,gi|134133872|gb|EF126059.1|1-870 gi|186911825|gb|EU441218.1|51-920,0
,atgagagtttttttagtaatattcatactatttattgccggggatttatgtgccggtgaggaaatgccaggttttagcgttgaggaaattgaaaagaatgtatttctacatgggtcctatagtcaggtaaacggttttgggttggtaagctcaaatgggttggtggttattgagaataagaaagcgtttattgtcgatactccttggtcggaaaaagataccattaatcttgttcagtggattgagggtagaaacttagtattaatagggagtatttccactcattcacatgaagatagaaccgccggaattaaatggcttaatgctcattcgattcctacgtatgcctccgccttaaccaacgagttattgaaaaaagacgacaaagaggttgcgacgaagtcgttcgagggggcagagctaatgttagccgacggcctaatagaagcgtattatcccggaggtgggcatacaatagataatatagtggtttggttgccaaaatctcaaatattatttggtggttgccttgtgcggagtgtagattcaactggacttgggtatgtaggcgaagcagatattaaaaactggtctagttccgtcgagaacgtgctgtcgaagtatcctgagattaaagcggttgttcctggtcatgggaagataggcgggctttcactattgactcatactaagaagcttgctatctcagctctacctaagttgtcaaattga,beta-lactamase,antibiotic inactivation,betalactams,MEG_7300,Drugs,MEG_7300|Drugs|betalactams|Class_B_betalactamases|TTU,506299221|WP_015818996.1|NG_059314|1|1|blaTTU-1|blaTTU|subclass_B1_metallo-beta-lactamase_TTU-1 NG_059314:101-832,0
,ATGCTAAACGAAGGAAAGATTTTGCCTGTAGATGTAAGTAAAGAAATGAAGAAATGTTATATAGACTATGCCATGAGTGTAATAGCTGGCCGTGCATTACCAGATGTAAGAGATGGGTTAAAGCCAGTACATAGAAGAATAATATATTCAATGCAGGGATTAGGATTAGCTCCAGAAAAAGGTTATAGAAAATGTGCGAGAATTGTAGGGGATGTACTAGGTAAGTATCATCCTCATGGAGATACAGCAGTTTATGAAGCTTTAGTAAGAATGGCTCAGAATTTTTCAATAAGATATACATTAGTAGATGGTCATGGAAATTTTGGTTCTGTAGATGGTGATGGAGCAGCAGCAATGAGATATACAGAAGCTAAGATGAGTAAAATATCTATGGAACTTATAAAAGACATAAATAAAAATACAGTTGATTTTATTCCTAACTTTGATGGGGAAGAAGAAGAACCATCTGTATTACCATCAAGGTTTCCTAATCTTTTAGTTAATGGTTCTTCAGGTATAGCAGTAGGTATGGCTACTAATATTCCACCTCATAATTTAACAGAGGTTATAGATGGAATAATAATGCTAATAGAAAATGAAGATGTAAATATACTTGATTTAATGACTAAAATAAAAGGACCAGATTTCCCTACTTCTGGATTAATCGTAGGTACAAGAGGAATAAGGGAAGCTTATGAAACTGGTAGAGGAAAAGTTATAATTAGAGCTAAAGCTGAGATTGAAGAGGAAAAAGGGAAAAATAAGATAATAGTTACAGAAATACCTTATCAAGTTAATAAAGCTAGACTTATAGAAAATATGGCTAACCTTGTAAAGGATAAAAAAATAAATGGAATTTCAGATTTAAGAGATGAATCAGATAGAGATGGTATGAGAATTGTTATAGAATTAAAAAGGGATGCAAATCCTAATATAGTTTTAAACCAATTATATAAGCATACAAAACTTCAAGATACCTTTGGAATAATCATGTTAGCTTTAGTTAATAACCAACCTCAAATTTTAAATTTAAAAGAAATATTAGTTAATTATGTGGAATTCCAAAAGGAAGTAATAAGAAGAAGAACTAGATTTGACTTAGATAAAGCATTAGCAAGGGCTCACATATTAGAAGGTTTAAGAATAGCCTTAGATCATATTGATGAAGTTATAAAACTTATAAGAGCATCTAAAAATACAGCTGAAGCTAAAGAAGGATTAATGAATAACTTTAATCTTTCAGAAAAACAAGCTCAAGCTATATTAGATATGAAGTTACAAAGGCTTACAGGTTTAGAAAGAGAAAAAATAGAAGAAGAATATAAAGAACTTATGGAAAAGATAAGTTATTTTAGAGAAATATTAGATAAAGAAGAATTAGTACTAAGTATAATAAAAGAAGAATTAATAGAGATAAAAAATAAATATGGTGATGAAAGAAAAACAGAAATAGTAAAAGGTGAACATGATATAGACATAGAGGACTTAATTGAAGATAAAAAGGTGATAGTAACTTTAACTCATGGTGGATACATAAAAAGATTAGATATGGATACATACTCTTCACAAAAAAGAGGAGGAAAGGGTATTCAAGCTACATCTACAAAACAGGATGATTTTATAGAAAATATGTTTGTAACATCTACTCATAGTACTATATTATTCTTTACTAATAGGGGTAAGGTATATAAACTTAAAGCTTATGAAATACCAGAAGCAGGAAGAACAGCTAAAGGTACAAATATAGTAAATCTTATACCTATAGAAAATAATGAGAAAATACAAACAGTAATAGGTTTAAAAGACATAGATGACATGAAGCATTTTGTAATGTGTACGAGAAATGGAATAATTAAAAAGACAGAGATAAGTAAATATTCTTCCATAAGAAAAGGTGGATTAAATGCCATAAATTTAAGAGAAGATGATGAATTAATAGATGTAAAAATGACCAAAGGAAATGATGAAATAATAGTAGTAACACAAAATGGGTACTGTATAAGATTTAATGAAGAAGATGTAAGACCTATGGGAAGAGTTGCAACAGGTGTTAAGGCTATAACACTAAGAAAAACTGATAAGGCTGTATCTATGGATGTAGTAATAGAAGATGAAACACTATTATCTATAAGTGAAAATGGATTTGGTAAACGAACAGACATAGAAGAATATCCTATCCATAGAAGAGGTGGAAAAGGTGTTATAACTTATAAGATAACTGACAAAACAGGACCTATAGTTGGAGCAAGGTTTGTAAAAGAAGATGATGAACTTATGCTTGTAAATAGTGGTGATGTTGCAATAAGAATAAATGTTTCGGAAATATCTAAAACTAGTAGAAATGCTATGGGTGTAAAACTAATGAGAACTAGTGAAGAAGAAAAAATAGTAGCTATAGCTAAAATAAAGAGTGAAGACATAATAGAAGAAGAAATTTTAAATGAAGAAAATCTAAATGAAGAAAATCTAAATGAAGAAAATCTAAATGAAGAAAATCTAAATGAAGAAAATCTAAATGAAGAAAATCTAAATGAAGAATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3196,Drugs,MEG_3196|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|226840737|gb|CP001581.1|6499-9039,3
,ATGACCGTAGTCACGACCGCCGATACCTCCCAACTGTACGCACTTGCAGCCCGACATGGGCTCAAGCTCCATGGCCCGCTGACTGTCAATGAGCTTGGGCTCGACTATAGGATCGTGATCGCCACCGTCGACGATGGACGTCGGTGGGTGCTGCGCATCCCGCGCCGAGCCGAGGTAAGCGCGAAGGTCGAACCAGAGGCGCGGGTGCTGGCAATGCTCAAGAATCGCCTGCCGTTCGCGGTGCCGGACTGGCGCGTGGCCAACGCCGAGCTCGTTGCCTATCCCATGCTCGAAGACTCGACTGCGATGGTCATCCAGCCTGGTTCGTCCACGCCCGACTGGGTCGTGCCGCAGGACTCGGAGGTCTTCGCGGAGAGCTTCGCGACCGCGCTCGCCGCCCTGCATGCCGTCCCCATTTCCGCCGCCGTGGATGCGGGGATGCTCATCCGTACACCGACGCAGGCCCGTCAGAAGGTGGCCGACGACGTTGACCGCGTCCGACGGCAGTTCGTGGTGAACGACAAGCGCCTCCACCGGTGGCAGCGCTGGCTCGACGACGATTCGTCGTGGCCAGATTTCTCCGTGGTGGTGCATGGCGATCTCTACGTGGGCCATGTGCTCATCGACAACACGGAGCGCGTCAGCGGGATGATCGACTGGAGCGAGGCCCGCGTTGATGACCCTGCCATCGACATGGCCGCGCACCTTATGGTCTTTGGTGAAGAGGGGCTCGCGAAGCTCCTCCTCACGTATGAAGCGGCCGGTGGCCGGGTGTGGCCGCGGCTCGCCCACCACATCGCGGAGCGCCTTGCGTTCGGGGCGGTCACCTACGCACTCTTCGCCCTCGACTCGGGTAACGAAGAGTACCTCGCTGCGGCGAAGGCGCAGCTGCCGCAGCGGAATGAGCGAACGTCGATATAG,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_4030,Drugs,MEG_4030|Drugs|MLS|Macrolide_phosphotransferases|MPHA,gi|1574935|gb|U34344.1|ECU34344|432-1352 gi|1408169|gb|U36578.1|ECU36578|432-1352,7
,TCACTCAAGGATGTATTGTGGTTATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTAGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACGCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCG,beta-lactamase,antibiotic inactivation,betalactams,MEG_6495,Drugs,MEG_6495|Drugs|betalactams|Class_A_betalactamases|SHV,gi|961666360|gb|KT185451.1|77484-76625 gi|954629879|gb|CP013215.1|268448-269307 gi|933686117|gb|KR827393.1|97036-97895 gi|918463070|gb|KP987216.1|9661-8802 gi|817046807|gb|KP893385.1|116976-116117 gi|908266278|gb|CP012170.1|159145-160004 gi|902618894|gb|CP011987.1|37137-37996 gi|902611358|gb|CP011977.1|33461-34320 gi|902604381|gb|CP011983.1|6491-7350 gi|873464235|gb|KR059865.1|7815-8674,0
,atgagggtagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttggtggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgaccttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgaaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggagcaattctttgacccggttcctgaacaggatgtattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcaataaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_858,Drugs,MEG_858|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502077|WP_071846229.1|NG_052241|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_052241:101-892,2
,atgaaaatcgtaaaaaggatattattagtattgttaagtttattttttacagttgtgtattcaaatgctcaaactgacaacttaactttgaaaattgagaatgttttaaaggcaaaaaatgccagaataggagtagcaatattcaacagcaatgagaaggatactttgaagattaataacgacttccatttcccgatgcaaagcgttatgaaatttccgattgctttagccgttttgtctgagatagataaagggaatctttcttttgaacaaaaaatagagattacccctcaagaccttttgcctaaaacgtggagtccgattaaagaggaattccctaatggaacaactttgacgattgaacaaatactaaattatacagtatcagagagcgacaatattggttgtgatattttgctaaaattaatcggaggaactgattctgttcaaaaattcttgaatgctaatcatttcactgatatttcaatcaaagcaaacgaagaacaaatgcacaaggattggaatacccaatatcaaaattgggcaaccccaacagcgatgaacaaactgttaatagatacttataataataagaaccaattactttctaaaaaaagttatgattttatttggaaaattatgagagaaacaacaggaagtaaccgattaaaaggacaattaccaaagaatacaattgttgctcataaaacagggacttccggaataaataatggaattgcagcagccactaatgatgttggggtaattactttaccgaatggacaattaatttttataagcgtatttgttgcagagtccaaagaaacttcggaaattaatgaaaagattatttcagacattgcaaaaataacgtggaattactatttgaataaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_7653,Drugs,MEG_7653|Drugs|betalactams|Class_A_betalactamases|VEB,1028110885|WP_063865154.1|NG_050322|1|1|blaVEB-14|blaVEB|class_A_extended-spectrum_beta-lactamase_VEB-14 NG_050322:1-897,0
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCAACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGCACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAAGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1392,Drugs,MEG_1392|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_30_JGUQ01000012,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagcccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5568,Drugs,MEG_5568|Drugs|betalactams|Class_C_betalactamases|PDC,1035157531|WP_064511496.1|NG_050818|1|1|blaPDC-145|blaPDC|class_C_beta-lactamase_PDC-145 NG_050818:1-1194,0
,CAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCTTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAARGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATAGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGACGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAACCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6911,Drugs,MEG_6911|Drugs|betalactams|Class_A_betalactamases|TEM,gi|38098484|gb|AY436361.1|1-992,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcttggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagctccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5606,Drugs,MEG_5606|Drugs|betalactams|Class_C_betalactamases|PDC,1343491217|WP_104009833.1|NG_056390|1|1|blaPDC-235|blaPDC|class_C_beta-lactamase_PDC-235 NG_056390:1-1194,0
,TTGTCCAAAGCCACCTTTGCAATTGCTAGTACTAACGCAAAGGAGGATATGAAAATGCAATACAAAATAATTAATGGTGCCGTTTACTATGATGGTAATATGGTGTTGGAAAACATCGGTATTGAAATCAATGATAATGAAAAGATTGCTATTGTTGGTAGAAATGGATGTGGAAAAACAACCTTGCTAAAAGCTATTATAGGCGAAATTGAATTAGAAGAAGGAACTGGTGAAAGTGAGTTTCAAGTAATAAAGACCGGTAACCCTTATATTAGCTATTTAAGACAGATGCCTTTTGAAGATGAAAGTATATCAATGGTGGATGAAGTCCGTACGGTATTTAAGACGCTTATTGATATGGAAAACAAGATGAAACAGCTGATAGATAAAATGGAGAATCAATATGATGATAAAATCATCAATGAATACTCTGATATCAGTGAAAGGTATATGGCTCTTGGAGGTCTAACCTACCAAAAAGAATATGAAACGATGATTCGTAGTATGGGTTTTACTGAAGCAGATGATAAAAAACCCATTTCTGAATTTTCAGGTGGTCAGCGAACTAAGATAGCTTTTATAAAAATACTTTTAACAAAGCCAGACATTCTATTACTTGATGAACCTACTAACCACCTTGATATAGAAACAATACAATGGTTGGAGAGTTATTTGAGAAGTTATAAATCTACATTGGTTATTATTTCCCATGATAGAATGTTTCTTAATCGAATTGTGGATAAGGTTTATGAAATCGAATGGGGAGAGACCAAATGTTATAAAGGTAATTATTCAGCCTTTGAGGAGCAAAAACGAGAAAATCATATCAAACAGCAAAAAGATTACGACTTGCAACAGATAGAAATTGAAAGGATTACACGCTTGATTGAACGTTTTCGTTATAAACCTACGAAAGCTAAAATGGTGCAATCTAAAATTAAATTATTACAGCGTATGCAAATATTAAATGCACCAGACCAATACGATACAAAAACTTATATGTCTAAATTTCAACCGAGAATCAGTAGTTCAAGGCAAGTATTAAGTGCTTCAGAACTTGTGATAGGCTATGATACTCCTCTTGCAAAGGTTAATTTCAACCTTGAAAGGGGACAGAAGCTTGGAATTGTTGGGAGTAATGGTATTGGTAAATCCACGTTGCTTAAAACACTTATGGGTGGTGTGGCAGCATTGTCTGGAGATTTTAAATTCGGATACAATGTTGAAATTAGCTATTTTGACCAACAGCTTGCTCAAATCAGTGGAGATGATACACTATTCGAAATTTTTCAAAGCGAATACCCTGAGCTAAATGACACAGAGGTCAGAACTGCTCTTGGCTCATTTCAGTTTAGTGGAGATGATGTTTTTAGACCGGTGTCCTCTTTGTCAGGTGGAGAAAAGGTTAGATTGACATTATGTAAATTATTATATAAACGTCCTAATGTTTTAATCTTAGATGAACCGACAAACCACATGGATATTATTGGAAAAGAGAATTTAGAGAATATCTTATGCAGTTATCAAGGTACAATTATTTTTGTGTCACATGATAGATATTTTACTAATAAGATTGCTGACAGATTACTTGTTTTTGATAAGGATGGTGTAGAGTTTGTACAATCTACTTATGGTGAGTACGAGAAAAAAAGGATGAATTCTGAAAAGCCATTTAATAACATTAAAGTTGAGCAGAAAGTAGAGAAAAATAACACAGTAAAAGGCGATCGTAACTCCATTGAGAAGGAGAAGGTTAAGAAGGAGAAACGAATTGAAAAGCTTGAAGTGTTAATAAATCAATATGATGAAGAATTAGAAAGATTGAATAAAATCATTTCTGAACCAAACAATTCTTCTGATTATATAGTACTGACGGAAATACAAAAATCAATTGATGATGTTAAAAGGTGTCAGGGTAATTATTTTAATGAATGGGAACAGTTGATGAGAGAATTGGAAGTTATGTAA,ABC-F ATP-binding cassette ribosomal protection protein,antibiotic efflux,Multi-drug_resistance,MEG_4318,Drugs,MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA,optrA_7_KT862775 ,1
,AATTCAATCTTATAAGTCTTATGAATATTAAAGCACTCTTACTTATAACAAGCGCTATTTTTATTTCAGCCTGCTCACCTTATATAGTGACTGCTAATCCAAATCACAGCGCTTCAAAATCTGATAAAAAAGCAGAGAAAATTAAAAATTTATTTAACGAAGCACACACTACGGGTGTTTTAGTTATCCAACAAGACCAAACTCAACAAAGCTATGGTAATGATCTTGCTCGTGCTTCGACCGAGTATGTACCTGCTTCGACCTTCAAAATGCTTAATGCTTTGATCGGCCTTGAGCACCATAAGGCAACCACCACAGAAGTATTTAAGTGGGACGGGCAAAAAAGGCTATTCCCAGAATGGGAAAAGGACATGACCCTAGGCGACGCTATGAAAGCTTCCGCTATTCCGGTTTATCAAGATTTAGCTCGTCGTATTGGACTTGAACTCATGTCTAAGGAAGTGAAGCGTGTTGGTTATGGCAATGCAGATATCGGTACCCAAGTCGATAATTTTTGGCTGGTGGGTCCTTTAAAAATTACGCCTCAGCAAGAGGCACAATTTGCTTACAAGCTAGCTAATAAAACGCTTCCCTTTAGCCAAAAAGTCCAAGATGAAGTGCAATCCATGTTATTCATAGAAGAAAAGAATGGAAATAAAATATACGCAAAAAGTGGTTGGGGATGGGATGTAGACCCACAAGTAGGCTGGTTAACTGGATGGGTTGTTCAGCCTCAAGGAAATATTGTAGCGTTCTCCCTTAACTTAGAAATGAAAAAAGGCATACCTAGCTCTGTTCGAAAAGAGATTACTTATAAAAGCTTAGAACTATTAGGTATTTTATAGAGTTAGTTTATAGCCCAGTTCACTTTTACCATTT,beta-lactamase,antibiotic inactivation,betalactams,MEG_5244,Drugs,MEG_5244|Drugs|betalactams|Class_D_betalactamases|OXA,gi|751813255|gb|KM979376.1|1-879,0
,atgctggtgcagcaaggcagattggcgatacgtgttttgcagaaaagcgatgcgccggtaatgctgcgctggctgcaggatgagcgggtgctggaattttatgaagggcgcgacaagcacttcgacctgcaaacgatcatcgaagtttttatcgatgatcagggggaaaccacaccgtgtctggtgttgctggatgataaaccgctgggctatgtgcagttctacccgctggatcgcgaagataaacaggcgctggaactaccggttgaggacgtgatctacgggctggatcagtttatcggcgaaccggatttctgggggctgggacttggcacgcagcttgttttactggtgcgggattatctcataacaaaaaaggccgcacatcgccttgttctcgacccgcaaagccgcaactcacgcgcaattgcctgttatgaaaaatgcggctttgaaaaactccgcatgctgcccgcccatgaaatgcacgaagggcagctgcaggattgctggctgatgcagtattatcccgcacgcagcaatctgattgcctcgtcacggccgaaaatatag,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_183,Drugs,MEG_183|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,916531646|WP_051139090.1|NG_052170|1|1|aac(6')-Ian|aac(6')-Ian|aminoglycoside_N-acetyltransferase_AAC(6')-Ian NG_052170:101-673,2
,ATGAGCGATATGGCAGAGCGCCTTGCGCTGCATGAATTTACGGAAAATGCTTACCTGAACTACTCCATGTACGTGATCATGGACAGGGCATTACCGTTTATTGGCGATGGCTTAAAACCGGTCCAGCGTCGCATCGTCTATGCGATGTCCGAGCTGGGGCTGAACGCCAGCGCGAAATTCAAAAAGTCCGCCCGCACCGTCGGCGACGTGTTGGGTAAATATCACCCGCACGGCGACAGCGCCTGCTATGAAGCGATGGTGCTGATGGCGCAGCCGTTCTCTTACCGCTATCCGCTGGTGGATGGTCAGGGAAACTGGGGGGCGCCGGACGATCCCAAATCTTTCGCCGCCATGCGTTACACCGAATCCCGCCTGTCGAAGTATGCCGAGCTGCTGCTCAGCGAGCTGGGGCAGGGGACGGTCGACTGGGTGCCAAACTTTGACGGCACGCTGCAGGAGCCGAAAATGCTGCCAGCGCGTTTGCCGAACATCCTGCTGAACGGCACCACCGGCATCGCGGTAGGCATGGCGACCGATATTCCTCCGCACAACCTGCGGGAAGTGGCCAAAGCGGCGATTACGCTGATTGAGCAGCCGAAAACCACCCTCGACGAACTGCTGGATATCGTACAGGGGCCGGATTTCCCGACCGAGGCGGAGATCATCACCTCGCGGGCGGAAATTCGCAAAATCTACCAGAACGGGCGCGGCTCAGTGCGCATGCGCGCGGTGTGGAGTAAAGAGGACGGCGCGGTGGTGATCAGCGCGCTGCCGCATCAGGTCTCCGGCGCCAAAGTGCTGGAGCAGATTGCGGCGCAGATGCGCAATAAAAAGCTGCCGATGGTTGACGATCTGCGCGACGAATCGGACCACGAAAACCCGACCCGTCTGGTAATTGTCCCGCGCTCCAACCGGGTGGATATGGAACAGGTGATGAACCACCTGTTCGCCACCACCGATCTGGAGAAGAGCTACCGCATCAACCTCAATATGATCGGCCTTGACGGCCGCCCGGCGGTGAAAAACCTGCTGGAGATCCTCAGCGAGTGGCTGGTGTTCCGTCGCGATACCGTGCGTCGCCGTCTAAACCATCGGTTAGAGAAAGTGCTGAAGCGCCTGCATATCCTCGAAGGTTTGCTGGTGGCGTTTCTTAATATCGATGAAGTGATTGAGATCATCCGCACTGAAGATGAACCGAAGCCGGCCCTGATGTCGCGCTTTGGCATCAGCGAAACCCAGGCGGAAGCGATTCTGGAATTAAAACTGCGCCACCTCGCCAAACTGGAAGAGATGAAGATCCGCGGCGAGCAGAGCGAGCTGGAAAAAGAGCGCGACCAGCTGCAGGCGATTCTGGCGTCTGAACGTAAGATGAACAACCTGCTGAAAAAAGAGCTGCAGGCCGATGCCGATGCCTTCGGCGACGACCGTCGCTCGCCGCTTCACGAGCGTGAAGAAGCGAAAGCGATGAGCGAACATGACATGCTGCCGTCTGAGCCGGTGACTATCGTTCTGTCGCAGATGGGCTGGGTGCGCAGCGCCAAAGGACACGACATTGACGCCCAGGGATTGAGCTATAAGGCGGGCGACAGCTGGAAAGCCTCGGCGAAGGGCAAGAGCAACCAGCCGGTGGTGTTTATCGATACCACCGGACGCAGCTATGCCATCGATCCGATTACTCTGCCTTCCGCGCGTGGCCAGGGTGAACCGCTTACCGGCAAACTGACCCTGCCGCCGGGCGCGACCGTGGAGCATATGCTAATGGAAAGCGACGATCAGAAACTGCTGATGGCTTCCGACGCGGGCTACGGTTTCGTCTGTACCTTCAACGATCTGGTGGCGCGCAACCGTGCCGGGAAAGCGCTAATCACCCTGCCTGACAACGCGCACGTGATGCCGCCGCTGGTGATTGAGGATGAGTCCGATATGCTGCTGGCCATCACCGCCGCCGGGCGGATGCTGATGTTCCCGGTCAGCGATCTGCCGCAGCTGTCGAAAGGCAAGGGCAACAAAATTATCAGCATTCCGGCGGCGGAAGCCGCAGCCGGCCAGGACGGTCTGGCACATCTGTTTGTTCTGCCGCCGCAGAGTACGCTGACCATTCACGTCGGCAAACGGAAGATCAAACTGCGTCCGGAAGAGCTGCAAAAAGTCACCGGCGAGCGCGGCCGCCGCGGTTCGCTGATGCGCGGGCTGCAGAAAATTGACCGCGTGGAAATTGACTCGCCGCGTCGTGCCGCGGCAGGCGATAGCGAAGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5334,Drugs,MEG_5334|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|150953431|gb|CP000647.1|3763448-3761190,3
,ATGACAATTCAAGATATTCAATCACTTGCTGAAGCACACGGCTTGTTGATTACGGACAAAATGAATTTCAATGAAATGGGCATTGATTTTAAGGTCGTTTTTGCTCTTGATACAAAGGGGCAACAATGGTTGCTGCGTATTCCTCGTCGTGATGGCATGAGGGAACAAATCAAGAAAGAAAAACGCATTTTAGAATTGGTAAAAAAACATCTTTCTGTAGAGGTTCCTGATTGGAGAATTTCATCTACAGAATTAGTGGCTTATCCCATACTTAAAGATAATCCTGTTTTAAATTTGGATGCTGAAACCTATGAAATAATTTGGAATATGGACAAAGATAGCCCGAAATACATAACATCTTTGGCAAAAACCTTATTTGAAATCCATAGTATTCCTGAAAAAGAAGTTCGGGAAAATGATTTGAAAATTATGAAACCTTCAGATTTAAGACCTGAAATAGCAAACAATTTGCAGTTAGTAAAATCTGAAATTGGTATAAGTGAGCAATTGGAAACCCGCTACAGAAAATGGTTGGATAATGATGTTCTATGGGCAGATTTCACCCAATTTATACATGGCGATTTATATGCTGGGCATGTACTAGCTTCAAAGGATGGAGCTGTTTCAGGCGTTATTGATTGGTCAACAGCCCATATAGATGACCCAGCGATTGATTTTGCTGGGCATGTAACTTTGTTTGGAGAAGAAAGCCTCAAAACTCTAATCATCGAGTATGAAAAACTAGGGGGTAAAGTTTGGAATAAACTATATGAACAGACTTTAGAAAGAGCAGCGGCCTCTCCTTTGATGTATGGTTTATTTGCCTTAGAAACTCAAAATGAAAGCCTTATCGTTGGAGCAAAAGCTCAGTTGGGAGTTATATAA,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_4042,Drugs,MEG_4042|Drugs|MLS|Macrolide_phosphotransferases|MPHE,(MLS)MphE:JF769133:8777-9661:885,7
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattgtgcctggggctatcgcgaagggaagcccgtacacgtttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattggcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1824,Drugs,MEG_1824|Drugs|betalactams|Class_C_betalactamases|CMY,695272306|WP_032494240.1|NG_048777|1|1|blaCMY-107|blaCMY|class_C_beta-lactamase_CMY-107 NG_048777:101-1246,0
,atgaaaaagttattcctgttggttgggctgatggtttgctcaactgttagttacgcctccaaattaaacgaagacatctccctcatcgagaaacaaacatctgggcgaattggagtgtcagtctgggatacacaaacggacgagcgttgggattatcgcggagacgaacgtttcccattaatgagcacattcaaaacgttagcgtgtgccaccatgctaagcgacatggatagcggcaaactcaacaaaaatgccacagcgaaaatcgatgaacgcaatattgtggtttggtctccggtgatggataaactggctggacaaagcacacgcatcgaacacgcttgtgaagccgccatgttgaggagcgacaacaccgccgcgaacttagtgctaaatgaaattggtggtcctaaagcggtcacgttgtttttgcgatctattggcgacaaagcaacgcgacttgaccgattggaaccccgtttgaatgaagcaaaaccgggcgacaagcgagacaccacaacgcctaacgccatggtaaacaccctacataccttgatggaagataacgccctatcttacgagtcacgcacacagctgaaaatctggatgcaagacaacaaagtatcggattcgctcatgcgctctgttctgccaaaaggttggtcgattgcagaccgctctggcgcaggtaactacggttcacgcggcattagcgcgatgatttggaaagacaactacaagccggtttacatcagtatttacgtcacagacaccgacctttcgcttcaagctcgcgatcaactgatcgcgcaaatcagccaactgattttagagcactacaaagaaagttaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic inactivation,betalactams,MEG_1511,Drugs,MEG_1511|Drugs|betalactams|Class_A_betalactamases|CARB,658935336|WP_029795186.1|NG_048729|1|1|blaCARB-26|blaCARB|carbenicillin-hydrolyzing_class_A_beta-lactamase_CARB-26 NG_048729:1-852,0
,atgcaatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcggacaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccattattagaaaaatatgatgtgccgggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagatcaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatgtttccggctcttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgctgagttttattcatgccaacctcaacccacagaaatatccgaaagatattcaacttgcaattaatgaaacacatcaagggttctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaatctaataaagtgactgctatttcaaaagagccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_508,Drugs,MEG_508|Drugs|betalactams|Class_C_betalactamases|ADC,1058243513|WP_068981609.1|NG_051441|1|1|blaADC-102|blaADC|class_C_beta-lactamase_ADC-102 NG_051441:1-1152,0
,atgatttatgctggtgatcttaccattagagcattaacccccaatgataccgctcacttagtcaaatggctttctgacgaacgcgttttggcctactatgaaggtcgtgatcggccacatgacgagtccctcgtgcagcaaagcttttttccggaagatgacggtgaaacccgctgcctgatcttgcacgcggacaaacctattggctatgcgcaattttatccgctcgatgccccggaaaaacaactgtatggttatgcaaaggacgatgttgtctacggcatggaccagttcatcggagagcctgcttactggaatcgcggtattggcactcagctcgttacagccatcctccactacctccaaacggaaaaacgagcacaaaaagtagcgattgacccgcaagcctggaatgaacgagccctccgttgctacgaaaaatgtggctttcgaaaagtaaaagagcttcccctgcacgaatggcacgaaggaagcatgcgtgattgctggctgatggaatggattgctcctgctgattaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_176,Drugs,MEG_176|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1199615747|WP_087349651.1|NG_063816|1|1|aac(6')-35|aac(6')-35|aminoglycoside_6'-N-acetyltransferase_AAC(6')-35 NG_063816:1-540,2
,atgtccgcgagcaccccccccataactcttcgcctcatgaccgagcgcgacctgccgatgctccatgattggctcaaccggccgcacatcgttgagtggtggggtggtgacgaagagcgaccgactcttgatgaagtgctggaacactacctgcccagagcgatggcggaagagtccgtaacaccgtacatcgcaatgctgggcgaggaaccgatcggctatgctcagtcgtacgtcgcgctcggaagcggtgatggctggtgggaagatgaagctgatccaggagtgcgaggaatagaccagtctctggctgacccgacacagttgaacaaaggcctaggaacaaggcttgtccgcgctctcgttgaactactgttctcggaccccaccgtgacgaagattcagaccgacccgactccgaacaaccatcgagccatacgctgctatgagaaggcaggattcgtgcgggagaagatcatcaccacgcctgacgggccggcggtttacatggttcaaacacgacaagccttcgagagaaagcgcggtgttgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_206,Drugs,MEG_206|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502037|WP_071846189.1|NG_052142|1|1|aac(6')-IIa|aac(6')-IIa|aminoglycoside_N-acetyltransferase_AAC(6')-IIa NG_052142:21-575,2
,ATGTTGAAAAAAATAAAAATAAGCTTGATTCTTGCTCTTGGGCTTACCAGTTTGCAGGCATTTGGACAGGAGAATCCTGATGTCAAAATTGAAAAGCTAAAAGATAATCTGTATGTATACACAACCTACAATACATTTAACGGGACTAAATATGCCGCAAATGCAGTATATCTGGTAACTGATAAGGGTGTTGTGGTTATAGACTGTCCGTGGGGAGAAGACAAATTTAAAAGCTTTACGGACGAGATTTATAAAAAACACGGAAAGAAAGTTATTATTAATATTGCAACACATTCTCATGATGATCGTGCCGGAGGTCTTGAATATTTTGGTAAAATAGGTGCAAAAACTTATTCTACTAAAATGACAGATTCTATTTTAGCAAAAGAGAATAAGCCAAGAGCACAATATACTTTTGACAATAATAAATCTTTCAAAGTAGGAAAATCCGAGTTTCAGGTTTACTATCCCGGAAAAGGGCACACAGCAGATAATGTGGTGGTATGGTTTCCAAAAGAAAAAGTATTGGTTGGAGGTTGTATTATAAAAAGTGCTGATTCAAAGGACCTGGGATATATTGGAGAAGCATATGTAAATGACTGGACGCAGTCTGTACACAATATTCAACAAAAGTTTTCCGGTGCTCAGTACGTTGTTGCAGGTCATGATGACTGGAAGGATCAAACATCAATACAGCATACATTGGATTTAATCAGTGAATATCAACAAAAACAAAAGGCTTCAAATTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1268,Drugs,MEG_1268|Drugs|betalactams|Class_B_betalactamases|BLAB,gi|9587057|gb|AF189299.1|AF189299|1-750,0
,atgcgttatgttcgcctgtaccttatctccctgattgccgccctgccactggcggtattcgccagccctcagccgcttgagcagattaaaatcagcgaaagtcagctggcgggccgggtgggctatgttgaaatggatctggccagcggccgcacgctggccgcctggcgcgccagtgagcgctttccgctgatgagcacctttaaagtgctgctctgcggcgcggtgctggcccgggtggatgccggcgacgaacagctggatcggcggatccactaccgccagcaggatctggtggactactccccggtcagcgaaaaacaccttgccgacgggatgaccgttggcgaactctgcgccgccgccatcaccatgagcgacaacagcgccggcaatctgctgttgaagatcgtcggcggccccgcgggattgaccgcttttctgcgccagatcggtgacaacgtcacccgtcttgaccgctgggaaacggaactcaatgaggcgcttcccggcgacgtgcgcgacaccaccaccccggccagcatggccaccaccctgcgcaagctgctaaccaccccctctctgagcgcccgttcgcagcagcagctgctgcagtggatggttgacgaccgggtggccggcccgttgatccgcgccgtgctgccggcgggctggtttatcgccgataaaaccggggccggtgagcggggctcacgcggcattgtcgccctgctcggcccggacggcaaagcggagcgtatcgtggtgatctatctgcgggataccgcagcgaccatggccgaacgtaaccagcagatcgccgggataggcgcggcgctgatcgaacactggcagcgctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4234,Drugs,MEG_4234|Drugs|betalactams|Class_A_betalactamases|OKP,556466428|WP_023318187.1|NG_050606|1|1|blaOKP-B-23|blaOKP-B|class_A_broad-spectrum_beta-lactamase_OKP-B-23 NG_050606:101-961,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggcaagaagaattggtatcaaaactatgcaagaatatttaaacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaaattttagaaaaatatttagatga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4650,Drugs,MEG_4650|Drugs|betalactams|Class_D_betalactamases|OXA,1559613014|WP_128268279.1|NG_063887|1|1|blaOXA-786|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-786 NG_063887:1-744,0
,TGTTATCTCCCTGTTAGCCACCCTGCCACTGGTGGTATACGCCGGTCCACAGCCGCTTGAGCAGATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTGGGGATGGTGGAAATGGATCTGGCCAGCGGCCGCACGCTGGCCGCCTGGCGCGCCGATGAACGCTTTCCCATGGTGAGCACCTTTAAAGTGCTGCTGTGCGGCGCGGTGCTGGCGCGGGTGGATGCCGGGCTCGAACAACTGGATCGGCGGATCCACTACCGCCAGCAGGATCTGGTGGACTACTCCCCGGTCAGCGAAAAACACCTTGTCGACGGGATGACGATCGGCGAACTCTGCGCCGCCGCCATCACCCTGAGCGATAACAGCGCTGGCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCGGGATTAACTGCCTTTCTGCGCCAGATCGGTGACAACGTCACCCGTCTTGACCGCTGGGAAACGGCACTGAATGAGGCGCTTCCCGGCGACGCGCGCGACACCACCACCCCGGCCAGCATGGCCGCCACGCTGCGCAAACTACTGACCGCGCAGCATCTGAGCGCCCGTTCGCAACAGCAACTCCTGCAGTGGATGGTGGACGATCGGGTTGCCGGCCCGCTGATCCGCGCCGTGCTGCCGCCGGGCTGGTTTATCGCCGACAAAACCGGGGCTGGCGAACGGGGTGCGCGCGGCATTGTCGCCCTGCTCGGCCCGGACGGCAAACCGGAGCGCATTGTGGTGATCTATCTGCGGGATACCCCGGCGAGTATGGCCGAGCGTAATCAACAAATCGCCGGGATCGGCGCGGCGCTGAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_3564,Drugs,MEG_3564|Drugs|betalactams|Class_A_betalactamases|LEN,gb|AY130286|+|0-822|ARO:3002475|LEN-3 [Klebsiella pneumoniae] ,0
,ATGGCAAAGCTAGATAAAGAACAAGTTATTGATAATGCGTTGATTTTACTTAATGAAGTTGGTATTGAAGGATTAACAACGCGTAAGCTGGCGCAAAAAATAGGTGTGGAACAACCCACATTGTATTGGCATGTAAAAAATAAACGCGCTTTGTTAGATGCATTAGCAGAAACTATTTTGCAAAAGCACCATCATCATGTTTTGCCATTGCCGAATGAAACATGGCAGGACTTTTTGCGAAATAACGCGAAAAGCTTCCGCCAAGCCTTATTAATGTATCGTGATGGTGGCAAAATTCATGCGGGAACACGCCCCTCTGAAAGTCAATTTGAGACATCAGAACAGCAACTACAGTTTTTGTGTGATGCTGGGTTTAGTCTATCTCAAGCCGTGTATGCATTAAGCTCTATTGCGCATTTTACATTAGGCTCCGTACTGGAAACTCAAGAGCATCAAGAAAGCCAAAAAGAGCGTGAAAAAGTAGAGACGGATACTGTTGCCTATCCGCCATTATTAACCCAAGCCGTTGCAATTATGGATAGTGATAATGGTGATGCTGCATTTTTGTTTGTCCTTGATGTGATGATCTCTGGACTTGAAACAGTATTAAAGAGCGCTAAATAA,tetR,antibiotic target alteration,Tetracyclines,MEG_7194,Drugs,MEG_7194|Drugs|Tetracyclines|Tetracycline_transcriptional_repressor|TETR,gi|817922503|gb|CP011374.1|2161239-2160616 gi|817922503|gb|CP011374.1|2173104-2173055 gi|785798809|gb|CP011099.1|1616219-1615596 gi|785795794|gb|CP011098.1|1616196-1615573 gi|678222343|gb|KJ909292.1|5025-4402 gi|575453416|gb|CP006956.1|241452-242075 gi|575450852|gb|CP006955.1|2348060-2348683 gi|575450852|gb|CP006955.1|2371899-2372522 gi|575439963|gb|CP006942.1|974821-975444 gi|511255433|gb|KC734562.1|4226-3603 gi|511255399|gb|KC734561.1|3704-4327 gi|511255369|gb|KC734560.1|4326-3703,4
,GTGAGTGAAATAATTCAAGATTTATCACTTGAAGATGTTTTAGGTGATCGCTTTGGAAGATATAGTAAATATATTATTCAAGAGCGTGCATTGCCAGATGTTCGTGATGGTTTAAAACCAGTACAACGTCGTATTTTATATGCAATGTATTCAAGTGGTAATACACACGATAAAAATTTCCGTAAAAGTGCGAAAACAGTCGGTGATGTTATTGGTCAATATCATCCACATGGAGACTCCTCAGTGTACGAAGCAATGGTCCGTTTAAGTCAAGACTGGAAGTTACGACATGTCTTAATAGAAATGCATGGTAATAATGGTAGTATCGATAATGATCCGCCAGCGGCAATGCGTTACACTGAAGCTAAGTTAAGCTTACTAGCTGAAGAGTTATTACGTGATATTAATAAAGAGACAGTTTCTTTCATTCCAAACTATGATGATACGACACTCGAACCAATGGTATTGCCATCAAGATTTCCTAACTTACTAGTGAATGGTTCTACAGGTATATCTGCAGGTTACGCGACAGATATACCACCACATAATTTAGCTGAAGTGATTCAAGCAACACTTAAATATATTGATAATCCGGATATTACAGTCAATCAATTAATGAAATATATTAAAGGTCCTGATTTTCCAACTGGTGGTATTATTCAAGGTATTGATGGTATTAAAAAAGCTTATGAATCAGGTAAAGGTAGAATTATAGTTCGTTCTAAAGTTGAAGAAGAAACTTTACGCAATGGACGTAAACAGTTAATTATTACTGAAATTCCATATGAAGTGAACAAAAGTAGCTTAGTAAAACGTATCGATGAATTACGTGCTGACAAAAAAGTCGATGGTATCGTTGAAGTACGTGATGAAACTGATAGAACTGGTTTACGAATAGCAATTGAATTGAAAAAAGATGTGAACAGTGAATCAATCAAAAATTATCTTTATAAAAACTCTGATTTACAGATTTCATATAATTTCAACATGGTCGCTATTAGTGATGGTCGTCCAAAATTGATGGGTATTCGTCAAATTATAGATAGTTATTTGAATCATCAAATTGAGGTTGTTGCAAATAGAACGAAGTTTGAATTAGATAATGCTGAAAAACGTATGCATATCGTTGAAGGTTTGATTAAAGCGTTGTCAATTTTAGATAAAGTAATTGAATTGATTCGTAGCTCTAAAAACAAGCGTGACGCTAAAGAAAACCTTATCGAAGTATTCGAGTTCACAGAAGAACAGGCTGAAGCAATTGTAATGTTACAGTTATATCGTTTAACAAACACTGACATAGTTGCGCTTGAAGGTGAACATAAAGAACTTGAAGCATTAATCAAACAATTACGTCATATTCTTGATAACCATGATGCATTATTGAATGTCATAAAAGAAGAATTGAATGAAATTAAAAAGAAATTCAAATCTGAACGACTGTCTTTAATTGAAGCAGAAATTGAAGAAATTAAAATTGACAAAGAAGTTATGGTGCCTAGTGAAGAAGTTATTTTAAGTATGACACGTCATGGATATATTAAACGTACTTCTATTCGTAGCTTTAATGCTAGCGGTGTTGAGGATATTGGTTTAAAAGATGGTGACAGTTTACTTAAACATCAAGAAGTAAATACGCAAGATACCGTACTAGTATTTACAAATAAAGGTCGTTATCTATTTATACCGGTTCATAAATTAGCAGATATTCGTTGGAAAGAATTGGGGCAACATGTATCACAAATAGTTCCTATCGAAGAAGATGAAGTGGTTATTAATGTCTTTAATGAAAAGGACTTTAATACAGATGCATTTTATGTTTTTGCGACTCAAAATGGCATGATTAAGAAAAGTACAGTGCCTCTATTTAAAACAACGCGTTTTAATAAACCTTTAATTGCTACTAAAGTTAAAGAAAATGATGATTTGATTAGTGTTATGCGCTTTGAAAAAGATCAATTAATTACCGTCATTACTAATAAAGGTATGTCATTAACGTATAATACAAGTGAACTATCAGATACCGGATTAAGGGCAGCTGGTGTTAAATCAATAAATCTTAAAGCTGAAGATTTCGTTGTTATGACAGAAGGTGTTTCTGAAAATGATACTATATTGATGGCCACACAACGCGGCTCGTTAAAACGTATTAGTTTTAAAATCTTACAAGTTGCTAAAAGAGCACAACGTGGAATAACTTTATTAAAAGAATTAAAGAAAAATCCACATCGTATTGTAGCTGCACATGTAGTGACAGGTGAACATAGTCAATATACATTATATTCAAAATCAAATGAAGAACATGGTTTAATTAATGATATTCATAAATCTGAACAATATACAAATGGCTCATTCATTGTAGATACAGATGATTTTGGTGAAGTAATAGACATGTATATTAGCTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5362,Drugs,MEG_5362|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|984671414|emb|LT009690.1|1401198-1403600 gi|927048389|gb|CP010890.1|1362542-1364944 gi|925190036|gb|CP012593.1|1360870-1363272 gi|595636499|gb|CP007454.1|2534271-2531869 gi|47118324|dbj|BA000018.3|1356325-1358727,3
,ATGCTCCTTTTGATTCTGATCCCTTTAACTGTTCGCTTTGTAGCAGGATTGAGGGTTTGGTACGGCTATGAGCCCATTTATCAAATATTACGGCTTTTTGCTGATTATTGGCTCGTCTGTCTAGCGATCGGTGCCTTGCTGATTTGGGTGAGCACAACGATTTATTATATGAGTAAAGCCATCAGCTATTTGAATGAAACGATTCAAGCCACGAATCAATTGATTGCTGAACCTACGAAGCGAATCGTTCTTTCCAGCAATCTGATCGACGTGCAAGAAGAAATGAACCAGTTGCGGGAAAAAAATCTACAGGATCAACGAGCTGCCAAAGAAGCAGAGCAGCGGAAAAATGATTTGATCGTCTATCTCGCACATGATTTACGCACACCTTTGACCAGTGTGATCGGCTATTTGACACTTCTAGAAGAAGAACCGCAGCTTTCTTCCGAACTACGCGCACGCTATACCAAGATCGCCTTGCAAAAAGCCCAGCGGCTAGAATTATTGATCAGCGAATTTTTCGAAATCACTCGTTTTAATCTTACAACGATCGCCTTACAGACCGAAACCACGGATCTTAGCTTGATGCTAGAACAGTTGACGTTCGAATTTTTACCGCTGCTAGAAGAAAAGAACCTTCATTGGCAACTGCAACTACAGAAAAAAGTCTATGCGACTGTCGATACAGAGAAGATGGAACGCGTCTTTGATAACTTGATTCGCAATGCCATCAATTATAGTTATGCCGATTCCCCCTTGCATTTAGCCATCAGTACCTCTGATGATATCCTGATTCGTTTGACCAATCATGGAAAAACGATCCCTGCTGAAAAGATTGGCTTGATTTTTGAGCCTTTTTACCGCATGGACGCTTCCCGAGCAACGGCGACGGGTGGGACCGGTCTGGGGCTGCCGATCGCCAAAGAAATCGTTGAAGCATTAGGTGGAAAAATCTGGGCGGAAAGCCGTGACGAAACCATCGTCTTTTCGATTCGCCTACCGAAGGTAGCAATGGAAAAAAATGAACAGCGGTCAAAGCCCCATCCATCTGAACCAACCGCTTAA,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7501,Drugs,MEG_7501|Drugs|Glycopeptides|VanC-type_regulator|VANSC,(Gly)VanSc4:EU151753:4599-5663:1065,5
,atgactctggcattagttggcgaaaaaattgacagaaatcgcttcaccggtgagaaagttgaaaatagtacattttttaactgcgatttttcaggtgccgacctgagcggcactgaatttatcggctgccagttctatgatcgcgaaagtcaaaaaggatgcaattttagtcgcgcaatgctgaaagatgccattttcaaaagctgtgatttatcaatggcagatttccgcaacgtcagcgcattgggcattgaaattcgccactgccgcgcacaaggcgcagatttccgcggtgcaagctttatgaatatgatcaccacgcgcacctggttttgcagcgcatatatcactaataccaatctaagctacgccaatttttcgaaagtcgtgttggaaaagtgtgagctatgggaaaaccgctggatggggactcaggtactgggtgcgacgtttagtggttcagatctctccggtggcgagttttcgactttcgactggcgagcagcaaacttcacacattgcgatctgaccaattcggagttaggtgacttagatattcggggtgttgatttacaaggcgttaagttagacaactaccaggcatcgttgctcatggagcgacttggcatcgcgattattggctag,beta-lactamase,antibiotic target alteration,Fluoroquinolones,MEG_5881,Drugs,MEG_5881|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,1028112027|WP_063866224.1|NG_050526|1|1|qnrB62|qnrB|quinolone_resistance_pentapeptide_repeat_protein_QnrB62 NG_050526:37-681,3
,atgatcgtcaactgcgaccacgacaacctcgacgcctggctggcgctgcgctcggcgctgtggcccacctgcccgttggaagagcaccgcgcggaaatgcgcgagatattggcttcgccgcaccacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgagatcgcgctgcgctacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttataccgtcgaacgcgcccgccgccagggttgggcggcgcgcctgatcgcgcaggtgcaggagtgggcgaagcaacaggggtgcagcgagctggcgtcggataccgacatcgctaatctggattcccaacgcctgcatgcggcgctgggctttgccgaaacggagcgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_101,Drugs,MEG_101|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,644365341|WP_025304332.1|NG_052448|1|1|aac(6')_Serra|aac(6')_Serra|aminoglycoside_6'-N-acetyltransferase NG_052448:101-541,2
,atgaggactgaaaaagaaattttaaatttagtttctgaatttgcttatcaacgaagcaatgtaaaaattattgctctcgagggttcaagaactaatgaaaatataaaaaaagataagtttcaagattatgattttgcttttttcgtatcagatattgagtgtttcacacatgaagaaagttggttaagtttatttggagaattattgtttatacagaaaccagaagatatggaattattcccacctgatttagattatggttacagttatataatgtattttaaagatggcataaaaatggatattacattaattaatttaaaagatttaaatcgttattttagtgattctgatggtcttgtaaaaattttagttgataaagataatttagtaactcaagaaattgttccagatgactcatattattggttaaaaaaaccaacagaacgagaattttatgattgctgcaatgagttttggagtgtctcaacgtatgtagcaaagggtgtttttagaagagaaatattatttgctttagatcatttcaataatattttacgtcctgaattattaagaatgatttcttggtatattggctttaataggggttttgattttagtttaggaaagaattataagtttataaacaaatatttaactgataaagaattcaatatgtttttagctacttttgagatgaatggatatagaaagacataccaatcttttaagctttgttgtgaattatttaaatattattcaaataaagtaagttgtttaggaaattataaatatccaaattacgaaaaaaatattgagaattttattcgtaataattatgagaattaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_989,Drugs,MEG_989|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT6,686417596|WP_031916103.1|NG_048079|1|1|str|str|streptomycin_adenylyltransferase_Str NG_048079:75-923,2
,ttgaatattaaatatttatttacggctgtaacttttctcttgattgcttgcgaaagtatggcttctgaaaaaaacttaacgcttacccatttcaaaggtccgctctatattgtagaagataaggagtatgtacaggaaaactcaatggtttacatcggcaccgatggtataaccatcattggtgcgacatggactcctgagactgctgaaactctttataaagaaatacggaaggtcagccccctccccataaacgaagtcattaataccaattaccatactgatcgagctggtggaaatgcttattggaaaacgcttggggcaaagatcgtggccacacagatgacctacgacctgcagaaaagccagtggggaagtattgtaaacttcactcgacaaggtaataataaatacccaaatctggagaaaagtctgccggatactgtttttcctggagactttaacttgcaaaatggcagcatccgcgccatgtatttaggcgaagcacatactaaggatggtatctttgtgtacttcccagcagagcgcgttttgtatgggaactgcattctcaaagaaaatctgggtaatatgagttttgccaacagaactgagtacccaaaaaccttggaaaaacttaaaggacttatcgagcagggggagcttaaagtcgactcgatcattgcagggcatgatactccgatacatgacgtaggcctgatcgatcactaccttacactgcttgagaaggcgcctaagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6183,Drugs,MEG_6183|Drugs|betalactams|Class_B_betalactamases|SFH,1104448840|WP_071766619.1|NG_052115|1|1|blaSFH-1|blaSFH|subclass_B2_metallo-beta-lactamase_SFH-1 NG_052115:101-862,0
,atgcgcgataccaaattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccaggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccagcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggatccaccaacggcttcggcgcctacgtggcgttcattccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5615,Drugs,MEG_5615|Drugs|betalactams|Class_C_betalactamases|PDC,1201190441|WP_087587961.1|NG_054979|1|1|blaPDC-193|blaPDC|class_C_beta-lactamase_PDC-193 NG_054979:1-1194,0
,ATGAAATTTTTTAAAATCAATCCAAACACCGATTTTAACTTGCTTTGTTCTCTTATAAACCCTCATAAAATGGGGCAAAAGATTATGAGTGAGAAAACAAAAACTCATTATATTTTTATCAAAGATATTTCTACTCCTGCAGCAAATATTTTAAAACAAGATGCTTTAAGAGTAGGAGCTGAACTTATTACCCATAAAGAAGTAATTACTGCAAAAATCACTCATTCAAATGCGCTTTTAATGGCAAGTAAAGAACAAATTCAAAAGCTTATTGCTAAAGAAAAACTTCAAGATTTTGGACTTAAAAATTTGGCTCTTTTTTTGCAAAAAGATTTTTTAAAACCAAAAAAAGCCGAGCTTATGGCAGTGATTAACGTCAATGAAGACAGTTTTAATGCAAAAAGTCGTGTGAGTGAAAAAGACTTTGAAAAAAGGCTTAATGATTTTCTTGCTTTAAAGCCTGAGTATATCGATATAGGTGCAGTAAGTTCAAGACCTGGGAGTGAGTATTGTGGTAAGGAAGAAGAATTTAAAAGACTCAAAAAAATACTTGACTTAATTCATGAGAAAAATTATCACGAAAAAGCGATTTTTAGTTTAGATAGTTTTGATGAGTATTGTCTAGAATATGCCTTAAATAAGGGTTTTAAACTCATTAATGATATTACAAGTTTAAGAAATCTTAATCTAGCTAAACTTGCAAGTAAATATGAGGCAAAATATTGCTTAATGCACATGCAAAACAATCCAAATAACATGCAAGATAATCCTTTTTATGAAGATTTACTTGATGAGATGACTTTGTTTTTTAAAGAAAAACTTGAACTTTTAGAAAGTTTTGGAGTAAAAGAAAGTATTTTAGATGTAGGTATTGGCTTTGGAAAGAGTGCGGAGCATAATATGATTTTAATCAAACATTTGGAGCATTTTTTGCAATTTAATAAACCTTTGCTTATAGGTGCGAGTCGCAAAAGTGTGATTAATGCATATTTTCAAAGCGAGATTAAAGATCGTTTGGCAGGGACTTTGTATTTGCATTTAAAGGCTTTTGAAAATGGTGCTAGTATTATAAGAGTGCATGATTTATATGAGCACAAACAACTTTTTGCTTTAGTACAGGCAATGGATAATATAGGAGTTTAG,antibiotic resistant folP,antibiotic target replacement,Sulfonamides,MEG_2937,Drugs,MEG_2937|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|FOLP,gi|152938384|gb|CP000768.1|958384-957242,8
,ATGACCAGCCTTGCGCATCATGCGACAGAAAACCGCTCTGTAGCCGAATTTACTGAACAGGCTTACTTGAATTATGCCATGTACGTCATTATGGACCGTGCATTACCGCATATCAGTGATGGCTTAAAGCCCGTACAGCGCCGTATTGTCTATGCCATGAGCGAGCTAGGCTTAAAAAGCAGTGGCAAGCCAAAAAAATCAGCGCGTACAGTGGGTGATGTACTTGGTAAATACCACCCACATGGTGACTTGGCATGTTATGAAGCCATGGTACTCATGGCTCAGCCATTTAGTTACCGCTATCCTTTAATCGAAGGTCAGGGGAACTGGGGCTCACCTGATGATCCTAAGTCTTTTGCTGCGATGCGTTATACCGAAGCAAAACTCTCGGCTTATAGTGAATTATTGCTGAGCGAATTAGGTCAGGGCACTAGCGAATGGCAAGATAACTTTGATGGTTCTTTAAAAGAACCGATCACTTTACCTGCGCGTGTACCTAATATTCTTCTTAATGGTACGACAGGTATTGCTGTTGGGATGGCAACTGATATCCCGCCACATAATTTGCGTGAAGTTGTAAAAGGCACAATTGCTTTAATCCGTAATCCGCAAACCTCGGACGAAAAATTAGCTGAATATATTCCGGCTCCGGATTTACCAACCAAAGCTGAAATTATTACCCCGCCAGAAGAATTACTCAAAATCCAGACCACTGGTCGTGGTAGTTATCGTATGCGAGCGGTATATACCATTGAGAAAAATGAAATTGTAATTACTGAGCTGCCATATCAAGTCTCTGGTTCTAAGGTAATTACTCAAATTGCTGACCAGATGCAGGCTAAAAAGCTGCCATTAGTTGTCGACGTGCGTGATGAATCGGATCATGAAAACCCGACACGACTCGTGATTGTACTGCGCTCTAACCGTATTGATGCGGAAGCAGTGATGAGCCACTTATTTGCGACCACCGATTTAGAATCAAGCTATCGTGTCAATTTGAACATGATTGGCGAAGATGGCCGTCCTCAGGTGAAATCAATTCGTCGTATTTTGCTTGAATGGATCGAGATCCGTAAAAAAACGGTAACTCGTCGTTTGCAGTACCATTTAAACCGTATTGAAAAGCGCCTGCATATTTTGGCAGGTCTTTTAATTGCTTATCTCGATATTGATACAGTCATTCGTATTATTCGTGAAGAAGACCAGCCTAAGCCAGTCTTGATGGAACACTTTAATATTGATGAGATACAGGCCGAGGCGATTTTAGAGCTTAAATTACGTCATTTGGCAAAGCTTGAAGAGATGGAAATCCGTCATGAACAAGATGAACTTTCTGCGAAAGCTGCCATTATTCGTGAACAACTCGAAAATCCTGAATCTTTAAAAAACCTAATTATCAGTGAATTAAAAGAAGATGCGAAAAAGTTCGGTGATGAGCGCCGTTCTCCAATTGTTGCACGTGCTGAAGCAGTTCAAATTAAAGAACAGGATTTAATGCCAGCTGAAACGGTAACGGTGGTTTTGTCTGAAGCAGGCTGGGTTCGTGCGGCAAAAGGTGCGGATGTGGATGCCGAAAATCTCAACTACCGTGCTGGGGACCAATATTTAAGTCATGCTGTCGGGAAAACCAATCAGCGAGTTTACTTCCTTGATGAAACAGGGCGCAGCTATGCCTTGCCAATTAGTAACTTACCTTCAGCGAGAGGCTTGGGGGATCCATTAAGTTCTAAATTATCACCAGCAAGTGGCGTATCGTTTATTCAGGTTTATTTAGATGATGATGAGTCTGAATTGATTGCTGCAAGTTCGGCAGGTTATGGTTTTAAAACGCAAACCAAGCAATTAGATACCAATGCGAAAGCCGGTAAGACATTCTTAACGGTTCCGGATAAGGCAAAGGCTTTACCACTCATTTCTGCCCAAAACATGACGCATTTGGCTGTACTGAGCTCAGCAGGGCGTTTGTTAATTTTAGATTTGGCAGAACTACCAAATTTAAATAAAGGTAAAGGTAATAAGTTGATACAACTTGAAGGCAAAGAGCAAATTTTATCCATGACAACCCTGAACTTAGATGAAATAATTCAGGTGGTTGCAGGTCAACAACATCTCAAATTAAAAGGTGATGATCTACAAAAATACATGGGTAAACGTGCTTCGAAAGGTCAGCTCTTACCACGTGGATATCAAAAAGCAAATAAACTGTTGATTCAGAGATAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5358,Drugs,MEG_5358|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|939559781|gb|CP012952.1|3863522-3861303 gi|169147133|emb|CU459141.1|3709146-3706927 gi|88758893|emb|CT025948.2|19-2238,3
,atgaaaaataataatgtaacagaaaaagaattattttatattttagatttatttgaacacatgaaagtaacttattggttagatggtggctggggggtagatgtattaactggaaaacaacaaagagaacacagagatatagatatagattttgacgctcaacacactcaaaaagttatacaaaaattagaagatataggatacaaaatagaagttgattggatgccttcacgtatggaacttaagcatgaagaatatgggtatttagatattcatcctataaatctaaatgatgatggatcaattacccaagcaaacccagaaggtggtaattatgttttccaaaatgactggttttcagaaactaattacaaagatcgaaaaataccatgtatttcaaaagaagctcaacttctttttcattctggttatgatttaacagaaacagaccattttgatataaaaaatttaaaatcaataacataa,lincosamide nucleotidyltransferase (LNU),antibiotic inactivation,MLS,MEG_3600,Drugs,MEG_3600|Drugs|MLS|Lincosamide_nucleotidyltransferases|LNUA,499964292|WP_011645010.1|NG_047917|1|1|lnu(A)|lnu(A)|lincosamide_nucleotidyltransferase_Lnu(A) NG_047917:101-586,7
,ttgaaaaaaatacttttactttttagtcttttttactcttttgctttggcaaatgataaattaaaagatttttttaaagactacaatacaagcggagtttttataacttttgatggaaaacattatgcaagtaataattttaaaagagctaaagaacctttttctcctgcttcgacttttaaaatttttaatgctttaattgcgcttgataacggtatagttaaagatacaaaggaaattttttatcattataagggtgaaaaagtatttttgccttcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcctatggaaatacaaaaatttcaaaaatcgataccttttggttggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcacaaaattctttacctttttccaagaaaagtcaagaagaagttaaaaaaattattctttttaaagaagataaaatccaaaaaatttatgctaaaacaggttttaatgatggtataaatttggcttggattgttggatttatagagagtaaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagagaagaattgctagaaaaatatatttattctttaaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4629,Drugs,MEG_4629|Drugs|betalactams|Class_D_betalactamases|OXA,1391852901|WP_109545086.1|NG_057506|1|1|blaOXA-632|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-632 NG_057506:1-747,0
,atggagctgcatggggacaaggtcgtactgcgcccggtgaccgatggcgataccgagatcctcgaaagggtcgtacgagaaccggaagtcgcggcgtggtggtcgcctccggacgactacgagggcatgctggccgtggttttcgagggtgaggtcatcggcgccgtccagttcgacgaagagaccgatcccgagttccgtcatgccggcatcgacatcttcctgacggcgaggcgtcacgggaaggggcttggtgccgacacggtgcgcacgctggcccggtggctggtccaggaacgcggccaccaccggctgaccatcgatcccgccgcggccaacaccgcggcgatccgctgttacagcaaggtcggtttcaaacccgtggggatcatgcgggcgtacggacgcgaccaccggacgggcgcctggcaggacgggctgctgatggatctgctcgcagacgagctgtcctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_197,Drugs,MEG_197|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,822211065|WP_046930149.1|NG_054689|1|1|aac(6')_Strep|aac(6')_Strep|aminoglycoside_6'-N-acetyltransferase NG_054689:101-574,2
,atgagggaagcggtgaccatcgaaatttcgaaccaactatcagaggtgctaagcgtcattgagcgccatctggaatcaacgttgctggccgtgcatttgtacggctccgcagtggatggcggcctgaagccatacagcgatattgatttgttggttactgtggccgtaaagcttgatgaaacgacgcggcgagcattgctcaatgatcttatggaggcttcggctttccctggcgagagcgagacgctccgcgctatagaagtcacccttgtcgtgcatgacgacatcatcccgtggcgttatccggctaagcgcgagctgcaatttggagaatggcagcgcaatgacattcttgcgggtatcttcgagccagccatgatcgacattgatctagctatcctgcttacaaaagcaagagaacatagcgttgccttggtaggtccggcagcggaggaattctttgacccggttcctgaacaggatctattcgaggcgctgagggaaaccttgaagctatggaactcgcagcccgactgggccggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaataaaacgcctacctgcccagtatcagcccgtcttacttgaagctaagcaagcttatctgggacaaaaagaagatcacttggcctcacgcgcagatcacttggaagaatttattcgctttgtgaaaggcgagatcatcaagtcagttggtaaatga,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_876,Drugs,MEG_876|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,695263466|WP_032490336.1|NG_064655|1|1|aadA2|aadA2|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA2 NG_064655:101-892,2
,atggttaaaaaatcactgcgccagttcacgctgatggcgacggcaaccgtcacgctgttgttaggaagtgtgccgctgtatgcgcaaacggcggacgtacagcaaaaacttgccgaattagagcggcagtcgggaggcagactgggtgtggcattgattaacacagcagataattcgcaaatactttatcgtgctgatgagcgctttgcgatgtgcagcaccagtaaagtgatggccgcggccgcggtgctgaagaaaagtgaaagcgaaccgaatctgttaaatcagcgagttgagatcaaaaaatctgaccttgttaactataatccgattgcggaaaagcacgtcaatgggacgatgtcactggctgagcttagcgcggccgcgctacagtacagcgataacgtggcgatgaataagctgattgctcacgttggcggcccggctagcgtcaccgcgttcgcccgacagctgggagacgaaacgttccgtctcgaccgtaccgagccgacgttaaacaccgccattccgggcgatccgcgtgataccacttcacctcgggcaatggcgcaaactctgcggaatctgacgctgggtaaagcattgggcgacagccaacgggcgcagctggtgacatggatgaaaggcaataccaccggtgcagagagcattcaggctggactgcctgcttcctgggttgtgggggataaaaccggcagcggtggctatggcaccaccaacgatatcgcggtgatctggccaaaagatcgtgcgccgctgattctggtcacttacttcacccagcctcaacctaaggcagaaagccgtcgcgatgtattagcgtcggcggctaaaatcgtcaccgacggtttgtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_2162,Drugs,MEG_2162|Drugs|betalactams|Class_A_betalactamases|CTX,1391852875|WP_109545060.1|NG_057474|1|1|blaCTX-M-208|blaCTX-M|class_A_extended-spectrum_beta-lactamase_CTX-M-208 NG_057474:1-876,0
,GTGTCCGGCCAACGGTCGCGACGCCAGTGGGGCTGGTATCCGCTCACTGATGACTGGGCGGCGCGGATCGTCGCCGAATCCGGTGTTCGCTCAGGGGAGTTCGTTGTGGATCTGGGCGCAGGACACGGCGCGCTGACGGCACATCTGGTTGCCGCTGGCGCCAGGGTGCTAGCCGTCGAGCTGCATCCGGGGCGGGCTCGACACCTTCGTTCACGGTTTGCCGAGGAAGATGTCCGGATAGCGGAAGCGGACCTGCTCGCCTTCCGGTGGCCGCGACGGCCATTTCGGGTGGTGGCGAGCCCGCCCTACCAAGTCACCAGCGCACTGATCCGGAGTCTCTTGACGCCGGAATCCCGGCTGCTGGCTGCCGACCTGGTGCTGCAGCGCGGGGCTGTGCACAAACATGCGAAGCGAGCACTTGTTCGCCATTGGACGCTACGGGCCGGAATCACATTGCCGCGAAGCGCTTTCCATCATCCACCGCAGGTGGATTCGTCGGTGCTGGTGATCAGGCGGCGCTGA,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2778,Drugs,MEG_2778|Drugs|MLS|23S_rRNA_methyltransferases|ERM41,(MLS)Erm41:EU590124:258-779:522,7
,ATGATGAAAAAATCGTTATGCTGCGCTCTGCTGCTGACAGCCTCTTTATCCACGTTTGCCGCCGCCAAAACAGAACAACAGATTGCCGATATCGTTAATCGCACCATCACCCCGTTGATGCAGGAGCAGGCTATTCCGGGTATGGCTATTGCCGTTATCTACCAGGGAAAACCCTATTATTTCACCTGGGGTAAAGCCGATATCACCAATAACCACCCAGTCACGCAGCAAACTCTGTTTGAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGATGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGCTGCACTTAGCCACCTACACGGCAGGCGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGTTTTTATCAAAACTGGCAGCCGCAATGGGCCCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCCTCAGGAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACAGTTCCGCAGAACGAACAAAAAGATTATGCCTGGGGCTATCGCGAAGGGAAGGCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGTGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAAGAGAAAACGCTCCAGCAGGGCATTGCGCTTGCGCAGTCTCGCTACTGGCGTATTGGCGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCAATCATCAACGGTAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCTGCCCCCGCAGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACTGGAGGATTTGGCAGCTACGTAGCCTTCGTTCCAGAAAAAAACCTTGGCATCGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGTGTCGAGGCGGCCTGGCGCATTCTTGAAAAGCTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1896,Drugs,MEG_1896|Drugs|betalactams|Class_C_betalactamases|CMY,gb|HQ832678|+|0-1146|ARO:3002077|CMY-64 [Escherichia coli] ,0
,atgaccaactactttgatagccccttcaaaggcaagctgctttctgagcaagtgaagaaccccaatatcaaagttgggcggtacagctattactctggctactatcatgggcactcattcgatgactgcgcacggtatctgtttccggaccgtgatgacgttgataagttgatcatcggtagtttctgctctatcgggagtggggcttcctttatcgtggctggcaatcaggggcatcggtacgactgggcatcatctttcccgttcttttatatgcaggaagaacctgcattctcaagcgcactcgatgccttccaaaaagcaggtaatactgtcattggcaatgacgtttggatcggctctgaggcaatggtcatgcccggaatcaagatcgggcacggtgcggtgataggcagccgctcgttggtgacaaaagatgtggagccttacgctatcgttggcggcaatcccgctaagaagattaagaaacgcttcaccgatgaggaaatttcattgcttctggagatggagtggtggaattggtcactggagaagatcaaagcggcaatgcccatgctgtgctcgtctaatattgttggcctgcacaagtattggctcgagtttgccgtctaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1602,Drugs,MEG_1602|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATB|RequiresSNPConfirmation,1105502213|WP_071846363.1|NG_052485|1|1|catB3|catB3|type_B-3_chloramphenicol_O-acetyltransferase_CatB3 NG_052485:101-733,6
,atgatgaaaaaatcgttatgctgcgctctgctgctgacagcctctttctccacatttgctgccgcaaaaacagaacaacagattgccgatatcgttaatcgcaccatcaccccgttgatgcaggagcaggctattccgggtatggccgttgccgttatctaccagggaaaaccctattatttcacctggggtaaagccgatatcgccaataaccacccagtcacgcagcaaacgctgtttgagctaggatcggttagtaagacgtttaacggcgtgttgggcggcgatgctatcgcccgcggcgaaattaagctcagcgatccggtcacgaaatactggccagaactgacaggcaaacagtggcagggtatccgcctgctgcacttagccacctatacggcaggcggcctaccgctgcagatccccgatgacgttagggataaagccgcattactgcatttttatcaaaactggcagccgcaatggactccgggcgctaagcgactttacgctaactccagcattggtctgtttggcgcgctggcggtgaaaccctcaggaatgagttacgaagaggcaatgaccagacgcgtcctgcaaccattaaaactggcgcatacctggattacggttccgcagaacgaacaaaaagattatgcctggggctatcgcgaagggaagcccgtacacagttctccgggacaacttgacgccgaagcctatggcgtgaaatccagcgttattgatatggcccgctgggttcaggccaacatggatgccagccacgttcaggagaaaacgctccagcagggcattgcgcttgcgcagtctcgctactggcgtattggcgatatgtaccagggattaggctgggagatgctgaactggccgctgaaagctgattcgatcatcaacggcagcgacagcaaagtggcattcgcagcgcttcccgccgttgaggtaaacccgcccgcccccgcagtgaaagcctcatgggtgcataaaacgggctccactggtggatttggcagctacgtagccttcgttccagaaaaaaaccttggcatcgtgatgctggcaaacaaaagctatcctaaccctgtccgtgtcgaggcggcctggcgcattcttgaaaagctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1796,Drugs,MEG_1796|Drugs|betalactams|Class_C_betalactamases|CMY,1343491233|WP_104009849.1|NG_056410|1|1|blaCMY-156|blaCMY|class_C_beta-lactamase_CMY-156 NG_056410:1-1146,0
,ATGGAAATAGGATTTACTTTTTTAGATAAAATAGTACACGGTGTTCGTTGGGACGCTAAATATGCCACTTGGGATAATTTCACCGGAAAACCGGTTGACGGTTATGAAGTAAATCGCATTGTAGGGACATACGAGTTGGCCGAAGCGCTTTTGAAGGCAAAGGAACTGGCTGCTACCCAAGGTTACGGATTGCTTCTATGGGACGGTTACCGTCCGAAGCGTGCTGTAAATTGTTTTATGAAATGGGCT,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7448,Drugs,MEG_7448|Drugs|Glycopeptides|VanN-type_resistance_protein|VANN,VanX_bc_1_Y15708,5
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatacttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttattcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4449,Drugs,MEG_4449|Drugs|betalactams|Class_D_betalactamases|OXA,1559612989|WP_128268254.1|NG_063859|1|1|blaOXA-755|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-755 NG_063859:14-838,0
,atgttcaaagttgttagtagtttattgttctacatgaccgcctctctaatggctgtagctagtccgttagcccattccggggagtcgagaggtgagtatccgacagtcagcgaaattccggtcggagaagttcggctgtaccagattgacgatggtgtttggtcgcatatcgcaacgcatacgtttgatggcgtggtgtacccgtccaatggtctcattgtccgtgatggcgatgagttgcttttgattgatacagcttggggtacgaaaaacacagtggcccttctcgcggagattgagaagcaaattggacttcccgtaacgcgttcagtctccacgcactttcatgacgaccgcgtcggcggagttgatgcccttagggcggctggagtggcgacgtacgcatcgccctcgacacgccgtctagccgaggcagaggggaacgaggttcccacacactctctagaagggctctcatcgagtggggacgcagtgcgtttcggtccagtagagctcttctatcctggtgctgcgcattcgaccgacaatctggttgtatacgtcccgtcagcgaacgtgctatacggtggttgtgccgttctggaattgtcacgcacatccgcgggaaacgtggccgatgccgacctggctgaatggcccggttccgttgagcggattcaacaacattacccagaagcagaggtggtcattcccgggcacggtctaccgggcggtctagacttgctccagcacacagcgaacgttgtcaaagcacacacaaatcgctcagtcgccgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7715,Drugs,MEG_7715|Drugs|betalactams|Class_B_betalactamases|VIM,1028110985|WP_063865197.1|NG_050375|1|1|blaVIM-47|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-47 NG_050375:1-801,0
,atgaatgaaaaaatcttagtggttgatgatgaaaaagaattggccgacttagttgaagtatatctgaaaaacgatggatataccgtttataaattttataatggcaaggatgcactaaagtgtattgaatccgtggaactggatttagccatattggatatcatgcttccggatgtagacgggtttcagatctgccaaaaaatccgggaaaagttttacttccctgttatcatgctgacagcaaaagtggaggacggagataaaatcatgggactgtccgtggcagatgattatattacgaagccatttaacccgctggaaatggttgcgagagtaaaggcgcagctaaggcagtatatgcggtacaagcagcccagcttaaagcaggaggctgaatgcacagaatacgatatcagagggatgacaatcagcaagagcagccataagtgtatcctgtttggaaaggagattcagctgacgccaacggagttttcgattctttggtatctgtgcgagcgtcaggggacggttgtttctacggaggaattatttgaggcagtatggggcgaacggtattttgacagcaataataccgtgatggcgcatatcgggcgtctccgggagaaaatgaaggaaccgtcaagaaatccgaaatttataaaaactgtgtggggagtgggatataccattgaaaaatag,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7475,Drugs,MEG_7475|Drugs|Glycopeptides|VanD-type_regulator|VANRD,1028100592|WP_063856727.1|NG_048422|1|1|vanR-D|vanR-D|VanD-type_vancomycin_resistance_DNA-binding_response_regulator_VanR NG_048422:1-699,5
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtaccatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgacaagcctggtaaatattggaaagaactaaaaaatacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacccaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagtgtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtagtgtttatacctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_543,Drugs,MEG_543|Drugs|betalactams|Class_C_betalactamases|ADC,1440786783|WP_114699271.1|NG_061395|1|1|blaADC-179|blaADC|class_C_beta-lactamase_ADC-179 NG_061395:1-1152,0
,ATGGGCGAACTGGCCAAAGAAATTCTCCCGGTCAATATCGAAGACGAGCTGAAACAGTCCTATCTCGACTACGCGATGAGCGTGATCGTCGGGCGGGCCCTGCCGGATGCACGTGACGGCCTGAAGCCGGTGCACCGCCGTGTGCTTTATGCCATGAGCGAGCTGGGCAACGACTGGAACAAGCCCTACAAGAAATCCGCCCGTGTGGTCGGCGACGTGATCGGTAAGTACCACCCGCACGGCGACACCGCGGTCTACGACACCATCGTGCGCATGGCGCAGCCGTTCTCGCTGCGCTACATGCTGGTAGACGGCCAGGGCAACTTCGGTTCGGTGGACGGCGACAACGCCGCAGCCATGCGATACACCGAAGTGCGCATGGCCAAGCTGGCCCACGAACTGCTGGCGGACCTGGAAAAGGAAACCGTCGACTGGGTGCCCAACTACGATGGCACCGAGCAGATCCCGGCGGTCATGCCGACCAAGATTCCCAACCTGCTGGTCAACGGTTCCAGCGGTATCGCCGTGGGCATGGCGACCAACATCCCGCCGCACAACCTCGGCGAAGTGATCGACGGCTGCCTGGCGCTGATGGACAACCCCGACCTGACCGTCGATGAGCTGATGCAGTACATCCCCGGTCCGGACTTCCCCACCGCCGGCATCATCAACGGCCGCGCCGGGATCATCGAGGCCTACCGCACCGGTCGCGGGCGCATCTACATCCGTGCCCGCGCCGTCGTCGAGGAGATGGAGAAGGGCGGCGGTCGCGAGCAGATTATCATCACCGAGCTGCCGTACCAGTTGAACAAGGCGCGGTTGATCGAGAAGATCGCCGAGCTGGTGAAAGAGAAGAAGATCGAGGGTATTTCCGAGCTGCGCGACGAGTCTGACAAGGACGGCATGCGCGTGGTCATCGAGCTGCGTCGCGGCGAGGTGGGCGAGGTGGTCCTCAACAACCTCTATGCCCAGACCCAGCTGCAGAGCGTGTTCGGCATCAACGTGGTGGCCCTGGTCGACGGCCAGCCGCGCACGCTGAACCTGAAGGACATGCTCGAGGTGTTCGTCCGCCACCGCCGCGAAGTGGTGACCCGGCGTACCGTCTACGAGCTGCGCAAGGCCCGCGAGCGCGGGCACATCCTGGAAGGCCAGGCGGTCGCCCTGTCGAACATCGACCCGGTGATCGAGCTGATCAAGAGTTCGCCGACCCCGGCCGAGGCCAAGGAACGCCTGATCGCCACTGCCTGGGAGTCCAGCGCGGTGGAAGCGATGGTCGAGCGTGCCGGCGCCGACGCCTGTCGTCCGGAAGACCTGGATCCGCAGTACGGCCTGCGCGACGGCAAGTACTACCTGTCGCCGGAGCAGGCCCAGGCGATCCTCGAGCTGCGCCTGCATCGCCTGACCGGCCTGGAGCACGAGAAGCTGCTCTCCGAATACCAGGAAATCCTCAACCTGATCGGCGAGCTGATCCGCATCCTGACCAACCCGGCGCGCCTGATGGAGGTGATCCGTGAGGAACTGGAAGCGGTCAAGGCCGAATTCGGCGATGCTCGCCGCACCGAGATCGTGGCTTCCCAGGTCGACCTGACCATCGCCGACCTGATCACCGAGGAAGACCGCGTGGTGACCATCTCGCACGGCGGCTACGCCAAGTCCCAGCCGCTGGCCGCCTACCAGGCGCAGCGTCGCGGCGGCAAAGGCAAGTCCGCCACCGGGATGAAGGACGAGGACTACATCGAACACCTGCTGGTGGCCAACAGCCATGCGACCCTCCTGCTGTTCTCCAGCAAGGGCAAGGTCTACTGGCTGCGTACCTTCGAGATTCCGGAAGCCTCGCGTACCGCGCGTGGCCGGCCGCTGGTGAACCTGCTGCCGCTGGATGAGGGCGAGCGGATCACCGCGATGTTGCAGATCGACCTGGAGGCGCTGCAGCAGAACGGTGGCGCCGATGACGACCTCGACGAAGCCGAAGGCGCGGTGCTCGAGGGCGAGGTGGTCGAGGCCGCCGAGGTCGAGGAAGTCGAGGGCGAGACCGCCGAGCTGGTGGCCGAGCCGACCGGCGCCTACATCTTCATGGCCACCGCCTTCGGTACCGTGAAGAAGACCCCGCTGGTGCAGTTCAGCCGTCCGCGCAGCAGCGGCCTGATCGCGCTCAAGCTGGAAGAGGGCGACACCCTGATCGCCGCCGCGATCACCGATGGCGCCAAGGAAGTCATGCTGTTCTCCAGCGCCGGCAAGGTGATCCGCTTCGCCGAGAGCGTGGTGCGCATCATGGGCCGCAACGCCCGCGGCGTACGTGGCATGCGCCTGGGCAAGGGGCAGCAGCTGATCTCCATGCTGATTCCGGAGTCCGGGGCGCAGATCCTCACCGCCTCCGAGCGCGGCTTCGGCAAGCGTACCCCGCTGAGCAAGTTCCCGCGTCGCGGCCGCGGCGGCCAGGGGGTGATCGCCATGGTCACCAACGAGCGCAACGGCGCGCTGATCGCCGCGGTACAGGTCCAGGAAGGCGAGGAGATCATGCTGATTTCCGACCAGGGCACCCTGGTGCGGACGCGTGTCGACGAAGTCTCCCTGTCCGGCCGCAATACCCAGGGCGTAACCCTGATCAAGCTCGCCAGCGACGAGGTACTGGTCGGTCTGGAGCGTGTCCAGGAGCCGTCGGGCGGAGATGACGAGGACCTGCCCGAGGGCGAGGAAGCTGCCGAATCTCTGGGCGAGTCGGCCGAGTCCGAGTCCGAGCCCGCGGCGGAAGCGGAAGGCAACGAAGAGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_3226,Drugs,MEG_3226|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|GYRA,gi|926451317|emb|LN871187.1|1956640-1959411 gi|553895034|gb|CP006832.1|3559193-3556422 gi|553886202|gb|CP006831.1|3559193-3556422 gi|543879514|gb|CP006705.1|3338780-3336009 gi|110227054|gb|AE004091.2|3559198-3556427 gi|459928|gb|L29417.1|PSEGAS|265-3036,3
,atggataatagaaattctaaaaactcacagaactttataacatcccgaaaatatatcaatgatatattaaaagaaacaagcataggcgctgatgataatataattgaaattggaactggaaaaggacattttacaaagcaattatctaatattgctagatttgtaactggcgtagaaattgataagtctttatatcgtaatttaaaaaaggatattgaattgtccaataatgtcgaattagtgaacaaagatatattgaagtatcagttccctaaatgtaaaaagtataaggtttttggtaatataccatacaatataagtactgaaatagttaaaaaaatcttatatgaggggaatgctgaatataattaccttattgtagaatatggttttgctaaacgaattatggataaacgaagagcactaggtctattacttttgactaaattagatgttgaaatattaaaagtaattcccaacacttattttcatcctaaacctagagtagaatcggcattaatcttattaaagcagcacaaatctttaatccaaaaaagagacgaaaaattatatcaattttttgtgtataaatgggtaaataaagagtataaacaattatttacaaaaaatcagtttaataaggcgttaaaaaatgctaaagtaaaaaatataaatgaaatgacaaatgaacaatttatatcaatttttcatagttataaattgtttaattaa,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2782,Drugs,MEG_2782|Drugs|MLS|23S_rRNA_methyltransferases|ERM44,751612012|WP_041079981.1|NG_055651|1|1|erm(44)v|erm(44)v|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(44)v NG_055651:101-832,7
,atggacacaacgcaggtcacattgatacaccaaattctagctgcggcagatgagcgaaatctgccgctctggatcggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatattgatctgacgtttcccggcgagaggcgcggtgagctcgaggcaatggttgaaatgctcggcgggcgcgtcacggaggagttggactatggattcttagcggagatcggggatgagttacttgactgcgaacctgcttggcgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgccgggcggccagtccgttgtaacagctgggaggcgatcatctgggattacttttactatgccgatgaagtaccaccaatggactggcctacaaagcacatagagtcctacaggctcgcatgcacctcactcggggcggaaaaggttgaggtcttgcgtgccgctttcaggtcgcgatatgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_748,Drugs,MEG_748|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,757605905|WP_042852798.1|NG_052540|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_052540:101-634,2
,ttgcccagacgcctgctccttgcggccctgctgctcgccggcccggcatcggcgcagcaggaagcgccgcgtcagtcgctgctgccgccgccgccccgctatatggtgagcgaatccgccatgaagtcggtccgcaatcccaaggagatcgaaagcgaaagcggcggtcgcctgggcgtggcgctggtcgacagcaagggcgcgctgatccttggcttcaaccgcgacgagcgtttcgccatgtgctcgaccttcaaggccccgcttgccgcggccgtcctgtccggcgcggaaggcaataaattcgggctggaaggccagattggctttaccaaggccgacctgctcgaccatgcgccggtggtcaagaagaacgccaggcgcggccgcatgtcgatggaggaactggccgccgccgccgtggaggtcagcgacaacagtgccgccaacctgctgctgccgatgatcggcggcccggaaggcttcacccgctatgttcgcgcccatggcgacaatgtgacgcgcctcgaccgcaccgaaccggcgctcaacgaaaatgccgagggcgacgaacgcgacaccaccagccccgccgccatggccgggttgatgcgccgcctgatcttcaccgatttgaagccggaaagcgccgccagactgcgcggctggctgaacgccagcaccacgggcggcaaccgcatcaaggcaggactgcccaaagactggacctccggcagcaagacggggacatgcggcaccgcctataatgacgtcgcgctggtgaaggcgccttcgggcgaggaatatatactcgccatctatctcgaccgccccacggtcgacgccaaggccgccgaagccgccatagccgaaaccgcccgcgccgcgctggatttcgtcggcaaggcgcagaagacggggctggagtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_1305,Drugs,MEG_1305|Drugs|betalactams|Class_A_betalactamases|BLASGM,503612518|WP_013846594.1|NG_049986|1|1|blaSGM-4|blaSGM|class_A_beta-lactamase_SGM-4 NG_049986:101-1030,0
,AAGGCAGTGGTAGCGCTGAAGAATATTCGTGCAATTGTCGTTATTCATTATAAAAGGGCAGGTTTTAAAGGATATTTTAAAATTTAAAACAAGCTTTTAAGAGCAGATGGCGGATGCCTTGCCAAAGAGAGGCGATGAAGGACGTACTAGACTGCGATAAGCTATGCGGAGCTGTCAAGGAGCTTTGATGCGTAGATGTCCGAATGGGGCAACCCAACTAATAGAGATATTAGTTACTCTAATTTAGAGAGCGAACCTAGTGAAGTGAAACATCTCAGTAACTAGAGGAAAAGAAATCAACGAGATTCCCTAAGTAGTGGCGAGCGAACGGGGAAAAGGGCAAACCGAGTGCTTGCATTCGGGGTTGAGGACTGCAACATCCAAGAGAACGCTTTAGCAGAGTTACCTGGAAAGGTAAGCCATAGAAAGTGATAGCCTTGTATGCGACAAGGCGTTCTTAGGTAGCAGGATCCAGAGTAGGCCAGGACACGAGAAATCCAGGTTGAAGCTGGGGAGACCACTCTCCAACCCTAAATACTACTCTTTGAGCGATAGCGAACAAGTACCGTGAGGGAAAGGTGAAAAGAACCGCAGTGAGCGGAGTGAAATAGAACCTGAAACCATCTGCTTACAATCATTCAGAGCCCTATGATTTATCAGGGTGATGGACTGCCTTTTGCATAATGATCCTGCGAGTTGTGGTATCTGGCAAGGTTAAGCGGATGCGAAGCCGTAGCGAAAGCGAGTCTTAATAGGGCGGTTTAAGTCAGATGCTGCAGACCCGAAGCTAAGTGATCTATCCATGGCCAAGTTGAAACGCGTGTAATAGCGCGTGGAGGACTGAACTCGTACCCATTGAAACGGGTTGGGATGAGCTGTGGATAGGGGTGAAAGGTCAAACAAACTTAGTGATAGCTGGTTCTCTTCGAAATATATTTAGGTATAGCCTCAAGTGATAATAAAAGGGGGTAGAGCTCTGATTGGGCTAGGGCTGCTCGCCGCGGTACCAAACCCTATCAAACTTCGAATACCTTTTATCGTATCTTGGGAGTCAGGCGGTGGGTGATAAAATCAATCGTCAAAAGGGGAACAACCCAGACTACCAAATAAGGTCCCTAAGTTCTATTCTGAGTGGAAAAAGATGTGTGGCTACTCAAACAACCAGGAGGTTGGCTTAGAAGCAGCCATCCTTTAAAGAAAGCGTAACAGCTCACTGGTCTAGTGGTCATGCGCTGAAAATATAACGGGGCTAAGATAGACACCGAATTTGTAGATTGTGTTAAACACAGTGGTAGAAGAGCGTTCATACCAGCGTTGAAGGTATACCGGTAAGGAGTGCTGGAGCGGTATGAAGTGAGCATGCAGGAATGAGTAACGATAAGATATATGAGAATTGTATCCGCCGTAAATCTAAGGTTTCCTACGCGATGGTCGTCATCGTAGGGTTAGTCGGGTCCTAAGCCGAGTCCGAAAGGGGTAGGTGATGGCAAATTGGTTAATATTCCAATACCGACTCATGGAGCGTGATGGGGGGACGCATAGGGTTAAGCGAGCTAGCTGATGGAAGTGCTAGTCTAAGGGCGTAGATTGGAGGGAAGGCAAATCCACCTCTGTATTTGAAACCCAAACAGGCTCTTTGAGTCCTTTCAGGACAAAGGGAGAATCGCTGATACCGTCGTGCCAAGAAAAGCCTCTAAGCATATCCATAGTCGTCCGTACCGCAAACCGACACAGGTAGATGAGATGAGTATTCTAAGGCGCGTGAAAGAACTCTGGTTAAGGAACTCTGCAAACTAGCACCGTAAGTTCGCGATAAGGTGTGCCGCAGCAATGCGGTCTCAGCAAAGAGTCCCTCCCGACTGTTTACCAAAAACACAGCACTTTGCCAACTCGTAAGAGGAAGTATAAGGTGTGACGCCTGCCCGGTGCTCGAAGGTTAAGAGGATGCGTCAGTCGCAAGATGAAGCGTTGAATTGAAGCCCGAGTAAACGGCGGCCGTAACTATAACGGTCCTAAGGTAGCGAAATTCCTTGTCGGTTAAATACCGACCTGCATGAATGGCGTAACGAGATGGGAGCTGTCTCAACCAGAGATTCAGTGAAATTGTAGTGGAGGTGAAAATTCCTCCTACCCGCGGCAAGACGGAAAGACCCCGTGGACCTTTACTACAACTTAGCACTGCTAACGGGAATATCATGTGCAGGATAGGTGGGAGGCTTTGAAGTAAGGGCTTTGGCTCTTATGGAGCCATCCTTGAGATACCACCCTTGATGTTTCTGTTAGCTAACTGGCCTGTGTTATCCACAGGCAGGACAATGCTTGGTGGGTAGTTTGACTGGGGCGGTCGCCTCCTAAAAAGTAACGGAGGCTTGCAAAGGTTGGCTCATTGCGGTTGGAAATCGCAAGTTGAGTGTAATGGCACAAGCCAGCCTGACTGTAAGACATACAAGTCAAGCAGAGACGAAAGTCGGTCATAGTGATCCGGTGGTTCTGTGTGGAAGGGCCATCGCTCAAAGGATAAAAGGTACCCCGGGGATAACAGGCTGATCTCCCCCAAGAGCTCACATCGACGGGGAGGTTTGGCACCTCGATGTCGGCTCATCGCATCCTGGGGCTGGAGCAGGTCCCAAGGGTATGGCTGTTCGCCATTTAAAGCGGTACGCGAGCTGGGTTCAGAACGTCGTGAGACAGTTCGGTCCCTATCTGCCGTGGGCGTAGGAAAGTTGAGGAGAGCTGTCCCTAGTACGAGAGGACCGGGATGGACGTGTCACTGGTGCACCAGTTGTTCTGCCAAGAGCATCGCTGGGTAGCTACACACGGATGTGATAACTGCTGAAAGCATCTAAGCAGGAAGCCAACTCCAAGATAAACTTTCCCTGAAGCTCGCACAAAGACTATGTGCTTGATAGGGTAGATGTGTAAGCGCAGTAATGCGTTTAGCTGACTACTACTAATAGAGCGTTTGGCTTGTTTTT,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3976,Drugs,MEG_3976|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|AB162858.1|+|0-2975|ARO:3004134|Helicobacter pylori 23S rRNA with mutation conferring resistance to clarithromycin [Helicobacter pylori] ,7
,atgagaaattttattgtatttatattgtttttgaatatagccattggagaggataaaatacttggtaatttttttaaagattgtaatacaagtgggacttttatagtctttgatggaaaaaattatgcaagtaatgattttcaaagagctaaacaagccttttctcctgcttcaacttttaaaatttttaatgctttaattgcacttgataatggtgtagttagagatacaaaggaaattttctatcattataagggtgaaaaagtatttttgccctcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaggcttaaataaactttcttatggaaatacaaaaatttcaaaaatcgataccttttggctcgataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcgcaaaattctttacctttttccaaaaaaagtcaagaagaagttaaagaaattattctttttaaggaagataaaatccaaaaaatttatgctaaaacaggttttaatgataatatcaatttagcttggattgttggatttgtaaagactgaaaacaaaattttatcttttgctttaaatgttgatataaaggacattaaaaatattaaaataagggaagaattattaaataagtatttagctaatttttccaacaataataggattaaaagcttttactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_4587,Drugs,MEG_4587|Drugs|betalactams|Class_D_betalactamases|OXA,1391852930|WP_109545115.1|NG_057552|1|1|blaOXA-615|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-615 NG_057552:1-774,0
,TTTTTAGAAATTCTGTAAGCAATACTATATAGCAGTTGACAATCATACAAATTTAATATATACTACGCAAAAATATCAAGGATTATAAATGTCTAAAAAAAATTTTATATTAATATTTATTTTTGTTATTTTAACATCTTGTAAAAATACAGAAAAAATATCAAATGAAACTACATTAATAGATAATATATTTACTAATAGCAATGCTGAAGGAACATTAGTTATATATAATTTAAATGATGATAAATATATAATTCATAATAAAGAAAGAGCTGAACAAAGATTTTATCCAGCATCAACATTTAAAATATATAATAGTTTAATAGGCTTAAATGAAAAAGCAGTTAAAGATGTAGATGAAGTATTTTATAAATATAATGGCGAAAAAGTTTTTCTTGAATCTTGGGCTAAGGACTCTAATTTAAGATATGCAATTAAAAATTCGCAAGTACCGGCATATAAAGAATTAGCAAGAAGAATAGGTCTTAAAAAGATGAAAGAGAATATAGAAAAACTAGATTTTGGTAATAAAAGTATAGGTGATAGTGTAGATACTTTTTGGCTTGAAGGACCTTTGGAAATAAGTGCGATGGAGCAAATTAAATTATTAACTAAATTAGCTCAAAATGAATTACCGTATCCTATAGAAATACAAAAAGCTGTTTCTGATATTACTATACTAGAGCAAACTTACAATTATACGCTTCATGGAAAAACTGGATTAGCTGATTCTAAAAACATGACAACTGAGCCTATTGGTTGGTTCGTAGGCTGGCTTGAAGAAAATGATAATATATATGTCTTTGCTTTAAATATTGATAATATAAATTCAGATGACCTTGCAAAAAGGATAAATATAGTAAAAGAAAGTTTAAAAGCATTAAATTTATTAAAATAAATTATATAAAAATTAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_5222,Drugs,MEG_5222|Drugs|betalactams|Class_D_betalactamases|OXA,gi|404429427|emb|HE793032.1|162272-161359 gi|158634583|gb|EU086834.1|1-914,0
,atgttggaagaaaagcgagtttcctttcgcccgatgagtgaggatgatttagttctaatgttaaaatggctgacagatgaccgtgttcttgaattttacgacggtagagataaaaggcatacacagaaaacgattcgtgagcattatacagagcaatgggcggatgagatttatcgagtcatcattgaatatgatacaattcccatcggttacgcacaaatatacagaattcagggggaacttttcgacgaatatgattaccatgagacggaagaaaagatttatgcgatggaccaatttatcggtgagccggaatattggaatatgggaatcggtgcagaatattgcagagtagtatgccaatatctacgaacggaaatgggtgccgatgcggtgattcttgacccacgaaaaaataatccacgagcggtacgagcatatcagaaggcgggatttgaaattattaaggagctgcccgaacatgagctacacgaagggaagaaggaagattgtgtgttgatggaatggagagcgtaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_213,Drugs,MEG_213|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,488663716|WP_002592614.1|NG_052530|1|1|aac(6')-Im|aac(6')-Im|aminoglycoside_N-acetyltransferase_AAC(6')-Im NG_052530:101-637,2
,atgatgacaaaatccctaagctgtgccctgctgctcagcgtcaccagctctgcattcgccgcaccgatgtccgaaaaacagctggctgaggtggtggaacgtaccgttacgccgctgatgaacgcgcaggccattccgggtatggcggtggcggtaatttatcagggtcagccacactactttaccttcggtaaagccgatgttgcggcgaacaaacccgtcaccccgcaaaccctgtttgagctgggctctataagtaaaaccttcaccggcgtactgggcggcgatgccattgcccgaggtgaaatagcgctgggcgatccggtagcaaaatactggcctgagctcacgggcaaacagtggcagggcattcgcatgctggatctggcaacctataccgcaggcggtctgccgttacaggtgccggatgaggtcacggataccgcttctctgctgcgcttttatcaaaactggcagccgcagtggaagccgggcaccacgcgtctttacgctaacgccagcatcggtctttttggtgcgctggcggttaaaccttccggcatgagctatgagcaggccatgacgacgcgggtctttaaacccctcaagctggaccatacctggattaacgtcccgaaagcggaagaggcgcattacgcctggggataccgtgagggtaaagcggtccacgtttcgccagggatgctggacgcggaagcctatggcgtaaaaactaacgtgaaggatatggcgagctgggtgatagccaacatgaagccggattctcttcaggctccctcactcaagcaaggcattgctctggcgcagtctcgctactggcgcgtgggggctatgtatcaggggttgggctgggagatgctcaactggccggtcgatgccaaaaccgtcgtcggaggcagtgataacaaggtggcgctggcaccattgcccgtggcagaagtgaatccacccgcaccgccggtcaaagcctcctgggtccataaaacaggctcgacgggcgggtttggcagctacgtggcatttattcctgaaaagcagctcggcattgtgatgctggcgaataaaagctatccgaacccggcacgcgttgaggcggcataccgtatccttgacgcgctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3950,Drugs,MEG_3950|Drugs|betalactams|Class_C_betalactamases|MIR,779900739|WP_045372339.1|NG_050723|1|1|blaMIR-21|blaMIR|cephalosporin-hydrolyzing_class_C_beta-lactamase_MIR-21 NG_050723:1-1146,0
,TCAATGTAAGTTGATTTTATTAAACATATGCCTTACTTTGTCTATTCTATTATTTGGACGACGTGGTTGGAAAGCAGACTTAATGTTAGTAACCTGATAACCTTTTAACTCTGTTAAACAGACACTGCGTCCATTTGTAAAGAAAGTTAAACTGTTTCGATACTCTTGAATACAACGGGCTGGAATTTCACCAATGAGAATGACCTCGTTACCTTTTAACTTAGTATTTAAAATATTTGCACAATATTTGGAAGCATCATTATATGCTCTCGAAAGATATTCTTGTGGTACATAAATTTCGAAGCTAAGATATGGCTCTAATAACTCTGTACCACTCTTTCTAAAAGCCTGCTCTAGTACAATAGGCGCAAGCATTCGGAAATCTGCTGGCGTACTGACAGGGCTGTAATATAGACCATACTTAAAACAGATCTTACAGTCTGTTAATTTCCAACCGTACAATCCTTGTTCACACCCATAGCGTATACCTTCCATAACTGCATTTTGAAATGATTGATTTAAATAACCTAGAGAAACCAGGCTCTCATACTGAATGCCACTACCCAAAGGAAGTGGTGTTACAGATAAACCAATAGAAGCCCAGAAAGGATTTGGAGGTACTTCGATATCAATGGTAAATTCAGATTTTTTTAATGGTCTTTCCATATAAATGACAGTTGGTTTTCTTGTTTCTATCTCAATATGATATTTTTCTTGAATCAGAGTACAAGTTACCTCCATTTGGACCTCACCTAAAAAAGATAGCACAATTTCGTGAGTTACTGTATCTACATAATATTGTAGAAGGGGATCACTATCGGATATTTCAAAAAGTGCATCTAGTAACTTTTCTCTTTGTACTGATTTACATGGTTCAATTGTTGTTTGTAACATAGGAAGAGGATTCTCAAGAATTTCTCTATGTGGTAATCTTTTTTTATCTCCAAGTACGTTATTTAGTTTTAAAAGCTCATTTTTTAAAATAATAATCTCACCAGGCTCTGCCTTATCTATCTGGCGTAATTCTCCATTTATTGAAGTATACATTTCTGTAACTTTTATTTTTTCCTTTTCTGATATATTGACTGAGTCTCGCAAATGTAGCGTTCCACTATAAAGACGTACATAGACAAGCCGTTGACCATCATCTGAATATTCTACTTTAAAAACATTTCCACAAAGTTTATCTGAATTGAGTTGTGTGGGTGAAAATAATTTGCTAGTAATTACCTCTATAAGTTGTTTAATTCCAATATTATTCTTTGCACTTCCGTGATAAACAGGATATAAGGAGCAACTTTGAATTCTTTCGTTTTCCTCCTTTTCAAGTTCTGCAATATTCAATGTTTTCCCAATGGTATATTTTTCTAATAAATAATCATTTCCCACAATTACTGTCTCCCATTGTTCTGGTTCAGTATAATCTATTACATAAGGTTTCAAATTTAGATTCACAGTCTGCTTAATTATGATGTCGTCAGAAAGTTTGTCCTTAATATCTTGATAAACATCTGGCAAATTTATTCCATTTTGATCAATTTTGTTAATAAAAAATATTATAGGTATGTTCATCTTTCTAAGTGCATGGAATAGTATACGAGTTTGTGACTGTACTCCATCTTTTGCAGAGATTAGCAAAATAGCTCCATCCAAAACAGATAATGAACGGTATACATCTGCCAAAAAATCCATGTGTCCAGGAGTATCTACAATATTTACTTTAACATTTTCCCGTTGAAAAGATGTTATTGCGGTCTGAATAGTAATACCTCTCTGGCGTTCCAAAAACATAGTATCCGTTTTCGTTGTACCGCTATCTACACTTCCTAACTCTTTAATTCGTCCGCTACTGTATAGTAAGCTTTCTGTCAAAGTAGTTTTTCCTGCATCAACATGTGCTAAGATACCGATATTAATAATTTTCAATTTTATTTCCTCCAT,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7200,Drugs,MEG_7200|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETS,gi|90811349|gb|DQ377340.1|2421-481 gi|2467210|emb|X92946.1|26034-27974 gi|388785684|gb|JQ762256.1|3410-3381,4
,atgaccatgtttaaaacaacatttcgccaaacagcagcgatcgcagtttcattaatatctctattagcatctccaatgctatgggctgacaacaataatacaattgaagagcaattaaatacgctggaaaaatatagccaaggtcgtttaggcgtggcattaatcaacaccgaagataactcacaaataacataccgtggtgaagaacgctttgcgatggcaagtacaagtaaggttatggcggttgcagccgttttaaaagcgagtgaaaaacaagccggattattagataagaatattacgattaaaaaatctgacttagttgcttacagccctattacagaaaaacatttaacaacaggaatgacactggctgaattaagtgcggctacattgcaatatagcgataatacagcaatgaataagatattagattatttaggcggtccagccaaagtcactcaatttgcacgttcaattaatgatgtcacttatcgccttgatcgtaaagagcctgaattaaatacagcaattcatggtgatcctcgtgatactacttctccaattgcgatggctaaaagtcttcaagcactgacattaggcgatgcactaggtcaatctcagcgtcaacaacttgttacttggttaaaaggtaatacaacgggtgataacagtattaaagcgggtttaccaaaacactgggttgttggggataaaaccggtagtggtgattatggtacaactaacgatattgccgttatttggcctgaaaaccatgcgccattaattttagtcgtttatttcacacaacaagaacaaaatgcaaaataccgtaaagatattattgctaaagcagctgaaattgtaacaaaagagatatctaattcacctcaaacaaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3281,Drugs,MEG_3281|Drugs|betalactams|Class_A_betalactamases|HUGA,1028094263|WP_063851301.1|NG_047909|1|1|hugA|hugA|class_A_beta-lactamase NG_047909:101-1003,0
,ATGACCGGGGACTTCGCCTTCGTGGACGAGCTGGTGTCCGGAATCCGGTGGGACGCCAAGTACGCCACCTGGGACAACTTCACCGGCAAACCCGTGGACGGATACCTGGCGAACCGGATCGTCGGCACCAAGGCCCTGTGCGCGGCTCTGGGAAGGGCGCAAGAACGGGCCGAAGACCTCGGCTTCGGGCTGCTCCTGTGGGACGGCTACCGCCCGCAGCGCGCCGTGGACTGCTTCCTCCGCTGGTCACAACAGCCGGAGGACGGCCGGACGAAGGCCCGGCACTACCCGAACATCGGCAGGGCCGAGATGTTCGACAGGGGGTACGTGGCCGCCAGGTCGGGCCACAGCCGAGGTGCCACCGTCGACTTGACGCTGTACCACCTGACCACCGGTGAACTCGCGGCCATGGGCGGCGGCCACGACCTCATGGACCCGATATCGCATCACGACGCCCGAGACGTCCCGCGGGCCGAGGCGGCGAACCGACGGCATCTGCGCTCGATCATGGCCGCCTGCGGTTTCGCCTCATACGCCTGCGAGTGGTGGCACTACACGCTGAAGGAGGAGCCGCACCCGGACACCTACTTCGACTTTCCCATCGCGTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7555,Drugs,MEG_7555|Drugs|Glycopeptides|VanA-type_resistance_protein|VANXA,(Gly)VanX-Sc:AL939117:55404-56012:609,5
,AAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAGCTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGTTGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGATCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACAAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCAT,beta-lactamase,antibiotic inactivation,betalactams,MEG_6876,Drugs,MEG_6876|Drugs|betalactams|Class_A_betalactamases|TEM,gi|1524022|emb|X95401.1|196-1091 gi|479327147|gb|KC354802.1|11954-11985,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaactttaaaccgttattagaaaaatatgatgtgccaggtatggctgtgggtgttattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccgtaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagagctaaaaaatacaccgattaaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagttcccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcttatttggaaaagttgttgctttgtctatgaataaacctttcgatcaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccaaatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatacggcgtcaaatccaccttaccggatatgttgagttttattcatgccaaccttaacccacagaaatatccgacagatattcaacgggcaattaatgaaacacatcaaggtcgctatcaagtaaataccatgtatcaagcgcttggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaagagccttcagttaagatgtaccataaaactggctcaactaacggtttcggaacatatgtagtgtttattcctaaagaaaatattggtttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_556,Drugs,MEG_556|Drugs|betalactams|Class_C_betalactamases|ADC,1058243563|WP_068981613.1|NG_051445|1|1|blaADC-106|blaADC|class_C_beta-lactamase_ADC-106 NG_051445:1-1152,0
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGACGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6897,Drugs,MEG_6897|Drugs|betalactams|Class_A_betalactamases|TEM,gi|260586479|gb|GQ896333.1|1-861,0
,atgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgagctggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttaagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaacgcgccttgatagttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgacgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6665,Drugs,MEG_6665|Drugs|betalactams|Class_A_betalactamases|TEM,1028110617|WP_063864895.1|NG_050237|1|1|blaTEM-205|blaTEM|class_A_beta-lactamase_TEM-205 NG_050237:1-861,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcaccacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_893,Drugs,MEG_893|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502164|WP_071846315.1|NG_052385|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052385:101-892,2
,GGTTAAAAAATCACTGCGTCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAGGAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCCGAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACACAGCAGATAATTCGCGAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGTTAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCAATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAGCCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAGCGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACCGGCAGCGGTGGCTATGGCACCACCAACGATATCGCGGTGATCTGGCCAAAAGATCGTGCGCCGCTGATTCTGGTCACTTACTTCACCCAGCCTCAACCTAAGGCAGAAAGCCGTCGCGATGTATTAGCGTCGGCGGCTAAAATCGTCACCAAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2216,Drugs,MEG_2216|Drugs|betalactams|Class_A_betalactamases|CTX,(Bla)CTX-M-109:JF274248:1-865:865,0
,atgcgcgataccagattctcctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggttcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccatctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccaaggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5695,Drugs,MEG_5695|Drugs|betalactams|Class_C_betalactamases|PDC,759352923|WP_043083525.1|NG_049919|1|1|blaPDC-46|blaPDC|class_C_beta-lactamase_PDC-46 NG_049919:1-1194,0
,ACAGTGGACGCGAGCATCTGTGGCCAAGTTTTTAAGGGCGCACGGTGGATGCCTTGGCACCAGGAACCGATGAAGGACGTGGGAGGCCACGATAGTCCCCGGGGAGCCGTCAACCAGGCTTTGATCCGGGGGTTTCCGAATGGGGAAACCCGGCAGTCGTCATGGGCTGTCACCCGCTGCTGAACACATAGGCAGTGTGGAGGGAACGCGGGGAAGTGAAACATCTCAGTACCCGCAGGAAGAGAAAACAACCGTGATTCCGGGAGTAGTGGCGAGCGAAACCGGATGAGGCCAAACCGTATACGTGTGAGACCCGGCAGGGGTTGCGTGTGCGGGGTTGTGGGATCTCTCTTTCACAGTCTGCCGGCTGTGAGGCGAGTCAGAAACCGTTGATGTAGGCGAAGGACATGCGAAAGGTCCGGCGTAGAGGGTAAGACCCCCGTAGTCGAAACATCAGCGGCTCGTTTGAGAGACACCCAAGTAGCACGGGGCCCGAGAAATCCCGTGTGAATCTGGCGGGACCACCCGCTAAGCCTAAATATTCCCTGGTGACCGATAGCGGATAGTACCGTGAGGGAATGGTGAAAAGTACCGCGGGAGCGGAGTGAAATAGTACCTGAAACCGTGTGCCTACAAGCCGTGGGAGCGTCGGACATCAAGCTTGCTTGGTGTCTCGTGACTGCGTGCCTTTTGAAGAATGAGCCTGCGAGTTTGCGGTGTGTTGCGAGGTTAACCCGAGTGGGGAAGCCGTAGCGAAAGCGAGTCCGAATAGGGCGTTTCAGTAGCACGCTCAAGACCCGAAGCGGAGTGATCTAGCCATGGGCAGGTTGAAGCGGAGGTAAGACTTCGTGGAGGACCGAACCCACCAGGGTTGAAAACCTGGGGGATGACCTGTGGTTAGGGGTGAAAGGCCAATCAAACTCCGTGATAGCTGGTTCTCCCCGAAATGCATTTAGGTGCAGCGTCGTGTGTTTCTTGCCGGAGGTAGAGCACTGGATAGGCGATGGGCCCTACCGGGTTACTGACCTTAGCCAAACTCCGAATGCCGGTAAGTGAGAGCGCGGCAGTGAGACTGTGGGGGATAAGCTCCATGGTCGAGAGGGAAACAGCCCAGAGCATCGACTAAGGCCCCTAAGCGTACGCTAAGTGGGAAAGGATGTGGAGTCGCACAGACAACCAGGAGGTTGGCTTAGAAGCAGCCACCCTTGAAAGAGTGCGTAATAGCTCACTGGTCTAGTGATTCCGCGCCGACAATGTAGCGGGGCTCAAGCGTACCGCCGAAGTCGTGTCATTCATACAATAGGGCCAACGCCTGTATGGATGGGTAGGGGAGCGTCGTGTGCCGGGTGAAGCAGCCGCGGAAGCGAGTTGTGGACGGTTCACGAGTGAGAATGCAGGCATGAGTAGCGATACAAACGTGAGAAACGTTTGCGCCGATTGACTAAGGGTTCCTGGGTCAAGCTGATCTGCCCAGGGTAAGTCGGGACCTAAGGCGAGGCCGACAGGCGTAGTCGATGGATAACCGGTTGATATTCCGGTACCCGCTGTGAAGCGTCAAACATCGAGCATCGTGATGCTAAGGCCGTGAAGCCGCCCTGATCTCTTCGGAGTTGAGGGGAGTGGTGGAGCCGCCGGACCAAGCGGTTAGTAGGTGAGTGATGGGGTGACGCAGGAAGGTAGTCCATCCCGGGCGGTGGTTGTCCCGGGGTAAGGGTGTAGGACGTCAGGTAGGTAAATCCGCCTGGCAATAGTCTGAGACCTGATGCCGAGCCGATTGTGGTGAAGTGGATGATCCTATGCTGTCGAGAAAAGCCTCTAGCGAGTTTCATGGCGGCCCGTACCCTAAACCGACTCAGGTGGTCAGGTAGAGAATACCGAGGCGTTCGGGTGAACTATGGTTAAGGAACTCGGCAAAATGCCCCCGTAACTTCGGGAGAAGGGGGGCCACACCTGGTGATGATCTTTACGGTCTGAGCTGGGGGTGGCCGCAGAGACCAGCGAGAAGCGACTGTTTACTAAAAACACAGGTCCGTGCGAAGCCGTAAGGCGATGTATACGGACTGACGCCTGCCCGGTGCTGGAACGTTAAGGGGACCGGTTAGCTCCATTTCGGTGGGGCGAAGCTGAGAACTTAAGCGCCAGTAAACGGCGGTGGTAACTATAACCATCCTAAGGTAGCGAAATTCCTTGTCGGGTAAGTTCCGACCTGCACGAATGGCGTAACGACTTCTCGACTGTCTCAACCATAGGCCCGGTGAAATTGCACTACGAGTAAAGATGCTCGTTTCGCGCAGCAGGACGGAAAGACCCCGGGACCTTTACTACAGTTTGATATTGGTGTTCGGTTCGGCTTGTGTAGGATAGCTGGGAGACTTTGAAGCTCGCACGCCAGTGTGGGTGGAGTCGTCGTTGAAATACCAGTCTGGTCGTGCTGGATGTCTAACCTGGGTCCGTGATCCGGATCAGGGACAGTGTCTGATGGGTAGTTTAACTGGGGCGGTTGCCTCCTAAAGAGTAACGGAGGCGCCCAAAGGTTCCCTCAGCCTGGTTGGCAATCAGGTGTTGAGTGTAAGTGCACAAGGGAGCTTGACTGTGAGACCGACGGGTCGAGCAGGGACGAAAGTCGGGACTAGTGATCCGGCGGTGGCTTGTGGAAGCGCCGTCGCTCAACGGATAAAAGGTACCCCGGGGATAACAGGCTGATCTTCCCCAAGAGTCCATATCGACGGGATGGTTTGGCACCTCGATGTCGGCTCGTCGCATCCTGGGGCTGGAGTCGGTCCCAAGGGTTGGGCTGTTCGCCCATTAAAGCGGTACGCGAGCTGGGTTTAGAACGTCGTGAGACAGTTCGGTCCCTATCCGCTGTGCGCGTAGGAGTCTTGAGAAGGGCTGTCCCTAGTACGAGAGGACCGGGACGGACGAACCTCTGGTGTGCCAGTTGTCCTGCCAAGGGCATGGCTGGTTGGCTACGTTCGGGAGGGATAACCGCTGAAAGCATCTAAGCGGGAAGCCTGCTTCGAGATGAGGACTCCCACCCCCTTGAGGGGTTAAGGCTCCCAGTAGACGACTGGGTTGATAGGCCGGATCTGGAAGCACCGCAAGGTGTGGAGGTGACCGGTACTAATAGGCCGAGGGCTTGTCCTCAGTTG,rRNA with mutation conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_3990,Drugs,MEG_3990|Drugs|MLS|Macrolide-resistant_23S_rRNA_mutation|MLS23S,gb|NZ_CP012949.1|+|4334992-4338141|ARO:3004171|Streptomyces ambofaciens 23S rRNA with mutation conferring resistance to macrolides [Streptomyces ambofaciens] ,7
,ATGACCTTCTCCTCGACCTCCTCGGCCCCTCCACCGTCACCGCTCCTCCCGGCAACGAGAATCACGGTTTACGGCTGCGGGCGGGACGAGGCCGCCTTGTTCCGCCGGACGGCACCCCGTTTCGGCGTCGAGGCGACTCTCACGGAGGCCGCCGTATCCGAAGAGAACGCCGAGATGGCGGCCGGAAACCAATGCATCAGCATTGACCACAAGACCCCGGTCACACCTGCCACTCTCCGCGCTCTCCACCGGGCCGGCGTGACGTACATATCCACCCGGAGTATCGGTTACAACCACATCGATGTGACATACGCGGCCGGCGTGGGGATATCCGTCGAGAACGTCACCTACTCCCCCGCCGGCGTGGCCGACTACACCCTGATGCTCATGCTGATGGCGGTGCGCAACGCGAAATCCACCGTCCGCCGCGCGGAGCTGCACGACTACCGGCTGAACGAGATACGCGGTAAGGAGCTGCGCGACCTGACCGTCGGAGTGATCGGGACGGGGCGTATCGGTGCGGCGGTCGTGGACAGGCTGCGGGGTTTTGGCTCCCGGGTACTGGCCTACGGAAAACGGCCCACCATCGCGGCAGATTACGTCTCTCTCGACGAGTTGCTGCGGTCGAGCGACATCGTGTCGCTGCACGTACCGCTGACCCCGGACACGCATCACCTTCTCGATCAAAGCCGTATCCGGCGGATGAAAAGTGGCGCTTTCGTCATCAACACCGGACGCGGCCCGCTCATCGACACCGAAGCGCTGGTACCGGCGTTGGAGAGCGGCAGGTTGAGCGGTGCGGCGCTGGATGTCATCGAGGGCGAGGAAGGGATCTTCTACGCCGACTGCAGAAACAGAACCATCGAAAGCACGTGGCTCCCGCGGCTGCAGAAAATGCCGAACGTACTCATCAGCCCGCACACCGCCTATTACACCGACCACGCCCTGATGGACACGGTCGAGAACTCCATCATCAACTGCCTTAATTTCGGAAGCAGGAAACAGCATGGCTGAGTCGGACAAGTTGGCCAGGTTGAAGGTCGGCATCGTATTCGGGGGCTCTTCCGAAGAACACGCCGTTTCCGTCAAGTCCGCCCAGGAGGTCGCACGCAACCTCGACACCGAGAAGTACCAGCCGTTCTTCGTGGGGATCACGAAGGACGGCGCCTGGAGACTCTGCGACGGGCCAGGCCAGGACTGGGAGAACGGCGACTGCCGTCCGGTCGTGCTGTCACCGGACCGGAGCGTGCACGGGCTGCTCGTCCTGGAGCAGGGGCAGTACCGGTCGGTCCGCCTGGACGTCGTCCTTCCCGTCCTGCACGGCACCCTCGGTGAGGACGGTGCGACGCAGGGGCTGCTGGAGCTCTCCGGCATTCCGTACGTGGGCTGCGACGTCCAGAGCTCCGCCCTGTGCATGGACAAATCCCTTGCGTACGTCGTCGCCAGGAGCGCGGGGATCGCCACGCCGGATTTCTGGACCGTGACAGGAGACGAGACCATCGATCCCGGCCGGCTCACGTATCCCGTCTTCGTGAAGCCGGCCCGTTCGGGGTCGTCCTTCGGCGTCAGCAAGGTGTGCCGCCCGGAAGACCTGGCGACCGCGGTGGAGTCCGCCCGGCGGTACGACACGAAGGTGCTGATCGAAGCGGCCGTCGTCGGCAGCGAGGTCGGCTGCGCCATCCTGGGGAACGACCCCGACCTGATCGTGGGCGAGGTGGACCGCATCGCGCTCTCCCACGGATTCTTCCGGATCCACCAGGAGGAGCAGCCCGAGAACGGCTCGGAGAACTCGACGCCGGTCGTTCCCGCCGACATCCCGACGGAGAAGCGGTCGCTCGTCCAGGAGACCGCGAAGGCCGTGTACCGAGCCCTGGGATGCCGGGGGCTGTCCCGCGTGGACATGTTCCTCAAGGAGGACGGGGAAGTCGTCCTCAACGAGGTCAACACCCTGCCCGGCATGACCTCGTACAGCCGTTATCCGAGGATGATGGCGGCCGCGGGGCTGCCACTGTCCGAGGTGATCGACCGGACGCTGTCCCTGGCGTTGACGGGGAAGCTCCGATGACCGGGGACTTCGCCTTCGTGGACGAGCTGGTGTCCGGAATCCGGTGGGACGCCAAGTACGCCACCTGGGACAACTTCACCGGCAAACCCGTGGACGGATACCTGGCGAACCGGATCGTCGGCACCAAGGCCCTGTGCGCGGCTCTGGGAAGGGCGCAAGAACGGGCCGAAGACCTCGGCTTCGGGCTGCTCCTGTGGGACGGCTACCGCCCGCAGCGCGCCGTGGACTGCTTCCTCCGCTGGTCACAACAGCCGGAGGACGGCCGGACGAAGGCCCGGCACTACCCGAACATCGGCAGGGCCGAGATGTTCGACAGGGGGTACGTGGCCGCCAGGTCGGGCCACAGCCGAGGTGCCACCGTCGACTTGACGCTGTACCACCTGACCACCGGTGAACTCGCGGCCATGGGCGGCGGCCACGACCTCATGGACCCGATATCGCATCACGACGCCCGAGACGTCCCGCGGGCCGAGGCGGCGAACCGACGGCATCTGCGCTCGATCATGGCCGCCTGCGGTTTCGCCTCATACGCCTGCGAGTGGTGGCACTACACGCTGAAGGAGGAGCCGCACCCGGACACCTACTTCGACTTTCCCATCGCGTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7344,Drugs,MEG_7344|Drugs|Glycopeptides|VanA-type_resistance_protein|VANA,dldHA2X_1_AL939117,5
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgctcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgataaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtgttttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgacctttaaaatgcttaatgctttgatcggccttgagcattataaggcaaccaccacagaagtatttaagtgggacgggcaaaaaaggctattccccgaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaaggaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattacgcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccctttagccaaaaagtccaagatgaagtgcaatccatgttattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaagggaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4456,Drugs,MEG_4456|Drugs|betalactams|Class_D_betalactamases|OXA,1509794600|WP_122630909.1|NG_062329|1|1|blaOXA-707|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-707 NG_062329:25-849,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgctggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctatgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacgactcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5553,Drugs,MEG_5553|Drugs|betalactams|Class_C_betalactamases|PDC,685983014|WP_031690214.1|NG_049870|1|1|blaPDC-103|blaPDC|class_C_beta-lactamase_PDC-103 NG_049870:1-1194,0
,ATGAGCAACGCAAAAACAAAGTTAGGCATCACAAAGTACAGCATCGTGACCAACAGCAACGATTCCGTCACACTGCGCCTCATGACTGAGCATGACCTTGCGATGCTCTATGAGTGGCTAAATCGATCTCATATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGACGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTTACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCATATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGATGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Multi-drug_resistance,MEG_3286,Drugs,MEG_3286|Drugs|Multi-drug_resistance|MDR_acetyltransferase|IBCR,gb|DQ303918|+|0-600|ARO:3002547|AAC(6')-Ib-cr [Escherichia coli] ,1
,ATGGCAGAAAAAATAATCGTTGTTGATGATGAAAAAGAAATCGCCGAGTTAGTCACGACGTTTCTAAGAAATGAAGGTTTCCAAGTGGAACCTTTTTATGATGGAACGAGTGCTTTGGCTTATCTCGAAAAAGAAACAGTCGATGTGGCAGTTTTAGATGTGATGCTGCCGGATATCGACGGCTTTCAGCTGTTACAGAACATTCGCAAAACCCACTTTTTTCCAGTACTGATGCTCACTGCTAAAGGAGAAGATCTGGATAAAATTACCGGTCTAAGTCTAGGTGCAGATGATTATGTGACCAAACCTTTCAATCCATTAGAAGTTGTTGCTCGGGTCAAAACGCAACTACGGCGATACCAACGATACAATCAGTCAGCTGTTCCGCAGAAGATTGAAGAATACGAAAAGGAAGGCTTACTGTTGAAAATCAACAGCCACCAATGTTTTCTTTATGGCAAAGAGGTTTTTTTGACCCCAATCGAATTTAAAATCTTGCTTTACTTATTTGAACACCAAGGATCGGTCGTTGCCTCGGAAACCCTTTTTGAAGCAGTCTGGAAAGAAAAATATTTAGACAACAATAACACAGTGATGGCACATATTGCCCGTCTGCGGGAAAAGCTAAACGAACAACCACGCAAACCGAAATTAATCAAAACTGTATGGGGGGTCGGCTATATCATTGAAAAATAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7474,Drugs,MEG_7474|Drugs|Glycopeptides|VanC-type_regulator|VANRC,gi|161779845|gb|EU151752.1|3849-4544,5
,TTATTCATCTATATCGTATTTTTTATTACCGTTCTCATATAGCTCATCATACACTTTACCTGAGATTTTGGCATTGTAGCTAGCCATTCCTTTATCTTGTACATCTTTAACATTAATAGCCATCATCATGTTTGGATTATCTTTATCATATGATATAAACCACCCAATTTGTCTGCCAGTTTCTCCTTGTTTCATTTTGAGTTCTGCAGTACCGGATTTGCCAATTAAGTTTGCATAAGATCTATAAATATCTTCTTTATGTGTTTTATTTACGACTTGTTGCATACCATCAGTTAATAGATTGATATTTTCTTTGGAAATAATATTTTTCTTCCAAACTTTGTTTTTCGTGTCTTTTAATAAGTGAGGTGCGTTAATATTGCCATTATTTTCTAATGCGCTATAGATTGAAAGGATCTGTACTGGGTTAATCAGTATTTCACCTTGTCCGTAACCTGAATCAGCTAATAATATTTCATTATCTAAATTTTTGTTTGAAATTTGAGCATTATAAAATGGATAATCACTTGGTATATCTTCACCAACACCTAGTTTTTTCATGCCTTTTTCAAATTTCTTACTGCCTAATTCGAGTGCTACTCTAGCAAAGAAAATGTTATCTGATGATTCTATTGCTTGTTTTAAGTCGATATTACCATTTACCACTTCATATCTTGTAACGTTGTAACCACCCCAAGATTTATCTTTTTGCCAACCTTTACCATCGATTTTATAACTTGTTTTATCGTCTAATGTTTTGTTATTTAACCCAATCATTGCTGTTAATATTTTTTGAGTTGAACCTGGTGAAGTTGTAATCTGGAACTTGTTGAGCAGAGGTTCTTTTTTATCTTCGGTTAATTTATTATATTCTTCGTTACTCATGCCATACATAAATGGATAGACGTCATATGAAGGTGTGCTTACAAGTGCTAATAATTCACCTGTTTGAGGGTGGATAGCAGTACCTGAGCCATAATCATTTTTCATGTTGTTATAAATACTCTTTTGAACTTTAGCATCAATAGTTAGTTGAATATCTTTGCCATCTTTTTTCTTTTTCTCTATTAATGTATGTGCGATTGTATTGCTATTATCGTCAACGATTGTGACACGATAGCCATCTTCATGTTGGAGCTTTTTATCGTAAAGTTTTTCGAGTCCCTTTTTACCAATAACTGCATCATCTTTATAGCCTTTATATTCTTTTTGTTTTAATTCTTCAGAGTTAATGGGACCAACATAACCTAATAGATGTGAAGTCGCTTTTCCTAGAGGATAGTTACGACTTTCTGTTTCATTAGTTGTAAGATGAAATTTTTTTGCGAAATCACTTAAATATTCATCCATTTTTTTAACGGTTTTAAGTGGAACGAAGGTATCATCTTGTACCCAATTTTGATCCATTTGTTGTTTGATATAGTCTTCAGAAATACTTAGTTCTTTAGCGATTGCTTTATAATCTTTTTTAGATACATTCTTTGGAACGATGCCTATCTCATATGCTGTTCCTGTATTGGCCAATTCCACATTGTTTCGGTCTAAAATTTTACCACGTTCTGATTTTAAATTTTCAATATGTATGCTTTGGTCTTTCTGCATTCCTGGAATAATGACGCTATGATCCCAATCTAACTTCCACATACCATCTTCTTTAACAAAATTAAATTGAACGTTGCGATCAATGTTACCGTAGTTTGTTTTAATTTTATATTGAGCATCTACTCGTTTTTTATTTTTAGATACTTTTTTTATTTTACGATCCTGAATGTTTATATCTTTAACGCCTAAACTATTATATATTTTTATCGGACGTTCAGTCATTTCTACTTCACCATTATCGCTTTTAGAAATATAACTGCTATCTTTATAAACTTGTTTGAAATTTTTATCTTCAATTGCATCAATAGTATTATTAATTTCTTTATCTTTGGAAGCATAAAAATATATACCAAACCCGACAACTACAACTATTAAAATAAGTGGAACAATTTTTATCTTTTTCAT,methicillin resistant PBP2,antibiotic target alteration,betalactams,MEG_3780,Drugs,MEG_3780|Drugs|betalactams|Penicillin_binding_protein|MECA,gi|166203514|gb|EU333401.1|32-2038 gi|47208328|dbj|BA000017.4|44992-46998 gi|47118324|dbj|BA000018.3|45031-47037 gi|13785452|dbj|D86934.2|46776-44770,0
,atgcgtaaaaaaatgcagaacacattgaagctgttatccgtgattacctgtctggcagcaactgtccaaggtgctctggctgctaatatcgatgagagcaaaattaaagacaccgttgatgacctgatccagccgctgatgcagaagaataatattcccggtatgtcggtcgcagtgaccgtcaacggtaaaaactacatttataactatgggttagcggcaaaacagcctcagcagccggttacggaaaatacgttatttgaagtgggttcgctgagtaaaacgtttgctgccaccttggcgtcctatgcgcaggtgagcggtaagctgtctttggatcaaagcgttagccattacgttccagagttgcgtggcagcagctttgaccacgttagcgtactcaatgtgggcacgcatacctcaggcctacagctatttatgccggaagatattaaaaataccacacagctgatggcttatctaaaagcatggaaacctgccgatgcggctggaacccatcgcgtttattccaatatcggtactggtttgctagggatgattgcggcgaaaagtctgggtgtgagctatgaagatgcgattgagaaaaccctccttcctcagttaggcatgcatcacagctacttgaaggttccggctgaccagatggaaaactatgcgtggggctacaacaagaaagatgagccagtgcacgtgaatatggagattttgggtaacgaagcttatggtatcaaaaccacctccagcgacttgttacgctacgtgcaagccaatatggggcagttaaagcttgatgctaatgccaagatgcaacaggctctgacagccacccacaccggctatttcaaatcgggtgagattactcaggatctgatgtgggagcagctgccatatccggtttctctgccgaatttgctcaccggtaacgatatggcgatgacgaaaagcgtggctacgccgattgttccgccgttaccgccacaggaaaatgtgtggattaataagaccggatcaactaacggcttcggtgcctatattgcgtttgttcctgctaagaagatggggatcgtgatgctggctaacaaaaactactcaatcgatcagcgagtgacggtggcgtataaaatcctgagctcattggaagggaataagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_388,Drugs,MEG_388|Drugs|betalactams|Class_C_betalactamases|ACC,695269887|WP_032491956.1|NG_048588|1|1|blaACC-1|blaACC|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACC-1 NG_048588:30-1202,0
,atgacatggagaacgaccaaaacacttttacagcctcaaaatctggacttcaatgagtttgagattcttacttccgtaattgagggcgcccgaattgtcggcattggcgagggcgctcattttgtcgcggagttttcactggctagagcaagtcttatccgctatttggtcgaaaggcatgattttaatgcgattggtttggaatgtggggcgattcaggcatcccggttatctgaatggctcaactcaacagccggtgctcatgaacttgagcgattttcggataccctgaccttttctgtgtatggctcagtgctgatctggctgaaatcatatctccgcgaatcaggaagaaaactgcagttagtcggaatcgacttacccaacaccctgaacccaagggacgacctagcgcaattggccgaaattatccagctcatcgatcacctcatgaaaccgcacgttgatatgctgactcacttgttggcgtccattgatggccagtcggcggttatttcatcggcaaaatggggggagctagaaacggctcggcaggagaaagctatctcaggggtaaccagattgaagctccgcttggcgtcgcttgcccctgtcctgaaaaaacacgtcaacagcgatttgttccgaaaagcctctgatcgaatagagtcgatagagtatacgttggaaaccttgcgtataatgaaaactttcttcgatggtacctctcttgagggagatacttccgtacgtgactcgtatatggcgggcgtagtagatggaatggttcgagcgaatccggatgtgaagataattctgctggcgcacaacaatcatttacaaaaaaccccagtctccttttcaggcgagcttacggctgttcccatggggcagcacctcgcagagagggtgaattaccgtgcgattgcattcacccatcttggacccaccgtgccggaaatgcatttcccatcgcccgacagtcctcttggattctctgttgtgaccacgcctgccgatgcaatccgtgaggatagtatggaacagtatgtcatcgacgcctgtggtacggagaattcatgtctgacattgacagatgcccccatggaagcaaagcgaatgcggtctcaaagcgcctctgtaaaaacgaaattgagcgaggcatttgatgccatcgtctgtgttccaagcgccggcaaggacagcctagttgccctatag,macrolide inactivation enzyme,antibiotic inactivation,MLS,MEG_2742,Drugs,MEG_2742|Drugs|MLS|Macrolide_esterases|EREA,1105502186|WP_071846336.1|NG_052426|1|1|ere(A)|ere(A)|EreA_family_erythromycin_esterase NG_052426:101-1321,7
,TTGAAAATTATTAATATCGGTATCTTAGCACATGTTGATGCAGGAAAAACTACTTTGACAGAAAGCTTACTATACAGTAGCGGACGAATTAAAGAGTTAGGAAGTGTAGATAGCGGTACAACGAAAACGGATACTATGTTTTTGGAACGCCAGAGAGGTATTACTATTCAGACCGCAATAACATCTTTTCAACGGGAAAATGTTAAAGTAAATATTGTAGATACTCCTGGACACATGGATTTTTTGGCAGATGTATACCGTTCATTATCTGTTTTGGATGGAGCTATTTTGCTAATCTCTGCAAAAGATGGAGTACAGTCACAAACTCGTATACTATTCCATGCACTTAGAAAGATGAACATACCTATAATATTTTTTATTAACAAAATTGATCAAAATGGAATAAATTTGCCAGATGTTTATCAAGATATTAAGGACAAACTTTCTGACGACATCATAATTAAGCAGACTGTGAATCTAAATTTGAAACCTTATGTAATAGATTATACTGAACCAGAACAATGGGAGACAGTAATTGTGGGAAATGATTATTTATTAGAAAAATATACCATTGGGAAAACATTGAATATTGCAGAACTTGAAAAGGAGGAAAACGAAAGAATTCAAAGTTGCTCCTTATATCCTGTTTATCACGGAAGTGCAAAGAATAATATTGGAATTAAACAACTTATAGAGGTAATTACTAGCAAATTATTTTCACCCACACAACTCAATTCAGATAAACTTTGTGGAAATGTTTTTAAAGTAGAATATTCAGATGATGGTCAACGGCTTGTCTATGTACGTCTTTATAGTGGAACGCTACATTTGCGAGACTCAGTCAATATATCAGAAAAGGAAAAAATAAAAGTTACAGAAATGTATACTTCAATAAATGGAGAATTACGCCAGATAGATAAGGCAGAGCCTGGTGAGATTATTATTTTAAAAAATGAGCTTTTAAAACTAAATAACGTACTTGGAGATAAAAAAAGATTACCACATAGAGAAATTCTTGAGAATCCTCTTCCTATGTTACAAACAACAATTGAACCATGTAAATCAGTACAAAGAGAAAAGTTACTAGATGCACTTTTTGAAATATCCGATAGTGATCCCCTTCTACAATATTATGTAGATACAGTAACTCACGAAATTGTGCTATCTTTTTTAGGTGAGGTCCAAATGGAGGTAACTTGTACTCTGATTCAAGAAAAATATCATATTGAGATAGAAACAAGAAAACCAACTGTCATTTATATGGAAAGACCATTAAAAAAATCTGAATTTACCATTGATATCGAAGTACCTCCAAATCCTTTCTGGGCTTCTATTGGTTTATCTGTAACACCACTTCCTTTGGGTAGTGGCATTCAGTATGAGAGCCTGGTTTCTCTAGGTTATTTAAATCAATCATTTCAAAATGCAGTTATGGAAGGTATACGCTATGGGTGTGAACAAGGATTGTACGGTTGGAAATTAACAGACTGTAAGATCTGTTTTAAGTATGGTCTATATTACAGCCCTGTCAGTACGCCAGCAGATTTCCGAATGCTTGCGCCTATTGTACTAGAGCAGGCTTTTAGAAAGAGTGGTACAGAGTTATTAGAGCCATATCTTAGCTTCGAAATTTATGTACCACAAGAATATCTTTCGAGAGCATATAATGATGCTTCCAAATATTGTGCAAATATTTTAAATACTAAGTTAAAAGGTAACGAGGTCATTCTCATTGGTGAAATTCCAGCCCGTTGTATTCAAGAGTATCGAAACAGTTTAACTTTCTTTACAAATGGACGCAGTGTCTGTTTAACAGAGTTAAAAGGTTATCAGGTTACTAACATTAAGTCTGCTTTCCAACCACGTCGTCCAAATAATAGAATAGACAAAGTAAGGCATATGTTTAATAAAATCAACTTACATTGA,tetracycline-resistant ribosomal protection protein,antibiotic target protection,Tetracyclines,MEG_7201,Drugs,MEG_7201|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TETS,gi|90811349|gb|DQ377340.1|496-2421 gi|2467210|emb|X92946.1|27959-26034 gi|388785684|gb|JQ762256.1|3381-3410,4
,atggacacaacgcaggtcacattgatacacaaaattctagctgcggcagatgagcgaaatctgccgctctggatcggtgggggctgggcgatcgatgcacggctagggcgtgtaacacgcaagcacgatgatattgatctgacgtttcccggcgagaggcgcggcgagctcgaggcaatagttgaaatgctcggcgggcgcgtcatggtggagttggactatggattcttagcggagatcggggatgagttacttgactgcgaacctgcttggtgggcagacgaagcgtatgaaatcgcggaggctccgcagggctcgtgcccagaggcggctgagggcgtcatcgccgggcggccagtccgttgtaacagctgggaggcgatcatctgggattacttttactatgccgatgaagtaccaccagtggactggcctacaaagcacatagagtcctacaggctcgcatgcacctcactcggggcggaaaaggttgaggtcttgcgtgccgctttcaggtcgcgatatgcggcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_741,Drugs,MEG_741|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT2-DPRIME,1105502151|WP_071846303.1|NG_052367|1|1|ant(2'')-Ia|ant(2'')-Ia|aminoglycoside_nucleotidyltransferase_ANT(2'')-Ia NG_052367:101-634,2
,ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCTGCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATGCAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGAGAAACCTTATTACTTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTTGAATTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACGCTATCGCCCGCGGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGCATTACTGCGCTTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGCGGTGCAACCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGCCTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGACAACTTGACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGGCGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCTGATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAGGTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACGGGATCCACAGGTGGATTTGGCAGCTACGTTGCCTTCGTTCCAGAAAAAAACCTTGGCATAGTGATGCTGGCAAACAAAAGCTATCCTAACCCTGTCCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTGCAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1907,Drugs,MEG_1907|Drugs|betalactams|Class_C_betalactamases|CMY,gb|JQ733573|+|1027-2173|ARO:3002089|CMY-76 [Citrobacter freundii] ,0
,atgacttttaatattattaatttggaaacttgggatagaaaagaatattttaatcattatttcaatcaacaaacaacttacagtgttactaaagaatttgatatcactttacttaaaagtatgataaaaaataaaggatatgaactgtatcctgctttgatttatacaattgtaaatattataaatcaaaataaagtatttagaacaggaattaatagtgagggaaatttgggttattgggataaattaaaccctttatatacagtctttaataaagaaactgaaaaattttctaacatttggacagaatcaaatgttagttttaattctttttataatagttataagagtgacttacttgaatataaagataaaaatgaaatgtttcctaaaaaaccaatacctgaaaacacagttcctatttcgatgattccttggattgattttagttcatttaatttaaatattggtaataatagtagattcctattgccaattattacaataggtaaattttatagtaagaataataagatctatttaccagtctcattgcaagttcatcatgcggtatgtgatggttaccatgtttcattatttatgagtgaatttcaaaatatagttgatagtgtaaatgaatggatttaa,beta-lactamase,antibiotic inactivation,Phenicol,MEG_1575,Drugs,MEG_1575|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATA,488281046|WP_002352254.1|NG_047574|1|1|catA8|catA8|type_A-8_chloramphenicol_O-acetyltransferase NG_047574:101-748,6
,TTTATCAAAATCCAATCGGCTTTTTCTTCAGCATACTTTTTGAAACACTACCAAATTTTAAAGTTGTATATCATGAAATTATTAAAAATATTGAGTTTAGTTTGCTTAAGCATAAGTATTGGGGCTTGTGCTGAGCATAGTATGAGTCGAGCAAAAACAAGTACAATTCCACAAGTGAATAACTCAATCATCGATCAGAATGTTCAAGCGCTTTTTAATGAAATCTCAGCTGATGCTGTGTTTGTCACATATGATGGTCAAAATATTAAAAAATATGGCACGCATTTAGACCGAGCAAAAACAGCTTATATTCCTGCATCTACATTTAAAATTGCCAATGCACTAATTGGTTTAGAAAATCATAAAGCAACATCTACAGAAATATTTAAGTGGGATGGAAAGCCACGTTTTTTTAAAGCATGGGACAAAGATTTTACTTTGGGCGAAGCCATGCAAGCATCTACAGTGCCTGTATATCAAGAATTGGCACGTCGTATTGGTCCAAGCTTAATGCAAAGTGAATTGCAACGTATTGGTTATGGCAATATGCAAATAGGCACGGAAGTTGATCAATTTTGGTTGAAAGGGCCTTTGACAATTACACCTATACAAGAAGTAAAGTTTGTGTATGATTTAGCCCAAGGGCAATTGCCTTTTAAACCTGAAGTTCAGCAACAAGTGAAAGAGATGTTGTATGTAGAGCGCAGAGGGGAGAATCGTCTATATGCTAAAAGTGGCTGGGGAATGGCTGTAGACCCGCAAGTGGGTTGGTATGTGGGTTTTGTTGAAAAGGCAGATGGGCAAGTGGTGGCATTTGCTTTAAATATGCAAATGAAAGCTGGTGATGATATTGCTCTACGTAAACAATTGTCTTTAGATGTGCTAGATAAGTTGGGTGTTTTTCATTATTTATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_5261,Drugs,MEG_5261|Drugs|betalactams|Class_D_betalactamases|OXA,gi|971493847|gb|CP010351.1|396906-395992 gi|971493847|gb|CP010351.1|395910-395964 gi|827342761|gb|KR055667.1|2553-3467 gi|827342761|gb|KR055667.1|3549-3495 gi|442769248|gb|JX101647.1|57483-56569 gi|442769248|gb|JX101647.1|56487-56541 gi|544205277|gb|KF208466.1|1598-2512 gi|544205277|gb|KF208466.1|2594-2540 gi|522376232|gb|CP003848.1|47906-48820 gi|522376232|gb|CP003848.1|48902-48848 gi|441494717|gb|JX968506.1|1575-661 gi|441494717|gb|JX968506.1|579-633 gi|695226605|ref|NG_041543.1|1484-2398 gi|695226605|ref|NG_041543.1|2480-2426 gi|695226596|ref|NG_041542.1|3628-4542 gi|695226596|ref|NG_041542.1|4624-4570 gi|695226589|ref|NG_041541.1|1905-2819 gi|695226589|ref|NG_041541.1|2901-2847 gi|695226580|ref|NG_041540.1|3606-4520 gi|695226580|ref|NG_041540.1|4602-4548,0
,atggctaaaatgagaatatcaccggaattgaaaaaactgatcgaaaaataccgctgcgtaaaagatacggaaggaatgtctcctgctaaggtatataagctggtgggagaaaatgaaaacctatatttaaaaatgacggacagccggtataaagggaccacctatgatgtggaacgggaaaaggacatgatgctatggctggaaggaaagctgcctgttccaaaggtcctgcactttgaacggcatgatggctggagcaatctgctcatgagtgaggccgatggcgtcctttgctcggaagagtatgaagatgaacaaagccctgaaaagattatcgagctgtatgcggagtgcatcaggctctttcactccatcgacatatcggattgtccctatacgaatagcttaaacagccgcttagccgaattggattacttactgaataacgatctggccgatgtggattgcgaaaactgggaagaagacactccatttaaagatccgcgcgagctgtatgattttttaaagacggaaaagcccgaagaggaacttgtcttttcccacggcgacctgggagacagcaacatctttgtgaaagatggcaaagtaagtggctttattgatcttgggagaagcggcagggcggacaagtggtatgacattgccttctgcgtccggtcgatcagggaggatatcggggaagaacagtatgtcgagctattttttgacttactggggatcaagcctgattgggagaaaataaaatattatattttactggatgaattgttttag,antibiotic molecule,antibiotic inactivation,Aminoglycosides,MEG_1039,Drugs,MEG_1039|Drugs|Aminoglycosides|Aminoglycoside_O-phosphotransferases|APH3-DPRIME,1028082240|WP_063841507.1|NG_047420|1|1|aph(3')-IIIa|aph(3')-IIIa|aminoglycoside_O-phosphotransferase_APH(3')-IIIa NG_047420:101-895,2
,atgcgattcaaaaaaatttcttacttaattctaccttctctttttatttttaatacctcaatttatgcaggtaacacatcaaaagaacaagatatcaagaaagttgttgatcaaaactttaaaccactattagaaaaatatgatgttcccggtatggcggttggcgtcatccaaaacaataaaaagtacgaaatgtattatggcctacaatcggttcaagataaaaaatctgtaaatggcaatacgatttttgagctaggttcagtcagtaaattatttactgccacggcaggtggatatgccaaaactaaaggaaaaatctcttttaacgacaccccaggaaaatactggaaagagctaaaaaatacaccgattgaccgagtgaacctacttcaacttgcgacctatacgagtggcaaccttggcttacaatttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacctaaaaaccaaattggtgaatatagacaatattcaaaccctagtattggcctatttggaaaagttgtaggcttatcgatgaaccagccttttagtcaggttttagaaaatacaatttttccgtctcttcacttaaaacatagctatgtgaatgttcctaaaactcagatgcaaaactatgcatttggctataaccaagaaaatcagcctattcgtgtgaccccaggcccactagatgcccctgcctacggcgttaaatccacattaccagacatgcttagctttattgatgccaatctaaatccacaaaaatatccggcagatattcgacgcgcaattgatgagactcataaaggtttttatcaagtcggtacgatgtatcaggcgcttggttgggaagagttttcttatccagctcctttacaaactttattagacagtaattctgaacaaatcgtgatgaaacctaataaagtgactgctatttcaaaagagccttcaatcaagatgttccataaaactggttcaactaacggatttggaacttatgtcgtgtttattcccaaagaaaatattggtttagtcatgttaaccaataaacgtattcccaatgaagaacgcattaaagcagcgtatgcagtgttgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_518,Drugs,MEG_518|Drugs|betalactams|Class_C_betalactamases|ADC,491187661|WP_005046018.1|NG_064683|1|1|blaADC-127|blaADC|class_C_beta-lactamase_ADC-127 NG_064683:101-1252,0
,atgaacattaaagcactcttacttataacaagcgctatttttatttcagcctgttcaccttatatagtgactgctaatccaaatcacagcgcttcaaaatctgatgaaaaagcagagaaaattaaaaatttatttaacgaagcacacactacgggtattttagttatccaacaaggccaaactcaacaaagctatggtaatgatcttgctcgtgcttcgaccgagtatgtacctgcttcgaccttcaaaatgcttaatgctttgatcggccttgagcaccataaggcaaccaccacagaagtatttaagtggaacgggcaaaaaaggctgttcccagaatgggaaaaggacatgaccctaggcgatgctatgaaagcttccgctattccggtttatcaagatttagctcgtcgtattggacttgaactcatgtctaatgaagtgaagcgtgttggttatggcaatgcagatatcggtacccaagtcgataatttttggctggtgggtcctttaaaaattactcctcagcaagaggcacaatttgcttacaagctagctaataaaacgcttccatttagccaaaaagtccaagatgaagtgcaatccatgctattcatagaagaaaagaatggaaataaaatatacgcaaaaagtggttggggatgggatgtagacccacaagtaggctggttaactggatgggttgttcagcctcaaggaaatattgtagcgttctcccttaacttagaaatgaaaaaaggaatacctagctctgttcgaaaagagattacttataaaagtttagaacaattaggtattttatag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4483,Drugs,MEG_4483|Drugs|betalactams|Class_D_betalactamases|OXA,1509794588|WP_122630897.1|NG_062317|1|1|blaOXA-695|blaOXA-51_like|OXA-51_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-695 NG_062317:19-843,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccgatgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcgctgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaattgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgccgcaaccacacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagcccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5612,Drugs,MEG_5612|Drugs|betalactams|Class_C_betalactamases|PDC,1393270442|WP_109791187.1|NG_057585|1|1|blaPDC-253|blaPDC|class_C_beta-lactamase_PDC-253 NG_057585:1-1194,0
,atgcgttatattcgcctgtgtattatctccctgttagccaacctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggccgcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgtgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgctttccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctggcgaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcggattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6189,Drugs,MEG_6189|Drugs|betalactams|Class_A_betalactamases|SHV,1058244172|WP_068981648.1|NG_051484|1|1|blaSHV-195|blaSHV|class_A_beta-lactamase_SHV-195 NG_051484:1-861,0
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgatacacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcccgcgcagatcagttggaagaatttgttcactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_887,Drugs,MEG_887|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1105502075|WP_071846227.1|NG_052238|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_052238:101-892,2
,ATGAGAAACTTTGCAATTTTATTTTTTTTACTGATCACTTTCAGCTGGAAAGCACAGGTTGTTAAAGAACCGGAAAATACAAATGAAGAATGGTCCCGATCATATGAGCCATTCAGAATTGCGGGTAACTTATACTATGTAGGAACTTACGATCTGGCTTCTTATTTAATAGTTACCGATAAAGGAAATATTCTCATTAATACAGGATTGGCTGGTTCTCTTCCTATGATAAAAGAGAATATTAAAAAACTGGGATTCAATTATAAAGACATTAAAATTCTGCTTTTAACCCAGGCGCATTATGATCATACAGGTGCATTAAAAGATTTGCAAACAGAAACAGGTGCGAAATTTTATGCAGACAGTGCTGATGCTGATGTATTGAAAACGGGCGGTAAATCCGATTATGAAATGGGGAAATACGGGGCAACCTTTAAGGCGATTAAGCCTGATATCCTGTTGAAAGATCAGGATAAAATAAAACTGGGGAATACAACCTTAACTTTACTTCATCATCCGGGGCACACAAAAGGTTCATGCAGTTTTATATTTGAAACAAAGGATGAAAACAGAAATTATAAAGTGCTGATAGCCAATATGCCATCGGTTATAGTTGACCGTAAGTTTTCCGAAATAAAAGATTACCCTAATATTCAGGCCGATTATGCTTATACATTTAAAGCCATGAAAAAACTGGATTTTGATCTTTGGGTCGCTTCACATGCAAGTCAGTTTGATTTACATACAAAACATAAAGAGGGAGACCCTTATAACCCACAGGTATTTATGGATAAGGCCAATTATTTTGCATTCCTCAATAGCCTGGAAACAGATTATCTGGAAAAAATTAAAAACGACTCACAAAAGAAATAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_3166,Drugs,MEG_3166|Drugs|betalactams|Class_B_betalactamases|GOB,gi|58802938|gb|AY899331.1|1-873,0
,atgcgttatgttcgcctgtgtgttatctccctgttagccaccctgccactggcggtatacgccggtccacagccgcttgagcagattaaacaaagcgaaagccagctgtcgggccgcgtggggatggtggaaatggatctggccagcggccgcacgctggccgcctggcgcgccgatgaacgctttcccatggtgagcacctttaaagtgctgctgtgcggcgcggtgctggcgcgggtggatgccgggctcgaacaactggatcggcggatccactaccgccagcaggatctggtggactactccccggtcagcgaaaaacaccttaccgacgggatgacgatcggcgaactctgcgccgccgccatcaccctgagcgataacagcgctggcaatctgctgctggccaccgtcggcggccccgcgggattaactgcctttctgcgccagatcggtgacaacgtcacccgtcttgaccgctgggaaacggcactgaatgaggcgcttcccggcgacgcacgcgacaccaccaccccggccagcatggccgccacgctgcgcaaactactgaccgcgcagcatctgagcgcccgttcgcaacagcaactcctgcagtggatggtggacgatcgggttgccggcccgctgatccgcgccgtgctgccgccgggctggtttatcgccgacaagaccggggctggcgaacggggtgcgcgcggcattgtcgccctgctcggcccggacggcaaaccggagcgcattgtggtgatctatctgcgggataccccggcgagcatggccgagcgtaatcaacatatcgccgggatcggcgcagcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_3544,Drugs,MEG_3544|Drugs|betalactams|Class_A_betalactamases|LEN,556339706|WP_023297577.1|NG_049270|1|1|blaLEN-16|blaLEN|class_A_beta-lactamase_LEN-16 NG_049270:101-961,0
,atgaatagttcgacaaagatcgcattggtaattacgttactcgatgccatggggattggccttatcatgccagtcttgccaacgttattacgtgaatttattgcttcggaagatatcgctaaccacttaggcgtattgcttgcactttatgcgttaatgcaggttatctttgctccttggcttggaaaaatgtctgaccgatttggtcggcgcccagtgctgttgttgtcattaataggcgcatcgctggattacttattgctggctttttcaagtgcgctttggatgctgtatttaggccgtttgctttcagggatcacaggagctactggggctgtcgcggcatcggtcattgccgataccacctcagcttctcaacgcgtgaagtggttcggttggttaggggcaagttttgggcttggtttaatagcggggcctattattggtggttttgcaggagagatttcaccgcatagtcccttttttatcgctgcgttgctaaatattgtcactttccttgtggttatgttttggttccgtgaaaccaaaaatacacgtgataatacagataccgaagtaggggttgagacgcaatcgaattcggtatacatcactttatttaaaacgatgcccattttgttgattatttatttttcagcgcaattgataggccaaattcccgcaacggtgtgggtgctatttaccgaaaatcgttttggatggaatagcatgatggttggcttttcattagcgggtcttggtcttttacactcagtattccaagcctttgtggcaggaagaatagccactaaatggggcgaaaaaacggcagtactgctcggatttattgcagatagtagcgcatttgcctttttagcgttcatatctgaaggttggttagttttccctgttttaattttattggctggtggtgggatcgctttacctgcattacagggagtgatgtctatccaaacaaagagtcatcagcaaggtgctttacagggattattggtgagccttaacaatgcaaccggtattattggcccattactgtttgctgttatttataatcattcactaccaatttgggatggctggatttggattattggtttagcgttttactgtattattatcctgctatcgatgaccttcatgttaacccctcaagctcaggggagtaaacaggagacaagtgcttag,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7037,Drugs,MEG_7037|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETB,1028099751|WP_063856066.1|NG_048166|1|1|tet(B)|tet(B)|tetracycline_efflux_MFS_transporter_Tet(B) NG_048166:1-1206,4
,atgatgaaaaaatccctgtgctgcgccctgctgctcagcacctcctgcgctgcattagccgcacctatgtcagaaacacagctggcgaaggtcgtggaacgtaccgttacgcccctgatgaaagcgcagtctattccgggtatggcggtcgccgtgatctatcagggccagccgcactacttcaccttcggcaaggccgatgtcgcagcgaacacacccgtcactgcacaaacgctgtttgagctgggctcaatcagcaaaaccttcaccggcgttctgggtggcgatgctattgctcgcggtgaaatttcgctgggcgatccggtgaccaaatactggcctgagctgaccggcaaacagtggcagggcgttcgcatgctggacctggcaacctatactgccggtggcctgccgttacaggtgcccgatgaggttaccgataatgcctcgctgctgcgtttttaccagtcctggcaaccacagtgggcgccaggcaccacgcgtctttatgcgaacgccagcatcggtctgtttggggctctggcggtgaaaccttctggcatgcgctttgagcaggcgatgacagagcgggtcctgaagccgcttaacctgaaccatacgtggattaacgttccgaagtcagaagaacagcattacgcctggggttatcgtgacggtaaagcggttcacgtttcgccgggcatgctcgacgccgaagcgtatggcgtgaaaaccaacgtgaaggatatggcgagctgggtgatggctaacatggctcccgatggcgtacaggatgcctcactgaagcagggcatggtgcttgcacagtctcgctactggcgcacaggctcgatgtaccagggcctgggctgggagatgctcaactggccggtagaagccaaaaccgtggtggagggcagcgacaacaaagtagcgcttgcgccgttgcccgtggcagaagtaaaccctcctgcaccaccggtaaaagcgtcatgggtacataaaacaggctcgacgggcggatttggcagctacgtggcatttattcctgagaaggaactcggcatcgttatgctggcgaacaagagctacccgaacccggcacgcgtggaagcggcataccgtattctgagcgctctgcagtaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_421,Drugs,MEG_421|Drugs|betalactams|Class_C_betalactamases|ACT,1270501827|WP_099156056.1|NG_055670|1|1|blaACT-54|blaACT|cephalosporin-hydrolyzing_class_C_beta-lactamase_ACT-54 NG_055670:1-1146,0
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccgccaccccggccattgccggcgaggccccggcggatcgcctgaaggcattggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagtcagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggccggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccctgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccacacaggatcgctaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccaacggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctatgccatcctcagcggcctggagcagcaggccaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5575,Drugs,MEG_5575|Drugs|betalactams|Class_C_betalactamases|PDC,1001048246|WP_061193023.1|NG_055480|1|1|blaPDC-116|blaPDC|class_C_beta-lactamase_PDC-116 NG_055480:1-1194,0
,GATGTGTCATAGTATTCGTCGTTAGAAAACAATTATTATGACATTATTTCAATGAGTTATCTATTTTTGTCGTGTACAGAGCTCTTTTTTATTTTCTATTGATCTGGTGTTTAAAATGAATAAATATTTTACTTGCTATGTGGTTGCTTCTCTTTTTCTTTCTGGTTGTACGGTTCAGCATAATTTAATAAATGAAACCCCGAGTCAGATTGTTCAAGGACATAATCAGGTGATTCATCAATACTTTGATGAAAAAAACACCTCAGGTGTGCTGGTCATTCAAACAGATAAAAAAATTAATCTATATGGTAATGCTCTAAGCCGCGCAAATACAGAATATGTGCCAGCCTCTACATTTAAAATGTTGAATGCCCTGATCGGATTGGAGAACCAGAAAGCGGATATTAATGAAATATTTAAATGGAAGGGCGAGAAAAGGTCATTTACCGCTTGGGAAAAAGACATGACACTAGGAGAAGCCATGAAGCTTTCTGCAGTCCCAGTCTATCAGGAACTTGCGCGACGTATCGGTCTTGATCTCATGCAAAAAGAAGTAAAACGTATTGGTTTCGGTAATGCTGAAATTGGACAGCAGGTTGATAATTTCTGGTTGGTAGGACCATTAAAGGTTACGCCTATTCAAGAGGTAGAGTTTGTTTCCCAATTAGCACATACACAGCTTCCATTTAGTGAAAAAGTGCAGGCTAATGTAAAAAATATGCTTCTTTTAGAAGAGAGTAATGGCTACAAAATTTTTGGAAAGACTGGTTGGGCAATGGATATAAAACCACAAGTGGGCTGGTTGACCGGCTGGGTTGAGCAGCCAGATGGAAAAATTGTCGCTTTTGCATTAAAAATGGAAATGCGGTCAGAAATGCCGGCATCTATACGTAATGAATTATTGATGAAATCATTAAAACAGCTGAATATTATTTAAGAGCTTGACAGAAACTCTAATTTTATAAAAAGCCCATTTGAGATAAATGGGCCTTTTATAATCTGACTAATAATGAAACCTGTTAATTTTTCTAGTTTAAAATTTTACAGTGCTTTTAGTTGTTG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5205,Drugs,MEG_5205|Drugs|betalactams|Class_D_betalactamases|OXA,gi|12060144|gb|AF201828.2|AF201828|1-1062 gi|939559781|gb|CP012952.1|1232386-1232467 gi|939559781|gb|CP012952.1|2561141-2561222 gi|939559781|gb|CP012952.1|2743155-2743074 gi|939559781|gb|CP012952.1|1035980-1036060 gi|939559781|gb|CP012952.1|1312277-1312197 gi|939559781|gb|CP012952.1|1549317-1549237 gi|939559781|gb|CP012952.1|1673965-1673885 gi|939559781|gb|CP012952.1|1976686-1976766 gi|939559781|gb|CP012952.1|2359896-2359816 gi|939559781|gb|CP012952.1|3581430-3581510 gi|939559781|gb|CP012952.1|3705318-3705238 gi|939559781|gb|CP012952.1|3838592-3838512 gi|939559781|gb|CP012952.1|3855125-3855045 gi|693578048|dbj|AP014649.1|718278-718359 gi|693578048|dbj|AP014649.1|477947-477867 gi|693578048|dbj|AP014649.1|2686880-2686960 gi|693578048|dbj|AP014649.1|2905183-2905103 gi|693578048|dbj|AP014649.1|3755940-3755860 gi|984881271|gb|CP014215.1|432616-432696 gi|984881271|gb|CP014215.1|2332338-2332258 gi|984881271|gb|CP014215.1|2825934-2826014 gi|984881271|gb|CP014215.1|3326705-3326785 gi|984686374|gb|HQ700358.2|8155-8235 gi|974022331|gb|CP013924.1|914680-914600 gi|974022331|gb|CP013924.1|1418214-1418294 gi|974022331|gb|CP013924.1|3335874-3335794 gi|884906331|gb|CP012008.1|45430-45350 gi|884902522|gb|CP012006.1|3691827-3691747 gi|827403829|gb|CP010779.1|3022167-3022087 gi|730910803|gb|KM977710.1|29944-30024,0
,atgcgatttaaaaaaatttcttgtctacttttatccccgctttttatttttagtacctcaatttatgcgggcaatacaccaaaagaccaagaaattaaaaaactggtagatcaaaattttaaaccgttattagaaaaatatgatgtgccgggtatggctgtgggtattattcaaaataataaaaagtatgaaatgtattatggtcttcaatctgttcaagataaaaaagccttaaatagcagtactatttttgagctaggttctgtcagtaaattatttaccgcgacagcaggtggatatgcaaaaaataaaggaaaaatctcttttgacgatacgcctggtaaatattggaaagaactaaaaaacacaccgattgaccaagttaacttacttcaactcgcgacgtatacaagtggtaaccttgccttgcagtttccagatgaagtacaaacagaccaacaagttttaacttttttcaaagactggaaacccaaaaacccaatcggtgaatacagacaatattcaaatccaagtattggcctatttggaaaggttgtagctttgtctatgaataaacctttcgaccaagtcttagaaaaaacaatttttccggcccttggcttaaaacatagctatgtaaatgtacctaagacccagatgcaaaactatgcttttggctataaccaagaaaatcagccgattcgagttaaccccggcccactcgatgccccagcatatggcgtcaaatcgacactacccgacatgttgagttttattcatgccaacctaaatccacaaaaatatccagcagatattcaacgggcaattaatgaaacacatcagtgtcgctatcaagtaaataccatgtatcaggcactcggttgggaagagttttcttatccggcaacgttacaaactttattagacagtaattcagaacagattgtgatgaaacctaataaagtgactgctatttcaaaggaaccttcagttaagatgtaccataaaactggctcaaccaacggtttcggaacatatgtagtgtttatacctaaagaaaatattggcttagtcatgttaaccaataaacgtattccaaatgaagagcgcattaaggcagcttatgctgtgctgaatgcaataaagaaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_603,Drugs,MEG_603|Drugs|betalactams|Class_C_betalactamases|ADC,691160398|WP_032068214.1|NG_056106|1|1|blaADC-164|blaADC|class_C_beta-lactamase_ADC-164 NG_056106:1-1152,0
,ATGCAGGAAAAAATAGATATTACGGTTTTTGGGTGTGAGCGGGATGAAGCGGCGGTATTCCGTAAACTTTCATCTGAGTATGGCGTCACAGTTTCGCTCATCGAAGATGTCGTATCAGAGCACAATGCAAAATTAGCGGACGGATGCCAGTGTGTCAGCGTAAGCCATAAGGCGGAGCTGTCGGAGCAGCTTCTCCTTGCGCTGAAACACGCAGGAGTGAAATACATCAGTACCCGGAGCATTGGATTCAACCATATTGATATACAGGCTGCAGGTCAGTTGGGTATGGCTGTTGGCACAGTGGCATACTCACCGGGAAGCGTGGCCGATTATACCGTCATGCTGATGCTCATGCTGCTGCGCGGCACAAAGTCGGTTCTACGAGGAACCCAGAAGCAGAATTATTGTCTGAATGACTGCCGTGGAAAAGAACTGCAGGATTTGACGGTTGGCGTCCTGGGAACCGGACGAATCGGACAGGCAGTCATGGAACGCCTGGAGGGATTCGGCTGCAAGGTGTTGGCCTATGACCGAACTCACAAAGCCGGAGCAAATTATGTTTCGTTTTGTGAATTATTGAAGAGCAGCGACATTGTTACGCTGCATGTGCCTCTGGCAGAGGATACCCGCCATATGATTGGGCGCGAGCAGCTAGAGATGATGAAGAGGGAGGCACTTCTGATCAACACGGCACGGGGGGCTTTAGTGGATACGGCTGCACTGGTTGCTGCGCTGAAAGAACAAAAAATCGGCGGAGCCGCCTTAGATGTCCTGGAAGGGGAAGAAGGCATCTTTTACCATGAATGCACACAAAAAACGATAGGGCATCCTTACCTCTCCGTTTTGCAGAAAATGCCCAATGTCATTGTTACGCCGCATACGGCCTATCATACGGATCGGGTACTGGTCGATACCGTGAGCAATACCATCCGAAATTGTCTGAATTTTGAAAGGAGTCTTGGAAATGTATAAGCTTAAAATTGCAGTCCTGTTTGGAGGCTGCTCAGAGGAACATGATGTTTCAGTGAAATCTGCGATGGAGGTTGCAGCAAATATAAACAAGGAAAAATACCAGCCGTTTTATATTGGAATCACAAAATCCGGCGCATGGAAACTATGCGATAAGCCCTGCCGGGACTGGGAGAACTATGCGGGATACCCGGCTGTGATTTCTCCGGACAGAAGGATCCATGGCCTGCTGATACAAAAGGACGGCGGATATGAGAGCCAGCCTGTAGACGTGGTGCTTCCGATGATTCATGGAAAATTTGGCGAGGACGGAACCATACAGGGTCTGCTTGAGCTGTCCGGCATTCCTTATGTGGTATGCGACATTCAAAGTTCTGTAATCTGTATGGATAAGTCGCTCGCTTATATGGTTGTGAAAAATGCGGGAATTGAGGTACCTGGGTTTCGAGTTCTACAAAAGGGGGACAGCCTGGAAGCAGAGACGCTCTCGTATCCGGTCTTTGTAAAGCCTGCCCGTTCCGGCTCCTCTTTTGGCGTGAATAAGGTATGCCGGGCAGAGGAACTGCAGGCAGCGGTCACAGAGGCGGGTAAGTATGACAGCAAAATATTGGTTGAGGAGGCCGTTTCCGGGAGTGAGGTAGGATGTGCCATACTGGGAAACGGAAACGATCTCATCACCGGCGAGGTCGATCAGATTGAATTGAAACACGGGTTTTTTAAGATCCATCAGGAAGCACAGCCGGAAAAGGGGTCTGAAAATGCTGTGATTAGAGTTCCAGCCGCCCTGCCGGATGAAGTTAGGGAGCAGATTCAGGAAACGGCGAAGAAGATTTACCGGGTACTTGGCTGCAGAGGTCTGGCCCGCATTGATTTGTTTTTACGGGAGGATGGAAGCATTGTCCTGAATGAAGTGAACACCATGCCTGGATTTACTTCCTATAGCCGTTATCCACGCATGATGACAGCAGCAGGGTTTACGCTTTCTGAAATATTGGACCGCTTGATTGGACTTTCACTTAGGAGGTAACCATCATGGAAAAGAACTTTGTCTTTTTGGATGAAATGCTGCCGGGCATCCGGTGGGATGCCAAATATGCCACATGGGACAATTTCACCGGGAAACCGGTAGACGGATACGAGGTAAACCGCATTGTGGGAACGAAAGAGCTTGGTGCCGCTTTACGTAAGGCACAGAAGGCGGCGGAGAAACTGGGATACGGTCTGCTCTTATGGGACGGCTACCGTCCCCAGTGTGCAGTGGACTGCTTTTTGACTTGGGCTTCCCTGCCGGAGAACAATCTGACGAAAAAGCGTTACTACCCAAATATCAAAAGGAACGAGATGATCACGAAAGGGTATGTGGCTTCTCAGTCCAGCCACAGTCGCGGGAGCGCGATTGATCTCACGATTTTTCGTTTGGACACGGGTATGCTTGTGCCAATGGGCGGAGATTTCGACTTTATGGATGTACGGTCGCATCATGCCGCCAGTGGTCTGAGCGAAGAGGAGGCCGGAAACCGTGAGCGCCTGCGTGATATCATGGAGCGCAGCGGATTTGAAGCCTACCGATATGAATGGTGGCATTATGTCTTGGCAGACGAGCCATACCCGGATACATATTTTGATTTTTGCATTGCCTAG,gene(s) or protein(s) associated with a glycopeptide resistance cluster,antibiotic target alteration,Glycopeptides,MEG_7434,Drugs,MEG_7434|Drugs|Glycopeptides|VanD-type_resistance_protein|VANHD,VanHDX_7_AB242319,5
,TTGAAAAAGTTAATATTTTTAATTGCAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTCCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAGATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAATACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGGATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATCCAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACACCTGCTGCTTTCGGTAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAGAAAACAAAAAATTCTTACTTGATTTAATGTTAAATAATAAAAGCGGAGATACTTTAATTAAAGACGGTGTTTCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1453,Drugs,MEG_1453|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_127_ACFR01000018,0
,ATGACCGAGCACGACCTTCCGATGCTCCATGACTGGCTAAATCGGCCTCACATCGTCGAGTGGTGGGGCGGAGAAGAAGCACGCCCGACACTTGCTGACGTACAGGAACAGTACTTGCCAAGCGTTTTAGCGCAAGAGTCCGTCACTCCATACATTGCAATGCTGAATGGAGAGCCGATTGGGTATGCCCAGTCGTACGTTGCTCTTGGAAGCGGGGACGGATGGTGGGAAGAAGAAACCGATCCAGGAGTACGCGGAATAGACCAGTCACTGGCGAATGCATCACAACTGGGCAAAGGCTTGGGAACCAAGCTGGTTCGAGCTCTGGTTGAGTTGCTGTTCAATGATCCCGAGGTCACCAAGATCCAAACGGACCCGTCGCCGAGCAACTTGCGAGCGATCCGATGCTACGAGAAAGCGGGGTTTGAGAGGCAAGGTACCGTAACCACCCCAGATGGTCCAGCCGTGTACATGGTTCAAACACGCCAGGCATTCGAGCGAACACGCAGTGTTGCCTAA,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_354,Drugs,MEG_354|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,gi|742797756|emb|LK054503.1|28152-27634 gi|290889360|gb|GU784921.1|133-651 gi|218963122|gb|FJ495083.1|120-638 gi|124377167|emb|AJ878850.1|584-1102,2
,ATGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGGTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGGCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6598,Drugs,MEG_6598|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|695200623|ref|NG_036153.1|6755-7594,8
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggatggtgggaagaagaaaccgatccaggagtacgcggaatagaccagtcactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagtggggtttgagaggcaaggtaccgtaaccaccccagatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_224,Drugs,MEG_224|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1105502211|WP_071846361.1|NG_052481|1|1|aac(6')-Ib|aac(6')-Ib|AAC(6')-Ib_family_aminoglycoside_6'-N-acetyltransferase NG_052481:101-655,2
,atggcaatccgattcctcaccatactgctatctactttttttcttacctcattcgtgcatgcgcaagaacacgtgctagagcgttctgactggaagaagttcttcagcgacctccgggccgaaggtgcaatcgttatttcagacgaacgtcaagcggagcatgctttattggtttttggtcaagagcgagcagcaaagcgttactcgcctgcttcaaccttcaagcttccacacacactttttgcactcgatgcagacgccgttcgtgatgagttccaggtttttcgatgggacggcgttaaacggagctttgcgggccataatcaagaccaagacttgcgatcagcgatgcgaaattctgcggtctgggtttatgagctatttgcaaaagagatcggagaggacaaagcaagacgctatttaaagcaaattgattatggcaacgccgacccttcgacaatcaagggcgattactggatagatggcaatcttgaaatctcagcgcacgaacagatttcgtttctcagaaaactctatcgaaatcagctgccatttcaggtggaacatcagcgcttggtcaaagatctcatgattacggaagccgggcgcaactggatactacgcgcaaagaccggctgggaaggcaggtttggctggtgggtagggtgggtggagtggccaaccggtcccgtattcttcgcactgaatattgatacgccaaacagaacggatgatcttttcaaaagagaggcaatcgcgcgggcaatccttcgctctatcgacgcattgccgcccaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4731,Drugs,MEG_4731|Drugs|betalactams|Class_D_betalactamases|OXA,695263575|WP_032490445.1|NG_064746|1|1|blaOXA-119|blaOXA-46_like|oxacillin-hydrolyzing_class_D_beta-lactamase_OXA-119 NG_064746:101-901,0
,atgacgaaaatgaaccgcctggcggccgcgctgatcgccgcactgatcttgccgaccgcgcacgccgcgcagcagcaggatatcgacgccgttattcagccgctgatgaaaaaatatggcgtgccgggcatggcgatcgccgtgtcggtcgacggcaaacagcagatttacccgtatggcgtcgcctcgaagcagaccggcaaaccgatcaccgagcagacgctgttcgaagtgggctcgctgagcaaaaccttcaccgcgacgctggcggtctatgcgcagcagcagggcaagctgtcgttcaacgatccggccagccgctacctgcccgagctgcgcggcagcgccttcgacggcgtcagcctgctgaatctggcgacgcatacctccggcctgccgctgttcgtgccggacgacgtgaccgacaacgcccaactgatggcctactaccgggcctggcagccgaaacatccggcgggcagctaccgcgtctattccaacctcggcatcggcatgctgggcatgatcgccgccaagagcctcgaccagccgtttacccaggcgatggagcaggggatgctgccggcgttgggcatgcgccacacctacgttcaggtgccggcggcgcagatggccaactatgcgcagggctacaacaaggacgataagccggtgcgggtcaatcccggcccgctggacgccgagtcttacggcatcaagtccaacgctcgcgatctgattcgctatctggacgccaacctgcagcaggtgaaggtcgcgcacgcgtggcgcgaggcgctgaccgcgacgcacgtcggttattacaaggcgggcgcgttcacgcaggatctgatgtgggagaactacccgtacccggtgaaattgtctcgtttgatcgagggcaacaacgccgggatgatcatgaacggcacgccggctaccgccatcacgccgccgcagccggaattgcgcgccggctggtataacaaaaccggctctaccggcggtttctccacctacgcggtgtttatcccggcgaagaatatcgccgtggtgatgctggccaacaaatggttcccgaacgacgatcgggtcgaggcggcttaccgcatcgtgcaagcgttggataagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_6565,Drugs,MEG_6565|Drugs|betalactams|Class_C_betalactamases|SRT,1028110380|WP_063864750.1|NG_050144|1|1|blaSST-1|blaSRT|cephalosporin-hydrolyzing_class_C_beta-lactamase_SST-1 NG_050144:101-1237,0
,ATGGAAAATCGACAAGAAGTACAAGAATTAACTTTAGAAGAAGTGATGGGTGACCGCTTCGGACGTTATTCCAAATATATTATCCAAGAACGTGCACTGCCTGATATCCGTGATGGATTGAAGCCAGTGCAACGCCGGATATTATTTGCCATGAACAAAGATGGCAATACGTATGACAAAGGATTCCGTAAATCAGCAAAATCTGTCGGAAATATCATGGGGAATTATCATCCTCATGGTGACAGCAGTATTTATGAAGCGATGGTCCGCATGAGCCAAGACTGGAAGTTGCGGGAAGTACTGATCGAAATGCACGGGAATAACGGGAGTATGGACGGTGATCCACCTGCTGCGATGCGTTATACTGAAGCCAGATTATCCAAGTTAAGTGGAGAGATGCTAGCAGATATCGAGAAAGAAACAGTCGATCTCGTGTGGAATTTTGATGATACAGAAAAAGAACCAACAGTCCTTCCAGCTCGATACCCAAACCTTCTCGTCAATGGATCGACAGGTATATCTGCTGGATATGCAACAGAAATCCCGACTCATAACTTAGCTGAAGTGATCGATGGCACAATCTATATGATCGATCATCCACAAGCGAGCCTTGAAAAATTGATGGAATATATTCCTGGACCTGACTTTCCAACAGGAGGGATCTTGCAAGGAAAAGATGAAATCAAAAAAGCTTATGAAACAGGACGAGGAAAAGTTATTCTTCGTTCGAAAACAAAGATAGAGGCAATGAAGGGTAATAAACAGCAAATCGTGATCACAGAAATCCCATATGAAGTAAATAAAGCGACCTTGGTGAAAAAAATGGATGAGATCCGTTTGAATAAGAAAATCGATGGAATAGCTGAAGTACGAGATGAAAGTGATAGAACAGGTCTGCAAATTGTCGTCGAATTGAAAAAAGACGCCAATGCTCAAGGAATTTTGAATTATTTGTTCAAAAACACTGAGCTACAGATCAATTACAATTTCAATATGGTCGCTATCGACCATATGACTCCGCATCAAGTTGGACTGAAAGACATTTTAAGAAGTTATATCGAGCATCGAAAGCAAGTCATAACAAAACGTAGTCAATTCGATTTAGCCAAAGCTCAAAAAAGACAGCATATCGTAGAAGGATTGATGAAAGCTTTATCGATTCTGGATGAAGTAATCGCAACGATTCGTGAAAGTAAAGACAAAAAAGACGCCAAAAAGAATTTAGTCGACGTCTTTCAATTTACAGAAGAACAAGCAGAAGCAATTGTCACATTGCAATTATACCGTTTGACGAACACGGATATCACAGAGCTTCAAAAGGAATCCGAAAGCTTGATTGCGCAAATCACAGAGTTGAATAAAATCCTTTCAAATGACAAAGAGCTTTTCTCTGTTATGAAAAAAGAATTGCGAGAAGTGAAAAAAAATTATTCTTCCGCTCGTCTAACGACAATCGAAGACGAAATCGAAGAAATCAAAATTGATACGCAAGTCTTAGTGGCACAAGAAGACGTAATTGTCAGTGTGACGCGAGAAGGCTATGTGAAGCGAACAAGCCTTCGTTCTTATAGTGCTTCCAAACCAGAAGAAATCGGGATGCGAGAAGGCGACTACTTGCTATACTCAGGTGAATTGAGTACATTGGACCATGTTCTTCTGATCACAAATAAAGCAAATGTGATCTACCGCCCTGTCCATGAACTACCCGATTTGAAATGGAAAGATGCTGGTGAGCACATTTCTCAAACAATCTCCAATCTGTCTGTAGACGAATCGATTTTAGCTGTTTTCCCATATCAAAAAATTCAAGCAGAGAAAACATTTGTATTCATCAGCAAGAATGGATTGATCAAGCAAACACGAATGACAGAGTTCGAACCATGGCGCACCTATAAGAGCCGTCCGCTCAGCTGTATGAAGCTAAAGGCGGAAGAAGATGAACTGATTGCTGTGTATCTGAAAGAAGATCAGCCAGGCTTAGATGTTTTCTTAGTAACGCATCAAGGAATGGGTTTGCGCTATCCTTTAACAGATGTTCCCGTTGTTGGAGCAAAGGCAGCTGGAGTGAAGTCTATGAATTTGAAAGATGGAGATAGGATTATCAACGGGCTGCTTGTGTTAGCAGAAGGTGATACGCCGATCGTAATCGTTACTCAGCGAGGAGCTGTTAAACGCATGCTTGCTCAAGAAATCAGCCAAACTTCACGTGCGAAGCGGGGAGTGACGGTCATGCGTGAGCTGAAAAAAAATCCGCACCGTATTATCTATATGTCGGAAGGAAGATCAAAAGAAATAACCTTGATGAATCAAAAAGGGCAGCAGTTAACGATTGACCCAACTGATTTCCCTATAGGTGATCGAACATCGAATGGATCATTTGCGATGGATGAGAAAAAAGGTGGAGAAGTCATCGAAGTTATCGATGCTCCTGAGATTTTCATCGAGTCGTAA,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5343,Drugs,MEG_5343|Drugs|Fluoroquinolones|Fluoroquinolone-resistant_DNA_topoisomerases|PARC,gi|388532432|gb|CP003583.1|1132335-1134785 gi|378937014|gb|CP003351.1|1199896-1197446,3
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGGTGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAACCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGAGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTCTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCCTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCCCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGGGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTAAAAGAAACCGCAAGAATTCGTTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6631,Drugs,MEG_6631|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|45332239|gb|AY524415.2|4116-4931,8
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctagccggctatgccctggcccaggacaagatgcgcctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaactgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctatggcaaggacgaccgccccctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctggacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggttccaccagcggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggactggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5462,Drugs,MEG_5462|Drugs|betalactams|Class_C_betalactamases|PDC,1034011089|WP_064484001.1|NG_050792|1|1|blaPDC-136|blaPDC|class_C_beta-lactamase_PDC-136 NG_050792:1-1194,0
,atgaaaaaaataactttatttttacttttcttaaatttagtgtttgggcaagataagatattaaataattggtttaaagagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgacttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctctaattgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggtgaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatattctaatgttcttgcttttaaagaagtggtaagaagaattggtatcaaaactatgcaagaatatttagacaagcttcattatggtaatgctaaaatttccaagatcgatactttttggcttgacaactcactaaaaataagcgctaaagaacaagcaattttgctttttagactttcacaaaatagcttacctttttctcaagaagcaatgaatagtgttaaggaaatgatttatttaaaaaatatggaaaatttagagctttttggaaaaacaggttttaatgatgagcaaaaaattgcttggattgtaggttttgtgtatttaaaagatgaaaataaatataaggctttcgcgctaaatttagatattgataaatttgaagatttatataaaagagaaaaaattttagaaaaatatttagatgaacttgtaaaaaaagttaaaaatgatggctag,beta-lactamase,antibiotic inactivation,betalactams,MEG_4657,Drugs,MEG_4657|Drugs|betalactams|Class_D_betalactamases|OXA,1391852912|WP_109545097.1|NG_057531|1|1|blaOXA-593|blaOXA-61_like|OXA-61_family_class_D_beta-lactamase_OXA-593 NG_057531:1-774,0
,ATGTTACGCAGCAGGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTCGATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGAGTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTATCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATGCACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGCGTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCTGAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGCACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGGGTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATGGGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAGCTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGCGCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCACGCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCAATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTAGATCATGCCTAG,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6612,Drugs,MEG_6612|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULI,gi|930190865|emb|LN555650.1|96536-95685 gi|930190865|emb|LN555650.1|259231-258394 gi|930189590|emb|HG530658.1|96281-95430 gi|930189590|emb|HG530658.1|194939-194102 gi|761589803|dbj|AP014651.1|316957-316106 gi|761589803|dbj|AP014651.1|5302118-5302969 gi|761589803|dbj|AP014651.1|324887-324361 gi|761589803|dbj|AP014651.1|5294188-5294714 gi|752502612|dbj|AP014611.1|152913-153764 gi|752502612|dbj|AP014611.1|147008-147845 gi|723243434|gb|CP009868.1|114218-113367 gi|674643852|emb|LM997414.1|1025-1876 gi|672940377|gb|AY963803.6|31568-32419 gi|672940377|gb|AY963803.6|23638-24164 gi|666688170|gb|KJ463833.1|32778-33629 gi|666688170|gb|KJ463833.1|24848-25374 gi|662716651|gb|CP008824.1|213061-213912 gi|662716651|gb|CP008824.1|271309-272146 gi|662716651|gb|CP008824.1|275283-276120 gi|640855459|gb|CP007732.1|165393-166244 gi|640855459|gb|CP007732.1|223641-224478,8
,atgagggaagcggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagctttgttcaacgaccttttggaaacgtcggcttccgctgaagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgtccactacgtgaaaggcgagatcaccaaggtagtcggcaaataa,aminoglycoside modifying enzyme,antibiotic inactivation,Aminoglycosides,MEG_894,Drugs,MEG_894|Drugs|Aminoglycosides|Aminoglycoside_O-nucleotidyltransferases|ANT3-DPRIME,1693892901|WP_140423278.1|NG_065405|1|1|aadA1|aadA1|ANT(3'')-Ia_family_aminoglycoside_nucleotidyltransferase_AadA1 NG_065405:101-892,2
,ATGTTTGCTAAAAATTCAAAGGCATATTCTGTCTACCTGCTGTTCCGATTTGTCTGTTCCCTGGCGGTTTCTATGTCCACAGTGCTTTCCATCGTGTACCACCTGGAGGTGGTGCAGCTGGATGCTTTCCAGCTTGTCCTGGTAGGGACGGTTCAGGAGACCTCCTGCTTTCTGTTCGAGATGCCCACCGGTGTGGTGGCGGATTTGTATAGCCGTCGGCGCTCGGTGCTGATTGGAATGTTCCTCTACGGCCTGGGCTTTCTGATGGAGGGTGCGCTACCGTGGTTCGCGCCGGTTCTGCTGGCCCAGGTTGTCTGGGGTTGCGGTGATACCTTCATCACCGGCGCTCTGGAGGCGTGGATTGCCTCGGAGGAAGAGGACAAACCCATAGACAAGGTGTTCCTGCGGGGCAGTCAAATGGGGCAAATCGGCGGCGTTCTGGGCGTGGTGCTGGGCACACTGCTGGGAAACATAAACCTGCAAATGCCTCTCATCTTGGGGGGCAGTTTGTGCTTGTTGTTGGGGCTGGTGATGGTTCGCATCATGCCAGAAACCAACTTCTCCCCTGCTATTGAGGAACGGCAGGGCTTGCTTAAAGACTTTGTCTGCCTGTTCAAGCTCAACCTGGGCTTTGTGAAAGGCGCACCTGTGTTGCTGGCGCTCTTAGCAATCACACTATGCGGGGGACTTGCCAGTGAAGGCTTTGACCGGCTCTCCACCGCTCATTTTCTGGATGACACGGTAATACCCGTTATCGGGCCGCTGAACAGCGTCACTTGGTTCGGTGTTATCAGTCTTATCGGCAACGGCTTAGGTATTCTGGCTTCTCAGTTGCTCATCGCCCGCATGGAGAAAAAAGGGACTGTCAGCCGAACCAGTGTGGTCATGTCCACCAGCGCCGGGTATATCCTGTTCCTGGTTCTCTTCGCGGTGGGGCGGAGCTTTTGGTTCATGTTGTTGGTGTTCCTGCTGGCGGGGCTTATGCGCACCATCAAGGAGCCTGTGCTGGCCGCCTGGATGAACGACCATGTGGATGAGAAAATGCGCGCCACAGTCTTTTCCACCAGCGGACAGCTGGACTCTTTCGGGCAGATCATCGGCGGGCCTATTGTGGGGCTGGTAGCCCAGCAGGTGTCCATACCCTGGGGGCTGGTCTGTACCGCTTTCCTGCTGTTGCCCGCGCTGTTCTTAGTGCCGGTGGCGGGAAAGAAGCGGGATTGA,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic target protection,Tetracyclines,MEG_6993,Drugs,MEG_6993|Drugs|Tetracyclines|Tetracycline_resistance_ribosomal_protection_proteins|TET40,gi|295089810|emb|FP929037.1|530945-529725 gi|162417574|emb|AJ295238.3|2134-3354 gi|379125718|gb|JQ280445.2|3221-3296,4
,atgaaaaaacggattaccccattttcccgatttgcatcaaaaggcctttccgcctgtagcgcaggcatgttgctggtgacggtggcacatgccgccaatacggcagcagcgccagccggcatggatgccatggtccaaaccgtgatgcaggcacaccagattccgggcatggccattgccatcatccagcctggcaagaccacttatcacaattatggtgtcgcctcccgcgaaaccggccagccggtccgggaaaccaccctgtttgaaatcggctccctttccaaaccgtttactgcactggtcgcccagcgggctgaaaccgaaggccggattgacctgtctgcaccggccagccgctacgttaccgccctgcggggcagtgcattcgaccggatcaccctcaggcagctcggtacttatagcgcaggcggattaccgctccagtttcctgacaatgtcaccaccccggcagatgtgctggcttattaccggcattggcaacctgtccatccggcaggcaccacccggctgtattccaatccgagcattggcctgatggggctggctgccagcctggcaaccggagagtcctttgccggcctgctcgggacaacggtgctgcaacccctcggcatgaactcgacctatctgcaagtgcccccggaggcccgttcacgttatgccatgggttataccgccgccgggaaaccggtcagggtcaaccccggtccgctggatgaggaaacctacggcgtcaagtccacaaccgcagacatggtcggatttttattggcgcatatggaccctgcacgcagcaaaggtgcattgcggtcggcattacagcaaacacgtgtaccggtttattgcgccggacagacccggcaaggactgggctgggaaagttatcaagactggaaaaacctcgacatgctgctggcgggaaattcaaatcaaatggtgtttgaaccgcagctggtaaaagcctgtcctgccggcaccatgaatgagcccaatgtgtgggtcaacaagaccggttctactgcgggattcggcgcttatgccgtattcctgcctgcccgacaaaccggcattgtcatcctggccaaccgtaattacccgattgcagaccgtatccggctcgctcacggaattttgaccgcattgcactga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3582,Drugs,MEG_3582|Drugs|betalactams|Class_A_betalactamases|LHK,1349894765|WP_104531868.1|NG_056486|1|1|blaLHK-5|blaLHK|class_C_beta-lactamase_LHK-5 NG_056486:1-1173,0
,TTACTTATTAAATAATTTATAGCTATTGAAAAGAGATAAGAATTGTTCAAAGCTAATATTGTTTAAATCGTCAATTCCTGCATGTTTTAAGGAATTGTTAAATTGATTTTTTGTAAATATTTTCTTGTATTCTTTGTTAACCCATTTCATAACGAAATAATTATACTTTTGTTTATCTTTGTGTGATATTCTTGATTTTTTTCTACTTAATCTGATAAGTGAGCTATTCACTTTAGGTTTAGGATGAAAATATTCTCTTGGAACCATACTTAATATAGAAATATCAACTTCTGCCATTAAAAGTAATGCCAATGAGCGTTTTGTATTTAATAATCTTTTAGCAAACCCGTATTCCACGATTAAATAAATCTCATTAGCTATACTATCAAAAACAATTTTGCGTATTATATCCGTACTTATGTTATAAGGTATATTACCATATATTTTATAGGATTGGTTTTTAGGAAATTTAAACTGCAATATATCCTTGTTTAAAACTTGGAAATTATCGTGATCAACAAGTTTATTTTCTGTAGTTTTGCATAATTTATGGTCTATTTCAATGGCAGTTACGAAATTACACCTCTTTACTAATTCAAGGGTAAAATGGCCTTTTCCTGAGCCGATTTCAAAGATATTATCATGTTCATTTAATCTTATATTTGTCATTATTTTATCTATATTATGTTTTGAAGTAATAAAGTTTTGACTGTGTTTTATATTTTTCTCGTTCAT,rRNA methyltransferase conferring antibiotic resistance,antibiotic target alteration,MLS,MEG_2821,Drugs,MEG_2821|Drugs|MLS|23S_rRNA_methyltransferases|ERMC,gi|909776345|gb|KP065813.1|3571-2837 gi|749502733|gb|KP255997.1|4304-3570 gi|749502730|gb|KP255996.1|3737-4471 gi|671774829|gb|KM017875.1|1306-572 gi|658131576|emb|HG380318.1|812-78 gi|378968505|gb|AY661563.2|5538-4804 gi|378968504|gb|AF424805.2|3478-4212 gi|375314803|gb|JN798465.1|7712-6978 gi|375331809|dbj|AB517728.1|3562-2828 gi|353127761|gb|JF968527.1|1298-564,7
,ATGAATAAATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGATGGAGGCCGGTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGATGGCCGAGGGGGCAGATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGACGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGGACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCGACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGGTTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCGTCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCTGGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCTGACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGTTTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGATGAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATCCTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACACTCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACACGAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAACCGCAAGAATTCGTTATCAGAAAACTGAAGGAACCTCCATTGAATCGAACTAA,antibiotic molecule,antibiotic target replacement,Sulfonamides,MEG_6627,Drugs,MEG_6627|Drugs|Sulfonamides|Sulfonamide-resistant_dihydropteroate_synthases|SULII,gi|224184694|gb|FJ197818.1|1663-2514 gi|189916535|gb|CP001093.1|1783-2634 gi|150499|gb|M83717.1|PASAMR|127-978 gi|975007785|gb|CP010832.1|4504-3690 gi|975007785|gb|CP010832.1|3652-3615 gi|954666075|gb|KT962845.1|19587-18773 gi|954666075|gb|KT962845.1|18735-18698 gi|971494279|gb|CP010355.1|2154-2968 gi|971339514|gb|CP006662.2|54921-54107 gi|971339514|gb|CP006662.2|54069-54032 gi|943457735|gb|KT818627.1|110623-109809 gi|943457735|gb|KT818627.1|109771-109734 gi|969995276|gb|KT317085.1|2977-2163,8
,atgatgaaaaaaacactctgctgcgcgctggttctgagcgcctctttctccgcctttgctgcacaaaaaacattgagtgacaaacagttagaagaggctgtcaatcaaacgcttaaaccgatgattacagcccaggccattcccggcatggcggtggcggtgatttatcagggcaagccgcactactttacctacggcgtggccgacatcgcgaaaaatcagccggtgacgacacagacgatttttgagctgggctccgtgagtaaaactttcaccggcgtgctgggcggcgatatcgtggcgcgcggggaagtgaagctgagtgacccggcgatgaaatactggccagaactgacgggcaagcagtggcagggcatcacgttgctggatctggcgacctacaccgccggcggcttgccgttgcaggtgccggatgaggtcgataatcaggccgcgctgctgaagttttaccagaactggcagccggactgggcgccgggaacccgtcgtcagtacgccaactcgagcattggcctgtttggtgcgttggcagtgaaaccgtccgggatgacgtttaacgatgcgatgcgccagcgcgttctgcaaccgctgaacctgaaacatacctggctcaccgttccggccagtgaagaaaatcattacgcctggggctatcgtgacggcaaagccatgcacgtcgggccgggcatgctggataccgaagcctacggtgtcaaatccaccatcgaagatatggcgagctgggtgcaatacaacatgaacccgcagcaggtgaaacagccgacgctgcaaaaagggctggagattgcgcagtcgcgctactggcgcagcggcagtatgtatcagggcttaggctgggaaatgctgaactggccggttgcggcggcgaccgtcattaacggcagcgataacaaagtggcgctggcggcttcgcccgtgacggccattgaaccgccggttgcgccggtgaaagcttctctggtgcataaaaccgggtcgaccaacggcttcggcgcgtacgtggcgttcattcctgaaaaacaaatcggcatcgtgatgctggctaacaaaatgtatccgaataccgagcgggttaaagcggcaaatactcttctcaacacgctgcaataa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1481,Drugs,MEG_1481|Drugs|betalactams|Class_C_betalactamases|BUT,1349894761|WP_104531864.1|NG_056481|1|1|blaBUT-2|blaBUT|class_C_beta-lactamase_BUT-2 NG_056481:101-1252,0
,TAAAATTTTAATGGAATTTATTTCTATGAGTTATCTATTTTTGTCGTGTACAGAGCTCTTTTTTATTTTCTATTGATCTGGTGTTTAAAATGAATAAATATTTTACTTGCTATGTGGTTGCTTCTCTTTTTCTTTCTGGTTGTACGGTTCAGCATAATTTAATAAATGAAACCCCGAGTCAGATTGTTCAAGGACATAATCAGGTGATTCATCAATACTTTGATGAAAAAAACACCTCAGGTGTGCTGGTTATTCAAACAGATAAAAAAATTAATCTATATGGTAATGCTCTAAGCCGCGCAAATACAGAATATGTGCCAGCCTCTACATTTAAAATGTTGAATGCCCTGATCGGATTGGAGAACCAGAAAACGGATATTAATGAAATATTTAAATGGAAGGGCGAGAAAAGGTCATTTACCGCTTGGGAAAAAGACATGACACTAGGAGAAGCCATGAAGCTTTCTGCAGTCCCAGTCTATCAGGAACTTGCGCGACGTATCGGTCTTGATCTCATGCAAAAAGAAGTAAAACGTATTGGTTTCGGTAATGCTGAAATTGGACAGCAGGTTGATAATTTCTGGTTGGTAGGACCATTAAAGGTTACGCCTATTCAAGAGGTAGAGTTTGTTTCCCAATTAGCACATACACAGCTTCCATTTAGTGAAAAAGTGCAGGCTAATGTAAAAAATATGCTTCTTTTAGAAGAGAGTAATGGCTACAAAATTTTTGGAAAGACTGGTTGGGCAATGGATATAAAACCACAAGTGGGCTGGTTGACCGGCTGGGTTGAGCAGCCAGATGGAAAAATTGTCGCTTTTGCATTAAATATGGAAATGCGGTCAGAAATGCCGGCATCTATACGTAATGAATTATTGATGAATTCATTAAAACAG,beta-lactamase,antibiotic inactivation,betalactams,MEG_5251,Drugs,MEG_5251|Drugs|betalactams|Class_D_betalactamases|OXA,gi|817490718|gb|KP264123.1|1-896,0
,atgcgttatattcgcctgtgtattatctccctgttagccaccctgccgctggcggtacacgccagcccgcagccgcttgagcaaattaaactaagcgaaagccagctgtcgggcagcgtaggcatgatagaaatggatctggccagcggccgcacgctgaccgcctggcgcgccgatgaacgctttcccatgatgagcacctttaaagtagtgctctgcggcgcagtgctggcgcgggtggatgccggtgacgaacagctggagcgaaagatccactatcgccagcaggatctggtggactactcgccggtcagcgaaaaacaccttgccgacggcatgacggtcggcgaactctgcgccgccgccattaccatgagcgataacagcgccgccaatctgctgctggccaccgtcggcggccccgcaggattgactgcctttttgcgccagatcggcgacaacgtcacccgccttgaccgctgggaaacggaactgaatgaggcgcttcccggcgacgcccgcgacaccactaccccggccagcatggccgcgaccctgcgcaagctgctgaccagccagcgtctgagcgcccgttcgcaacggcagctgctgcagtggatggtggacgatcgggtcgccggaccgttgatccgctccgtgctgccggcgggctggtttatcgccgataagaccggagctagcaaacggggtgcgcgcgggattgtcgccctgcttggcccgaataacaaagcagagcggattgtggtgatttatctgcgggatacgccggcgagcatggccgagcgaaatcagcaaatcgccgggatcggcgcggcgctgatcgagcactggcaacgctaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_6196,Drugs,MEG_6196|Drugs|betalactams|Class_A_betalactamases|SHV,1028110270|WP_063864640.1|NG_050029|1|1|blaSHV-154|blaSHV|class_A_beta-lactamase_SHV-154 NG_050029:1-861,0
,ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTAAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGACGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCAGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6948,Drugs,MEG_6948|Drugs|betalactams|Class_A_betalactamases|TEM,gi|909636667|emb|LN850164.1|64082-63222 gi|667695876|gb|CP008734.1|10552-11412 gi|665823426|gb|KJ484639.1|63013-62153 gi|695224107|ref|NG_041019.1|877-1737 gi|695212177|ref|NG_036345.1|3944-4804 gi|58615621|gb|AY883411.1|167-1027,0
,atgcaacaacgacgtgcgttcgcgctactgacgctgggtagcctgctgctagccccttgtacttatgccggcggggaggctccgctgaccgccgctgtggacggcattatccagccgatgctcaaggagtatcggatcccggggatggcggtcgccgtgctgaaagatggcaaggcccactatttcaactatggggttgccaaccgcgagagcggccagcgggtcaatgagcagaccctgttcgagattggctcggtcagcaagaccctgacagcgaccctcggagcctatgccgcggtcaaggggggctttgagctggatgacaaggtgagccagcacggcccttggctcaaaggttccgccttggatggtgtgaccatggccgagcttgccacctacagtgcgggtggtttgccgctgcagttccccgatgaggtagattcgaatgacaagatgcgcacttactatcagagctggtcaccggtttatccggcagggacccatcgccagtattccaaccccagcataggcctgtttggtcacctggccgcaaatagtctgggccagccatttgagcaactgatgagccagaccctgctgcccaagctgggtttgcaccacacctatatccaggtgccggagtcggccatggtgaactatgcctacggctattcgaaggaagataagcccgtccgggtcactccgggtgtgctggcggccgaggcttacgggatcaagaccggctcggcggatctgctgaagtttgtcgaggccaacatggggtatcagggagatgccgcggtaaaaagcgcaatcgcgctgacccacaccggtttctactcggtgggagaaatgacccagggattaggatgggagagttatgcctatccggtgaccgagcagacattgctggcgggcaattcaccagcggtgagcttccaggccaatccggttacgcgctttgcggtgcccaaagcgatgggcgagcagcggctctataacaagacgggctcgactggcggctttggcgcctatgtggcgttcgtgcccgccagagggatagccatcgtcatgctggccaatcgcaactatcccatcgaggccagggtgaaggcggctcacgccatcctgagtcagttggccgagtga,beta-lactamase,antibiotic inactivation,betalactams,MEG_3032,Drugs,MEG_3032|Drugs|betalactams|Class_C_betalactamases|FOX,1035157527|WP_064511492.1|NG_050814|1|1|blaFOX-14|blaFOX|cephalosporin-hydrolyzing_class_C_beta-lactamase_FOX-14 NG_050814:1-1149,0
,ttgaaaaaaatacttttactttttagtcttttttactcttttgctttggcaaatgataaattaaaagatttttttaaagactacaatacaagcggagtttttataacttttgatggaaaacattatgcaagtaatgattttaaaagagctaaagaacctttttctcctgcttcgacttttaaaatttttaatgctttaattgcgcttgataacggtgtagttaaagatacaaaggaaattttttatcattataagggtgaaaaagtatttttgccttcttggaaacaagatgctagtttaagctcagccataaaacgctctcaagtgcctgcttttaaagaattggcaagaaaaataggacttaaaaccatgcaagaaagcttaaataaactttcctatggaaatgcgaaaatttcaaaaatcgataccttttggttggataattctttacaaatttctgcaaaaaatcaagctgatttgctttttaaactttcacaaaattctttacctttttccaagaaaagtcaagaagaagttaaaaaaattattctttttaaagaagataaaatccaaaaaatttatgctaaaacaggttttaatgatggtataaatttggcttggattgtcggatttatagagagtaaaaacaaaattttatcttttgccttaaatgttgatataaagaatattaaaaatcttaaaataagagaagaattgctagaaaaatatatttattctttaaactaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_4638,Drugs,MEG_4638|Drugs|betalactams|Class_D_betalactamases|OXA,919259413|WP_052794776.1|NG_057505|1|1|blaOXA-625|blaOXA-184_like|OXA-184_family_class_D_beta-lactamase_OXA-625 NG_057505:1-747,0
,atggaaaaaaacagaaaaaaacaaatcgtagttttgagtatagctttagtttgcattttcatcttggtattttcattgttccataaatcagcgacaaaagatagcgcaaatcctcctttaacaaatgttttgactgatagcatttctcaaattgtctcagcttgtcctggcgaaattggtgtggcggttattgttaataacagagatacggttaaggtcaataataagagtgtttatcctatgatgagtgtgtttaaggttcatcaggcattagctctttgtaatgactttgacaataaaggaatttcacttgataccttagtaaatataaatagggataaacttgacccaaagacttggagtcctatgctgaaagattattcagggccagtcatatcattgacagtgagagatttgctgcgttatactcttactcagagtgacaacaatgcaagcaaccttatgtttaaggatatggttaatgtcgctcaaacagatagttttatagccacactcattcctcgttcaagttttcagatagcttatacgaaagaggaaatgtcggctgaccataacaaggcttactctaactatacatctcctcttggtgctgcaatgttgatgaatcgttggtttactgaaggtcttatcgatgatgagaaacaaagtttcattaagaatacgttaaaagaatgcaaaacaggtgtagataggatagcagctccacttcttgataaagaaggggtggttatagcgcataagacaggttcaggttatgttaatgaaaatggtgttcttgcagctcacaatgatgttgcctatatatgtctgcctaataatatcagttataccttagcggtatttgttaaggatttcaagggaaatgaatcacaagcgtcacaatatgttgcgcatatatcagctgtagtatattctttattaatgcaaacttcagtaaaatcttaa,beta-lactamase,antibiotic inactivation,betalactams,MEG_1688,Drugs,MEG_1688|Drugs|betalactams|Class_A_betalactamases|CFX,1028084270|WP_063843238.1|NG_047635|1|1|cfxA_gen|cfxA_gen|CfxA_family_class_A_broad-spectrum_beta-lactamase NG_047635:1-966,0
,ATGGTGACAAAGAGAGTGCAACGGATGATGTTCGCGGCGGCGGCGTGCATTCCGCTGCTGCTGGGCAGCGCGCCGCTTTATGCGCAGACGAGTGCGGTGCAGCAAAAGCTGGCGGCGCTGGAGAAAAGCAGCGGAGGGCGGCTGGGCGTCGCGCTCATCGATACCGCAGATAATACGCAGGTGCTTTATCGCGGTGATGAACGCTTTCCAATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCGGTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGCTTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGTTAACTACAATCCGATTGCCGAAAAACACGTCAACGGCACAATGACGCTGGCAGAGCTGAGCGCGGCCGCGTTGCAGTACAGCGACAATACCGCCATGAACAAATTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACGGCTTTTGCCCGCGCGATCGGCGATGAGACGTTTCGTCTGGATCGCACTGAACCTACGCTGAATACCGCCATTCCCGGCGACCCGAGAGACACCACCACGCCGCGGGCGATGGCACAGACGTTGCGTCAGCTTACGCTGGGTCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTGGTGACGTGGCTCAAAGGCAATACGACCGGCGCAGCCAGCATTCGGGCCGGCTTACCGACGTCGTGGACTGTAGGTGATAAGACCGGCAGCGGCGACTACGGCACCACCAATGATATTGCGGTGATCTGGCCGCAGGGTCGTGCGCCGCTGGTTCTGGTGACCTATTTTACCCAGCCGCAACAGAACGCAGAGAGCCGCCGCGATGTGCTGGCTTCAGCGGCGAGAATCATCGCCGAAGGGCTGTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_2436,Drugs,MEG_2436|Drugs|betalactams|Class_A_betalactamases|CTX,blaCTX-M-14b_1_DQ359215 ,0
,atgaaatctaacaatgcgctcatcgtcatcctcggcaccgtcaccctggatgctgtaggcataggcttggttatgccggtactgccgggcctcttgcgggatatcgtccattccgacagcatcgccagtcactatggcgtgctgctagcgctatatgcgttgatgcaatttctatgcgcacccgttctcggagcactgtccgaccgctttggccgccgcccagtcctgctcgcttcgctacttggagccactatcgactacgcgatcatggcgaccacacccgtcctgtggatcctctacgccggacgcatcgtggccggcatcaccggcgccacaggtgcggttgctggcgcctatatcgccgacatcaccgatggggaagatcgggctcgccacttcgggctcatgagcgcttgtttcggcgtgggtatggtggcaggccccgtggccgggggactgttgggcgccatctccttgcatgcaccattccttgcggcggcggtgctcaacggcctcaacctactactgggctgcttcctaatgcaggagtcgcataagggagagcgtcgaccgatgcccttgagagccttcaacccagtcagctccttccggtgggcgcggggcatgactatcgtcgccgcacttatgactgtcttctttatcatgcaactcgtaggacaggtgccggcagcgctctgggtcattttcggcgaggaccgctttcgctggagcgcgacgatgatcggcctgtcgcttgcggtattcggaatcttgcacgccctcgctcaagccttcgtcactggtcccgccaccaaacgtttcggcgagaagcaggccattatcgccggcatggcggccgacgcgctgggctacgtctgtctggcgttcgcgacgcgaggctggatggccttccccattatgattcttctcgcttccggcggcatcgggatgcccgcgttgcaggccatgctgtccaggcaggtagatgacgaccatcagggacagcttcaaggatcgctcgcggctcttaccagcctaacttcgatcattggaccgctgatcttcacggcgatttatgccgcctcggcgagcacatggaacgggttggcatggattgtaggcgccgccctataccttgtctgcctccccgcgttgcgtcgcggtgcatggagccgggccacctcgacctga,major facilitator superfamily (MFS) antibiotic efflux pump,antibiotic efflux,Tetracyclines,MEG_7058,Drugs,MEG_7058|Drugs|Tetracyclines|Tetracycline_resistance_MFS_efflux_pumps|TETC,1028099800|WP_063856072.1|NG_048180|1|1|tet(C)|tet(C)|tetracycline_efflux_MFS_transporter_Tet(C) NG_048180:58-1248,4
,ATGAAGGATACCTTGATGAAAAAAATTTTGCTGCTGCATATGTTGGTGTTCGTTTCCGCCACTCTCCCAATCAGTTCCGTGGCTTCTGATGAGGTTGAAACGCTTAAATGCACCATCATCGCAGACGCCATTACCGGAAATACCTTATATGAGACCGGAGAATGTGCCCGTCGTGTGTCTCCGTGCTCGTCTTTTAAACTTCCATTGGCAATCATGGGGTTTGATAGTGGAATCTTGCAGTCGCCAAAATCACCTACGTGGGAATTGAAGCCGGAATACAACCCGTCTCCGAGAGATCGCACATACAAACAAGTCTATCCGGCGCTATGGCAAAGCGACTCTGTTGTCTGGTTCTCGCAGCAATTAACAAGCCGTCTGGGAGTTGATCGGTTCACGGAATACGTAAAGAAATTTGAGTACGGTAATCAAGATGTTTCCGGTGACTCGGGGAAGCATAACGGCTTGACCCAGTCATGGCTGATGTCGTCGCTCACCATATCTCCCAAGGAGCAAATTCAGTTTCTTCTACGCTTTGTCGCGCATAAGCTGCCTGTATCCGAAGCGGCTTATGACATGGCGTATGCCACAATCCCGCAGTACCAGGCAGCCGAAGGATGGGCTGTACATGGAAAAAGCGGCAGCGGCTGGCTTCGGGACAATAACGGCAAGATAAATGAAAGTCGTCCGCAGGGCTGGTTCGTGGGCTGGGCTGAAAAAAACGGACGGCAAGTTGTTTTCGCCCGATTGGAAATAGGAAAGGAAAAGTCCGATATTCCCGGCGGGTCTAAAGCACGAGAGGATATTCTCGTGGAATTACCCGTGTTGATGGGTAACAAATGA,beta-lactamase,antibiotic inactivation,betalactams,MEG_4757,Drugs,MEG_4757|Drugs|betalactams|Class_D_betalactamases|OXA,(Bla)OXA-9:NC_015515:451-1290:840,0
,atgttaaaagttattagtagtttattggtctacatgaccgcgtctgtcatggctgtcgcaagtccgttagcccattccggggagccgagtggtgagtatccgacagtcaacgaaattccggtcggagaggtccgactttaccagattgccgatggtgtttggtcgcatatcgcaacgcagtcgtttgatggcgcggtctacccgtccaatggtctcattgtccgtgatggtgatgagttgcttttgattgatacagcgtggggtgcgaaaaacacagcggcacttctcgcggagattgaaaagcaaattggacttcccgtaacgcgtgcagtctccacgcactttcatgacgaccgcgtcggcggcgttgatgtccttcgggcggctggggtggcaacgtacgcatcaccgtcgacacgccggctagtcgaggcagaggggaacgagattcccacgcattctctagaaggactctcatcgagcggggacgcagtgcgcttcggtccagtagagctcttctatcctggtgctgcgcattcgaccgacaatctggttgtatacgtcccgtcagcgaacgtgctatacggtggttgtgccgttcatgagttgtcacgcacgtctgcggggaacgtggccgatgccgatctggctgaatggcccacctccgttgagcggattcaaaaacactacccggaagcagaggtcgtcattcccgggcacggtctaccgggcggtctagacttgctccagcacacagcgaacgttgtcaaagcacacaaaaatcgctcagtcgccgagtag,beta-lactamase,antibiotic inactivation,betalactams,MEG_7703,Drugs,MEG_7703|Drugs|betalactams|Class_B_betalactamases|VIM,1028110978|WP_063865190.1|NG_050368|1|1|blaVIM-40|blaVIM|subclass_B1_metallo-beta-lactamase_VIM-40 NG_050368:1-801,0
,ATGGCACTGGCACTCGTTGGCGAAAAAATTGACAGAAACCGCTTCACCGGTGAGAAAATTGAAAATAGTACATTTTTTAACTGTGATTTTTCAGGTGCCGACCTGAGCGGCACTGAATTTATCGGCTGTCAGTTCTATGATCGTGAAAGCCAGAAAGGGTGCAATTTTAGTCGTGCGATGCTGAAAGATGCCATTTTTAAAAGCTGTGATTTATCCATGGTGGATTTTCGCAATGCCAGTGCGCTTGGCATTGAAATTCGCCACTGTCGTGCGCAAGGCGCAGATTTCCGCGGCGCAAGCTTTATGAATATGATCACTACTCGCACCTGGTTTTGCAGCGCATATATCACTAACACAAATCTAAGCTACGCCAATTTTTCGAAAGTCGTGCTGGAAAAATGTGAGCTGTGGGAAAACCGTTGGATGGGTGCCCAGGTACTGGGCGCGACGTTCAGTGGTTCAGATCTTTCCGGCGGCGAGTTTTCGACTTTCGACTGGCGAGCAGCAAACTTCACACATTGCGATCTGACCAATTCGGAGTTGGGTGACTTAGATATTCGGGGCGTTGATTTACAAGGCGTTAAGTTGGACAACTACCAGGCATCGTTGCTCATGGAACGTCTTGGCATCGCGGTGATTGGCTAG,fluoroquinolone resistant DNA topoisomerase,antibiotic target alteration,Fluoroquinolones,MEG_5998,Drugs,MEG_5998|Drugs|Fluoroquinolones|Quinolone_resistance_protein_Qnr|QNRB,gi|695224419|ref|NG_041071.1|37-681,3
,gtgaccaacagcaacgattccgtcacactgcgcctcatgactgagcatgaccttgcgatgctctatgagtggctaaatcgatctcatatcgtcgagtggtggggcggagaagaagcacgcccgacacttgctgacgtacaggaacagtacttgccaagcgttttagcgcaagagtccgtcactccatacattgcaatgctgaatggagagccgattgggtatgcccagtcgtacgttgctcttggaagcggggacggaaggtgggaagaagaaaccgatccaggagtacgcggaatagaccagttactggcgaatgcatcacaactgggcaaaggcttgggaaccaagctggttcgagctctggttgagttgctgttcaatgatcccgaggtcaccaagatccaaacggacccgtcgccgagcaacttgcgagcgatccgatgctacgagaaagcggggtttgagaggcaaggtaccgtaaccaccccatatggtccagccgtgtacatggttcaaacacgccaggcattcgagcgaacacgcagtgatgcctaa,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_220,Drugs,MEG_220|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,1028080938|WP_063840321.1|NG_051711|1|1|aac(6')-Ib-cr5|aac(6')-Ib-cr|fluoroquinolone-acetylating_aminoglycoside_6'-N-acetyltransferase_AAC(6')-Ib-cr5 NG_051711:101-655,2
,TTGAAAAAGTTAATATTTTTAATTGTAATTGCTTTAGTTTTAAGTGCATGTAATTCAAACAGTTCACATGCCAAAGAGTTAAATGATTTAGAAAAAAAATATAATGCTCATATTGGTGTTTATGCTTTAAATACTAAAAGTGGTAAGGAAGTAAAATTTAATTCAGATAAGAGATTTGCCTATGCTTCGACTTCAAAAGCGATAAATAGTGCTATTTTGTTAGAACAAGTACCTTATAATAAGTTAAATAAAAAAGTACATATTAACAAAGATGATATAGTTGCTTATTCTCCTATTTTAGAAAAATATGTAGGAAAAGATATCACTTTAAAAGAACTTATTGAGGCTTCAATGACATATAGTGATAATACAGCAAACAATAAAATTATAAAAGAAATCGGTGGAATCAAAAAAGTTAAACAACGTCTAAAAGAACTAGGAGATAAAGTAACAAATACAGTTAGATATGAGATAGAATTAAATTACTATTCACCAAAGAGCAAAAAAGATACTTCAACGCCTGCTGCTTTCGGCAAGACTTTAAATAAACTTATCGCAAATGGAAAATTAAGCAAAAAAAATAAAAATTTCTTACTTGATTTAATGTTTAATAATAAAAACGGAGACACTTTAATTAAAGATGGTGTTCCAAAAGACTATAAGGTTGCTGATAAAAGTGGTCAAGCAATAACATATGCTTCTAGAAATGATGTTGCTTTTGTTTATCCTAAGGGCCAATCTGAACCTATTGTTTTAGTCATTTTTACGAATAAAGACAATAAAAGTGATAAGCCAAATGATAAGTTGATAAGTGAAACCGCCAAGAGTGTAATGAAGGAATTTTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_1379,Drugs,MEG_1379|Drugs|betalactams|Class_A_betalactamases|BLAZ,blaZ_86_AIZE01000023,0
,ATGAATATTTTGACCGTCGAACAGGTAACAAAAAGCTATGGAGACAAAATTCTGTTTCAAGATGCATCCTTCGGAATGGAGGATCAGGATAAAATCGGCATTATCGGCGTGAATGGCACGGGGAAATCCACATTTCTGCGGGTCATCGCGGGGCTCGAGCCGCCCGACTCCGGTAAAATATCGATGGGCAATCGCATCCGGGTTCGTTACCTCGCGCAAAATCCGGAGTTTGATCCGGACAAAACCGTCCTGCAGCAGGTGTTTGAGGGCGATCTTCCGGAGATGAAGGCCGTGCGGGAATACACCGAAACGATGGAACTGCTGGAGCTGCATCCAAGTCATGAGGAGCTCCAGCAGAAACTGCTGAAGCTCAATCAGACGCTGGAAACGCTGCAGGCATGGCAGCTTGAAAGCGATGCGAAAACCATCCTGTCCAAGCTGGGGATTCGGAATTATGAAGCGAAGATGGGAACGCTGTCGGGCGGCCAGCGTAAGCGGGTGGCATTAGCCGCCGCCTTGATTCAGCCTTCCGACTTGCTTATTTTGGACGAGCCGACCAACCACATTGACAATGAATCCGTTGCCTGGCTGGAGCAGTATTTGCAGAAGCGCCGCGGCGCGCTGCTCATGATTACGCATGACCGGTATTTTCTGGACCGGGTAGCCAATGTTATGCTGGAGCTGGATCACGGACGGCTGTTTCGATATGAGGCGAACTACAGCCGTTTTCTGGAGCTGAAGGCAGAACGCGAGGAGCGTGAAGCCGCTTCCGAGCAAAAGCGCCAAAATTTGCTGCGGAGCGAGCTTGCCTGGATCCGCAGAGGGGCCAAGGCCCGCACGACCAAGCAGAAGGCGAGGATTGAACGCTTCGAGAAACTCAAGGATCAGGAGATGGTGCACAGCTCCGGTGAACTGGACGTTTCGGTCGCTTCCACCCGCTTGGGACGCAAAATTCTGGAGATTGAAGGTCTCCGGATGAAGATCGACGACAAAACGTTAATTCAGGACCTTTCCTATATCGCCGTTCCCGAGGATCGGATAGGTATCGTAGGCCCGAACGGCAGCGGCAAATCCACGCTGCTCAATCTGATTGCCGGGCGGATTCAGCCGGGTGGCGGGGAAGTCGTGCTCGGACCGACGGTCAAGCTCGGTTATTTCACGCAGGAGCATCAGGAGATGGACGGCAGTCAGCGCGTGATTGAGTATATCAAGGATGAGGCCGAGGTTGTCCGCACGGCGGACGGTTCGGCGATTACCGCAGCCCAGATGCTGGAACGCTTTCTGTTCCCGCCCGCGCTGCAGTGGACGCCGATTGCGAAGCTGTCCGGAGGCGAGAAGCGCCGCTTGTATCTGCTGCGGGTGCTGATGAGCGCACCGAATGTGCTGCTGCTTGATGAACCGACCAATGATTTGGATATCCAGACATTGTCCGTCCTGGAGCAGTATTTGGATGAGTTCCCGGGCGTCTGTATCGTGGTATCCCATGATCGCTTTTTCCTGGATCGAACCGTGGACAAGATTATGGCTTTTGAGGGCGACGGTCAGATTCGTGTCCATGTCGGCTCTTACAGCGAATATGCGGAATGGATGCAGCGTCACGGCGGTGAAGCTTCCGGGAGCAAGGCGGAGGCATCCATAGCCAAATCTGCTTCGGGGAGCAGCGATGGCACGGACAGTGATTCAGCTAAAGAAGCGCCGCGTGAGCGCTTGAAATTCAGTTACAAAGAACAACGGGAGTTTGATCAGATTGACGGGCTCATCGAGGATACCGAGAGCAAGCTCGCTTCGATTCAATCCGAGATGGAGACCGCCGGCAGCGACGCAGCCAGGCTTCAGGAGCTGATGAAGGCTCAGGAGGAAACGGAACGTGAGCTGGAGCATCTGATGGAACGCTGGACCTATCTGAACGAGCTCGCGGAGAAGATTGAACAGAGCAAGAAATCGTAA,ATP-binding cassette (ABC) antibiotic efflux pump,antibiotic efflux,Multi-drug_resistance,MEG_6643,Drugs,MEG_6643|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|TAEA,gb|KX531049.1|+|0-1947|ARO:3003986|TaeA [Paenibacillus sp. LC231] ,1
,atgatcgtcaactgcgaccacgacaacctcgacgcctggctggcgctgcgctcagcgctgtggcccacttgtccgttggaagagcaccgcgcggagatgcgcgaaatattggcttcgccgcatcacaccgcgtttatggcgcgggggctggacggcgctttcgttggctttgccgaggtcgcgctgcgccacgattacgtcaacggctgcgaatcgtcgccggtggcgtttttggaagggatttacaccgtcgaatgcgcccgtcgccagggctgggccgcgcacctgatcgcgcaggtgcaggagtgggcgaagcaacaggggtgcagcgagctggcgtcggataccgacatcgccaacctggactcccaacgcctgcatgcagcgctgggctttgccgaaacggaacgggtggtgttttaccgcaaaacgctgggctga,beta-lactamase,antibiotic inactivation,Aminoglycosides,MEG_100,Drugs,MEG_100|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC6-PRIME,515496910|WP_016930164.1|NG_047281|1|1|aac(6')-Ial|aac(6')_Serra|aminoglycoside_N-acetyltransferase_AAC(6')-Ial NG_047281:10-450,2
,atgcgcgataccagattcccctgcctgtgcggcatcgccgcttccacactgctgttcgccaccaccccggccattgccggcgaggccccggcggatcgcctgaaggcactggtcgacgccgccgtacaaccggtgatgaaggccaatgacattccgggcctggccgtagccatcagcctgaaaggagaaccgcattacttcagctatgggctggcctcgaaagaggacggccgccgggtgacgccggagaccctgttcgagatcggctcggtgagcaagaccttcaccgccaccctcgccggctatgccctggcccaggacaagatgcgtctcgacgaccgcgccagccagcactggccggcactgcagggcagccgcttcgacggcatcagcctgctcgacctcgcgacctataccgccggcggcttgccgctgcagttccccgactcggtgcagaaggaccaggcacagatccgcgactactaccgccagtggcagccgacctacgcgccgggcagccagcgcctctattccaacccgagcatcggcctgttcggctatctcgccgcgcgcagcctgggccagccgttcgaacggctcatggagcagcaagtgttcccggcactgggcctcgaacagacccacctcgacgtgcccgaggcggcgctggcgcagtacgcccagggctacggcaaggacgaccgcccgctacgggtcggtcccggcccgctggatgccgaaggctacggggtgaagaccagcgcggccgacctgctgcgcttcgtcgatgccaacctgcatccggagcgcctgaacaggccatgggcgcaggcgctcgatgccacccatcgcggttactacaaggtcggcgacatgacccagggcctgggctgggaagcctacgactggccgatctccctgaagcgcctgcaggccggcaactcgacgccgatggcgctgcaaccgcacaggatcgccaggctgcccgcgccacaggcgctggagggccagcgcctgctgaacaagaccggctccaccagcggcttcggcgcctacgtggcgttcgtcccgggccgcgacctgggcctggtgatcctggccaaccgcaactatcccaatgccgagcgggtgaagatcgcctacgccatcctcagcggcctggagcagcagggcaaggtgccgctgaagcgctga,beta-lactamase,antibiotic inactivation,betalactams,MEG_5659,Drugs,MEG_5659|Drugs|betalactams|Class_C_betalactamases|PDC,1509794543|WP_122630852.1|NG_062265|1|1|blaPDC-314|blaPDC|class_C_beta-lactamase_PDC-314 NG_062265:1-1194,0
,ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACACGCCAGCCCGCAGCCGCTTGAGCAAATTAAACAAAGCGAAAGCCAGCTGTCGGGCCGCGTAGGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAACGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTGGATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGACTACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCCGCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTGCTGGCCACCGTCGGCGGCCCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGCTGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCCAGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAACGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTGCTGCCGGCGGGCTGGTTTATCGCCGATAAGAACGGAGCTAGCAAGCGGGGTGCGCGCGGGATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGGGATACCCCGGCGAACATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTTATCGAGCACTGGCAACGCTAA,beta-lactamase,antibiotic inactivation,betalactams,MEG_6459,Drugs,MEG_6459|Drugs|betalactams|Class_A_betalactamases|SHV,gi|41584427|gb|AY502000.1|1-861,0
